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CHAPTER 1
General introduction 
and outline of the thesis
(Adaption of)
Risk factors and clinical outcomes of patients with 
node-positive disease after radical cystectomy for 
muscle-invasive bladder cancer.
Bruins HM a and Stein JP b
Expert Review of Anticancer Therapy 2008;8(7):1091-101
Department of Urology, Radboud University Medical Center,
Nijmegen, The Netherlands
Department of Urology, Keck School of Medicine, 
University of Southern California, Los Angeles, California
a)
b)
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Bladder cancer epidemiology and diagnosis
Bladder cancer (BC) is an important health problem. In 2013, a total of 6,426 patients 
were diagnosed with BC accounting for approximately 5.5% of all new cancer cases in 
the Netherlands.[1] Beyond the major impact on an individual level, the financial burden 
of BC for our society is significant. In fact, the per-patient costs are higher for BC than 
for any other cancer due to the high recurrence rate requiring multiple treatments and 
in a substantial number of cases life-long follow-up.[2] A number of risk factors for BC 
have been established of which tobacco smoking and occupational exposure to aromatic 
amines and certain organic chemicals are the most important risk factors.[3,4] 
 Symptoms of BC may include painless macroscopic hematuria, recurrent urinary 
tract infections and urinary urgency. These symptoms require further analysis including 
an urethrocystoscopy. When finding a lesion suspicious for BC during urethrocystoscopy, 
a complete transurethral resection of the bladder tumor (TURBT) is required to confirm 
the diagnosis of BC and to determine the extent of invasion in the bladder wall. A complete 
TURBT indicates that both the tumor and a part of the underlying detrusor muscle have 
been resected. Both aspects are important from a staging perspective and likely have a 
therapeutic value as well.[5] 
Staging
Various histological types of BC have been reported, but the vast majority (>90%) are 
urothelial carcinomas (UC). Regardless of the histological type, the American Joint 
Committee on Cancer-tumor, node, metastasis (AJCC-TNM) classification is used for BC 
staging.[6] This staging classification separately assesses the extent of tumor growth 
in the bladder wall, lymph node status and whether distant metastasis are absent or 
present (Table 1). At presentation most patients have non-muscle invasive bladder cancer 
(NMIBC), that is a form of bladder cancer confined to the bladder mucosa (Ta, Tis) or 
submucosa (T1). Overall, 20-40 % of bladder cancer patients present with, or develop 
muscle-invasive bladder cancer (MIBC; ≥T2) that may eventually extend outside the 
bladder to involve the perivesical fat (T3) and adjacent organs (T4, Figure 1). 
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Figure 1: TNM staging of bladder cancer [6]
Recently, the 7th edition (published in 2009, implemented in 2010) of the AJCC-TNM 
staging classification has taken effect.[6] This current edition differs from the previous 
6th edition (published in 2002) [7] in a number of aspects including: 
1. Primary tumor staging: sub-epithelial invasion of prostatic urethra does not 
constitute T4 staging status. 
This modification is based on studies reporting that BC invading the prostatic urethra/
ducts confers a better prognosis compared to BC invading the prostatic stroma.[8-11] 
However, despite the difference in prognosis, limited data is available on the occurrence 
rate and risk factors for prostatic ducts and prostatic stoma invasion in patients undergoing 
radical cystectomy (RC) for BC. Obtaining this data was one of the goals of a study where 
the histology- and clinical records of nearly 1,500 male patients who underwent RC was 
reviewed (chapter 2). 
T1 
Invades subepithelial
connective tissue
(lamina propria)
T2a Invades 
superficial muscle
T2b Invades 
deep muscle
T3a Invades 
perivesical tissue
(micro-scopically)
T3b Invades 
perivesical tissue
(macro-scopically)
T4 Invades 
contiguous organs
Ta 
Affects the
subepithelial
Carcinoma 
in situ
Mucosa
Lamina propria
Superficial 
muscle
Deep muscle
Peritoneum
Prostate
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2. Lymph node (LN) staging: LN staging is based on the location of the LN(s) involved. 
Location-based LN staging has replaced size-based LN staging. Also, LN metastasis at 
the common iliac vessels are now considered regional LN metastasis rather than distant 
metastatic disease. Nevertheless, the rationale for these modifications are not clear as 
no data was available supporting this modification at the time of its effectuation. In fact, 
it has been suggested that the site of LN metastasis is not associated with survival.[12-
14] Hence, a study was performed evaluating whether prognostication for LN-positive 
patients has improved in the 7th TNM edition (chapter 8). 
Table 1: The AJCC-TNM bladder cancer staging classification (7th edition) [6]
T - Primary Tumor
Tx Primary tumor cannot be assessed
T0 No evidence of primary tumor
Ta Non-invasive papillary carcinoma
Tis Carcinoma in situ: “flat tumor”
T1 Tumor invades subepithelial connective tissue
T2 Tumor invades muscle:
T2a Tumor invades superficial muscle (inner half)
T2b Tumor invades deep muscle (outer half)
T3 Tumor invades perivesical tissue:
T3a Microscopically
T3b Macroscopically (extravesical mass)
T4 Tumor invades any of the following: prostate stroma, seminal vesicles, uterus, 
vagina, pelvic wall, abdominal wall
T4a Tumor invades prostate stroma, seminal vesicles, uterus, or vagina
T4b Tumor invades pelvic wall or abdominal wall
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N - Regional Lymph Nodes
Nx Regional lymph nodes cannot be assessed
N0 No regional lymph-node metastasis
N1 Metastasis in a single lymph node in the true pelvis (hypogastric, obturator, 
external iliac, or presacral)
N2 Metastasis in multiple lymph nodes in the true pelvis (hypogastric, obturator, 
external iliac, or presacral)
N3 Metastasis in common iliac lymph node(s)
M - Distant Metastasis
M0 No distant metastasis
M1 Distant metastasis
Surgical treatment
Non-muscle invasive bladder cancer
The standard therapy for Ta-T1 BC is a complete TURBT. In case of an incomplete TURBT, 
absence of detrusor muscle in the specimen, T1 tumor or high-grade tumor (except 
for primary CIS) a second TURBT is recommended.[15] All patients with NMIBC are 
offered adjuvant intravesical treatment to reduce the recurrence rate. Yet, as NMIBC 
is a heterogeneous disease, the risk of progression and/or recurrence differs. Adjuvant 
intravesical treatment strategies are therefore based on well-defined risk factors.[15,16] 
RC for NMIBC should be considered in patients with high-risk NMIBC who fail to respond 
on intravesical therapy. 
Muscle-invasive bladder cancer
If left untreated, less than 15% of the patients with MIBC will survive more than 2 years.
[17] To improve survival in patients with MIBC, an aggressive treatment paradigm has 
been advocated. In patients with localized MIBC the gold standard treatment is RC. This 
treatment consists of complete resection of the urinary bladder with its adjacent organs 
and the construction of a urinary diversion. The classical technique in male patients is to 
entirely resect the prostate, while in female patients the uterus, fallopian tubes, ovaries, 
upper third of the anterior vaginal wall are removed. The most frequently used urinary 
diversion techniques are the ileal conduit according to Bricker [18] and the orthotopic 
neobladder (various types used). 
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In experienced hands, RC can provide good local control in most patients, however, 
impairment of quality of life is reported by many. For this reason, a sexual organ sparing 
cystectomy has been advocated in both males and females.[19-24] In this approach, the 
prostate is preserved in men while in females (parts of ) the reproductive organs (vagina, 
uterus and adnexa) are preserved. Although often technically feasible, the oncological 
outcomes of these procedures are inferior to RC if routinely performed.[19,25] Thus, 
careful patient selection is crucial. To understand in whom a sexual organ sparing 
cystectomy may be safely performed, it is important to have knowledge of the incidence 
and risk factors of BC invading its adjacent organs. In addition, the risk of leaving behind 
incidental, yet clinical significant, prostate cancer is an important consideration in male 
patients. Aiming to assess the incidence and risk factors for UC invading the adjacent 
organs, a detailed clinical and histopathological analysis of RC specimens was performed 
in both males and females using a large RC database (chapters 2 and 3).
Lymph node dissection in bladder cancer
Despite the early and aggressive approach in patients with MIBC, approximately 25% of 
patients have regional LN metastasis at the time of RC providing a sound rationale to 
perform a LND.[26] Nonetheless, several studies have suggested that LND is often not 
performed.[27,28] In 2010, an estimated 20% of patients in the Netherlands underwent 
RC without LND.[29] The reason for this may vary, but one hypothesis is that LND may not 
ought to be of benefit in patients undergoing RC for clinical NMIBC. Indeed, data on the 
incidence as well as the distribution of LN metastasis in this patient group is lacking. This 
raises the question whether or not to perform LND, and how extended the LND template 
should be. For these reasons, a LN mapping study was undertaken to assess the incidence 
and location of LN metastasis in patients undergoing RC for clinical NMIBC (chapter 5). 
 The discussion on the optimal extent of LND is not restricted to patients with 
NMIBC but applies to patients with MIBC as well, if not more. In the absence of prospective 
randomized trials, current data on the role of LND originate from observational studies. 
The results of these studies are conflicting and difficult to interpret as no uniform 
definition for the different LND templates have been used. In addition, most studies 
suffered from several biases. Although two randomized controlled trials (RCTs) looking at 
the staging and therapeutic value of the extent of LND are ongoing, it may years before the 
final results are published.[30,31] Also, there is no guarantee that these studies provide 
the definitive answer to the question. Lacking level 1 evidence, it is important to base 
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current treatment decisions on the second best possible evidence base. Such evidence 
can arise from a systematic review of the literature including a critical appraisal of bias. A 
systematic review was performed evaluating the impact of the extent of LND on survival 
and peri-operative outcomes in patients undergoing RC (chapter 6).
Chemotherapy
Neo-adjuvant therapy has been advocated in patients with MIBC. The most commonly 
used chemotherapy regimens include a combination of methotrexate, vinblastine, 
doxorubicin and cisplatinum (MVAC) or gemcitabine with cisplatinum (GC). Data from 
RCTs have reported neo-adjuvant chemotherapy to increase the absolute 5-year overall 
survival by 5-8%.[32,33] Despite this level 1 evidence, neo-adjuvant chemotherapy has 
been infrequently used for many years, although increasing over time.[34] The role of 
adjuvant chemotherapy is under debate.[35] Although there is some evidence that 
adjuvant chemotherapy may prolong survival, this evidence originates from older RCTs 
with methodological concerns.[36-39] A recent RCT did not find a survival difference 
between adjuvant chemotherapy and deferred chemotherapy in patients with (locally) 
advanced MIBC, but was closed early due to poor recruitment.[40] Thus, we still do not 
know which patients, if any, may actually benefit from adjuvant chemotherapy. Further 
research is needed and an updated individual patient data meta-analysis may provide 
more definitive answers on this topic.
Prognosis
The prognosis of patients with MIBC varies greatly depending on a number of patient 
related and histopathological variables. Arguably the most consistent and important 
prognostic variables are the pathological tumor stage and LN status.[41] As shown in 
table 2, the 5-year recurrent free survival ranges between 22% in patients with LN positive 
and extravesical (>pT2) disease to 85% in patients with LN negative and organ-confined 
(pT0-T2) disease.[26] Over the last years a number of other clinical and pathological 
prognostic factors have been identified (e.g. lymphovascular invasion) that may allow 
further refinement of prognostication. In addition, multiple potential biomarkers have 
been suggested to improve prognostication. Yet no single biomarker, nor panel of 
biomarkers, is routinely used at this time. Ultimately, improved prognostication allows 
for better selection of those patients that may benefit from neo-adjuvant or adjuvant 
chemotherapy. For this reason, a number of studies looking at potential risk factors for 
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disease recurrence or progression in patients requiring RC (chapter 9) and patients that 
have undergone RC (chapters 4,7,8) were performed.
Table 2: Relation between LN status and pathologic stage for 5-year recurrence free 
survival [26]
Author Median 
follow-
up 
(months)
No Pts Probability of 5 year recurrence-free survival in %
Entire 
cohort
LN+
Pts
LN+/EV
Pts
LN+/OC
Pts
LN-/EV
Pts
LN-/OC
Pts
Stein 122 1054 68 35 30 46 58 85
Vieweg 92 686 57 31 22 58 43 82
Madersbacher 31 507 62 33 N/A N/A 56 73
OC=organ-confined (pT0-pT2), EV=extravesical (pT2-pT4), LN+=lymph node positive, LN-=lymph 
node negative
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Outline of this thesis
As outlined in the previous paragraphs, several questions regarding the staging, treatment 
and prognosis of patients with MIBC were the basis for further research that resulted in 
this thesis. 
Part I, the introduction, contains the current chapter 1 providing a general introduction 
and outline of the thesis.
Part II focuses on cancer of the urinary bladder and/or its adjacent organs. 
In chapters 2 and 3, the BC database of the University of Southern California (USC) 
was used, containing comprehensive data of over 2,000 patients who underwent RC. 
In chapter 2, the incidence and risk factors of UC involving the prostate and incidental 
prostate adenocarcinoma were analyzed reviewing the records of nearly 1,500 male 
patients. Similarly, in chapter 3, the records of approximately 250 female patients who 
underwent anterior pelvic exenteration were reviewed to evaluate the incidence and risk 
factors of BC invading the adjacent reproductive organs. Chapter 4 focuses on cancer of 
the urachus; an embryonic remnant anatomically closely related to the urinary bladder. 
Due to its low incidence, long-term survival data on a population-based level is scarce. 
Data from the Netherlands Cancer Registry (NCR) was analyzed to describe the long-term 
clinical outcomes and identify potential prognostic variables. 
Part III addresses the role of LND at the time of RC. 
In Chapter 5, the results of a LN mapping study that was performed at USC are presented 
looking at the incidence and location of LN metastasis in patients undergoing RC for 
clinical NMIBC. Chapter 6 describes the results of a systematic review of the literature that 
was performed aiming to determine the current evidence base in regard to oncological 
benefits and peri-operative outcomes of different LND templates in patients with MIBC.
Part IV discusses potential prognostic variables in (locally advanced) bladder cancer. 
In chapter 7, the results of a study evaluating survival outcomes and potential prognostic 
variables in patients with low-volume LN (1 or 2 positive LNs) positive disease are 
presented. Chapter 8 contains a critical evaluation of both the 6th and 7th edition of the 
TNM nodal classification system and aimed to evaluate whether the current 7th edition 
has improved prognostication in patients with node-positive disease. Both chapters 7 and 
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8 were performed using the USC bladder cancer database. In chapter 9, the impact of the 
time from diagnosis of MIBC to RC on staging and survival was assessed analyzing the 
nationwide database of the NCR including nearly 1,800 patients. 
Part V, the epilogue, includes the general discussion and future perspectives in chapter 
10 and summary (samenvatting) in chapter 11.
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Abstract 
Purpose
To identify risk factors and determine the incidence and prognosis of incidental, clinically 
significant prostate adenocarcinoma, prostatic urothelial carcinoma and HGPIN in 
patients treated with radical cystoprostatectomy for urothelial carcinoma of the bladder.
Materials and Methods
We analyzed the records of 1,476 patients without a history of prostatic adenocarcinoma. 
We determined the incidence of clinically significant prostatic adenocarcinoma, prostatic 
urothelial carcinoma and HGPIN in the total cohort and in select patient subgroups. 
Prostatic urothelial carcinoma was stratified in prostatic stromal and prostatic urethra/
duct involvement. Univariable and multivariable analyses were performed with multiple 
variables. Recurrence-free and overall survival rates were calculated. Median follow-up 
time was 13.2 years.
Results
Of the 1,476 patients 753 (51.0%) had cancer involving the prostate. Prostatic 
adenocarcinoma, clinically significant prostatic adenocarcinoma, prostatic urothelial 
carcinoma and HGPIN were present in 37.9%, 8.3%, 21.1% and 51.2% of patients, 
respectively. Of the 312 patients (21.1%) with prostatic urothelial carcinoma 163 (11.0%) 
had prostatic urethral/duct involvement only and 149 (10.1%) had prostatic stromal 
involvement. We identified risk factors for clinically significant prostatic adenocarcinoma, 
prostatic urothelial carcinoma and HGPIN but the absence of these risk factors did not 
rule out their presence. Ten-year overall survival in patients with no prostatic urothelial 
carcinoma, and prostatic urethral/duct and prostatic stromal involvement was 47.1%, 
43.3% and 21.7%, respectively (p <0.001). No patient with clinically significant prostatic 
adenocarcinoma died of prostatic cancer.
Conclusions
More than half of the patients undergoing radical cystoprostatectomy had cancer 
involving the prostate. Prostatic urothelial carcinoma, particularly with prostatic stromal 
involvement, was associated with a worse prognosis, while clinically significant prostatic 
adenocarcinoma did not alter survival. Preoperative clinical and histopathological 
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risk factors are not reliable enough to accurately predict clinically significant prostatic 
adenocarcinoma and/or prostatic urothelial carcinoma.
Abbreviations and Acronyms
cNMIBC  = clinically nonmuscle invasive bladder cancer
csPCA  = clinically significant PCA
HGPIN  = high grade intra-epithelial neoplasia
OS   = overall survival
PCA  = prostatic adenocarcinoma
PSA  = prostate specific antigen
PUC  = prostatic urothelial carcinoma
PUC-d  = PUC with prostatic urethral and/or prostatic duct involvement  
PUC-s  = PUC with prostatic stromal involvement
RCP  = radical cystoprostatectomy
RFS  = recurrence-free survival
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Introduction
The standard surgical approach in male patients with muscle-invasive bladder cancer 
is radical cystoprostatectomy (RCP) with lymphadenectomy and urinary diversion. To 
improve sexual and functional outcomes, prostate sparing cystectomy was advocated. 
[1-3] While it is technically feasible, the oncological safety of a prostate sparing 
approach is under debate. [4] Oncological concerns include the risk of incidental 
csPCA, PUC and to a lesser extent HGPIN. Several studies demonstrated that prostatic 
involvement is common at RCP. [5-12] However, few studies mention the incidence 
of prostatic involvement (PUC, (cs)PCA and/or HGPIN) in subgroups of patients 
considered to be at low risk based on pre-operatively available data. [5-7] In addition, 
limited pre-operative risk factors for prostatic involvement have been identified. [5,11] 
 In this study we report the incidence of prostatic involvement in RCP specimens 
in the total cohort and select subgroups of patients. We identified pre-operative risk 
factors for prostatic involvement and assessed the impact of prostatic involvement on 
survival outcomes after RCP.
 
Materials and methods
 
Cohort selection
A total of 1,553 men underwent RCP for primary urothelial bladder carcinoma at the 
University of Southern California between 1971 and 2008. After excluding 77 patients 
with previously histologically proven (31) or treated (46) PCA, we reviewed data of 1,476 
patients. Clinical and histopathologic data were prospectively collected by an experienced 
data-entry team, double-checked by a single database manager (G.M.) and stored in our 
institutional review board approved database. The incidences of (cs)PCA and PUC were 
determined in all 1,476 patients. The incidence was also determined in patient subgroups 
often eligible for inclusion in prostate sparing cystectomy series, including age 60 years 
or younger, pre-operative PSA ≤ 2.5, cNMIBC (cT1 or less) and/or a bladder tumor located 
outside the bladder neck/trigone. For the purpose of this analysis we considered only the 
1,003 patients treated between 1990 and 2008 (‘PSA-era cohort’) since PSA information 
was not routinely available before 1990. This PSA-era cohort was also used to determine 
the incidence of HGPIN, because presence of HGPIN was not routinely reported before 
1990.
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Specimen processing
After RCP, the prostatic surface was inked and fixed in 10% neutral buffered formalin 
solution for 24 hours. The prostate was subsequently cross-sectioned at 3 to 5 mm 
intervals perpendicular to the urethra from apex to base to the junction of the seminal 
vesicles and prostate. In addition to the prostatic apex, representing the distal margin if 
not submitted separately for frozen section, a complete slice or cross-section of the distal, 
mid and proximal prostate was submitted along with any other abnormal or suspicious 
areas and sections including the right and left seminal vesicles at the junction with the 
prostate. Each section was embedded in paraffin, sectioned by microtome and mounted 
on glass slides according to standard procedure. Hematoxylin and eosin staining was 
done. As needed, immunohistochemical staining with monoclonal antibodies was 
performed to aid in diagnosing PCA. Tissue samples were microscopically examined by a 
team of dedicated uropathologists.
Histopathologic variables
Bladder cancer and PCA were staged according to the 2002 American Joint Committee on 
Cancer (AJCC) TNM staging classification.[13] csPCA was defined as extraprostatic exten-
sion, seminal vesicle invasion, positive surgical margin, lymph node metastasis or Gleason 
score 7 or greater. We used the 2005 modified Gleason score.[14] HGPIN was defined as 
grade II or higher prostatic epithelial neoplasia.[15] PUC was stratified as PUC-d and PUC-s. 
 
Follow-up and statistical analysis
We performed univariable analysis with the Pearson chi-square or Fisher exact test 
for categorical variables and the Wilcoxon rank sum test for not normally distributed 
continuous variables as well as multivariable analysis with multiple logistic regressions 
to test the association of demographic and clinical characteristics with prostatic 
involvement. Multivariable analysis included preoperative variables only except for 
bladder cancer location and disease focality. Since the latter 2 variables were not available 
preoperatively, they were based on the RCP specimen. Median bladder cancer follow-
up was 13.2 years (range 0.1 to 36.6). Bladder cancer OS and RFS were calculated using 
Kaplan-Meier plots. The log rank test and Cox proportional hazard modeling were used 
to compare OS and RFS between subgroups with 2-sided p <0.05 considered significant.
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Results
Of the 1,476 patients included in analysis 753 (51.0%) had PCA and/or PUC, of whom 96 
(6.5%) received neo-adjuvant chemotherapy. A total of 462 patients (31.3%) had recurrent 
disease, including 357 (77.3%) with distant and 105 (22.7%) with local pelvic recurrence.
Prostatic Adenocarcinoma
PCA was present in 559 patients (37.9%) with a median age of 69 years and a median 
preoperative PSA of 1.66 ng/ml (range 0.01 to 83). Six patients (0.4%) had preoperative 
PSA greater than 20 ng/ml, including 2 with csPCA and 1 with PCA. csPCA was present in 
123 cases (8.3%), due to a Gleason score of 7 or greater in 90 (73.2%; Table 1). Preoperative 
variables independently associated with csPCA were increasing age and PSA (Table 4). 
Table 2 lists the incidence of PCA and csPCA in the patient subgroups. Of the 162 patients 
60 years or younger with PSA 2.5 ng/ml or less PCA was present in 61 (37.7%), including 
9 (14.8%) with csPCA. The 10-year bladder cancer RFS rate was not impacted by csPCA 
(64.8% vs 64.2%, p = 0.92). The 10-year OS rate was higher in patients without than with 
csPCA (45.2% vs 27.8%, p = 0.02). This was most likely due to the higher median age in 
the csPCA group (70 vs 66 years) since no patient with csPCA died of prostatic cancer. 
Also, csPCA was not associated with OS after adjusting for age, bladder cancer stage, 
lymph node status and lymphovascular invasion (HR = 1.20, p = 0.13).
Table 1: Characteristics of 559 patients with incidental prostatic adenocarcinoma 
Number of patients (%)
Age
65 or less  
Greater than 65
 
199 (35.6) 
360 (64.4)
Pre-operative PSA 
2.5 or less 
2.6 – 3.9 
4.0 – 9.9 
10.0 – 19.9 
20.0 or greater 
Missing  
Not applicable*
 
272 (48.7) 
50 (8.9) 
63 (11.3) 
10 (1.8) 
3 (0.5) 
62 (11.1) 
99 (17.7)
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Gleason score
5 or less
6
7
8-10
Missing
184 (32.8)
274 (49.0)
78 (14.0)
12 (2.2)
11 (2.0)
PCA pathologic stage
pT2a
pT2b/c
pT3a
pT3b
pT4a
320 (57.2)
207 (37.0)
25 (4.5)
6 (1.1)
1 (0.2)
PCA lymph node involvement
Negative
Positive
552 (98.7)
7 (1.3)
PCA surgical margin status
Negative
Positive
535 (95.5)
24 (4.3)
Clinically significant PCA 
 - Gleason score ≥ 7
 - Extraprostatic extension 
 - Seminal vesicle involvement
 - Positive surgical margin 
 - Lymph node involvement
123 (22.0) 
   90
   32
   6
   24
   7
PCA = prostate adenocarcinoma
* PSA data were not available before 1990 
Table 2: Prostatic involvement in the PSA-era cohort 
No of pts 
(%)
No. Age 
60 or less 
(%)
No. PSA 
2.5ng/ml 
or less (%)
No. cTa-
cT1 blad-
der cancer 
(%)
No. 
cancer 
outside 
bladder 
neck/ 
trigone 
Overall 1,003 249 592 392 677
Prostate adenocarcinoma 460 (45.9) 90 (36.1) 270 (45.6) 174 (44.4) 304 (44.9)
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Clinical significant prostate adeno-
carcinoma 
103 (10.3) 15 (6.0) 46 (7.8) 42 (10.7) 70 (10.3)
Prostatic urothelial carcinoma 203 (20.2) 41 (16.5) 117 (19.8) 84 (21.4) 80 (11.8)
High-grade prostatic intra-epithelial 
neoplasia 
514 (51.2) 110 (44.2) 333 (56.3) 196 (50.0) 347 (51.3)
Prostatic Urothelial Carcinoma
PUC was present in 312 patients (21.1%), including 163 (52.2%) with PUC-d only and 149 
(47.8%) with PUC-s (table 3). Of the 149 patients with PUC-s 120 (80.5%) had stromal 
invasion secondary to PUC-d (noncontiguous) and 29 (19.5%) had stromal invasion from 
an extravesical tumor (contiguous). We analyzed the total cohort to identify PUC risk 
factors (Table 4). PUC was present in 6 of the 76 patients (7.9%) 60 years or younger with 
cNMIBC outside the bladder neck/trigone. Ten-year RFS in patients with no PUC, PUC-d 
and PUC-s was 68.2%, 59.6% and 39.5%, respectively (p <0.001, part A of figure 1). PUC-d 
(HR 1.34, 95% CI 1.01-1.78, p = 0.043) and PUC-s (HR 1.36, 95% CI 1.04-1.78, p = 0.023) 
were associated with decreased RFS after adjusting for age, bladder cancer stage and 
grade, lymph node status, surgical margin status, lymphovascular invasion and adjuvant 
chemotherapy. Ten-year OS in patients with no PUC, PUC-d and PUC-s was 47.1%, 43.3% 
and 21.7%, respectively (p <0.001; part B of figure 1). After adjusting for the mentioned 
variables, PUC-s (HR 1.26, 95% CI 1.03-1.57, p = 0.038) was independently associated 
with decreased OS, while PUC-d (HR 1.00, 95% CI 0.82-1.24, p = 0.96) did not alter OS. 
Contiguous invasion was associated with lower 10-year RFS than noncontiguous invasion 
(27.3% vs 40.3%, p <0.001). However, this effect did not attain statistical significance 
after adjusting for the mentioned variables (HR 1.65, p = 0.07). 
Table 3: Characteristics of patients with prostatic urothelial carcinoma
No. PUC-d only (%) No. PUC-s (%) 
Overall 163 149
Age
  Younger than 65
  Older than 65 
75 (46.0)
88 (54.0)
56 (37.6)
93 (62.4)
Urinary diversion
  Orthotopic
  Non-orthotopic
90 (55.2)
73 (44.8)
67 (45.0)
82 (55.0)
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Clinical stage
  cT2 or less
  Greater than cT2
147 (90.2)
16 (9.8)
94 (63.1)
55 (36.9)
Pathological subgroup
  ≤ pT2, pN0
  > pT2, pN0
  pTany, pN1-3
110 (67.5)
14 (8.6)
39 (23.9)
-
84 (56.4)
65 (43.6)
Tumor grade
  Low
  High
20 (12.3)
143 (87.7)
6 (4.0)
143 (96.0)
Multifocal disease
  Yes
  No
66 (40.5)
97 (59.5)
77 (51.7)
72 (48.3)
Lymphovascular invasion
  Yes
  No
117 (71.8)
46 (28.2)
73 (49.0)
76 (51.0)
Carcinoma-in-situ
  Yes
  No
35 (21.5)
128 (78.5)
41 (27.5)
108 (72.5)
Tumor location
  At or below trigone
  Other
82 (50.3)
81 (49.7)
85 (57.0)
64 (43.0)
Adjuvant chemotherapy
  Yes
  No
35 (21.5)
128 (78.5)
61 (40.9)
88 (59.1)
PUC-d = Prostatic urothelial carcinoma involving the prostatic ducts 
PUC-s = Prostatic urothelial carcinoma involving the prostatic stroma
High Grade Prostatic Intra-epithelial Neoplasia
Analysis of the PSA era cohort of 1,003 patients revealed that 514 (51.2%) had HGPIN, 
including 289 of 460 (62.8%) with PCA, 55 of 103 (53.4%) with csPCA and 225 of 543 
(41.4%) without PCA. Factors associated with HGPIN on univariable analysis included 
increasing age, increasing PSA and csPCA (each p <0.001). On multivariable analysis
including age and PSA, only increasing age was associated with HGPIN (OR 1.02, 95% CI 
1.01-1.04, p = 0.005). Ten-year OS rates were similar in patients with and without HGPIN 
(41.6% and 44.7%, respectively, p = 0.73).
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Table 4: Association of clinical and histopathologic variables with presence of clinical 
significant prostatic adenocarcinoma and prostatic urothelial carcinoma 
csPCA (N = 123)
Univariable
analysis
Multivariable
analysis  OR (95%CI)
Clinical variables
Increasing age p < 0.001
OR 1.03 (1.01-1.06)
p = 0.004
Increasing PSA p < 0.001
OR 1.09 (1.04-1.14)
p < 0.001
Pre-operative radiotherapy (yes vs no) p = 0.07 -
Pre-operative chemotherapy (yes vs no) p = 1.00 -
TURBT specimen related variables
Bladder cancer stage  
(>cT2 vs ≤cT2)
p = 0.62 -
Bladder cancer grade  
(high vs low)
p = 1.00 -
Concomitant LVI (present vs absent) p = 1.00 -
Concomitant CIS  
(present vs absent)
p = 0.30 -
RCP specimen related variables
Bladder cancer stage (> pT2 vs ≤ pT2) p = 0.62 -
Bladder cancer focality  
(multifocal vs unifocal)
p = 0.85 -
Bladder cancer at or below trigone  
(yes vs no)
p = 0.92 -
Concomitant LVI (present vs absent) p = 0.83 -
Concomitant CIS (present vs absent) p = 0.44 -
OR = Odds Ratio; 95%    CI = 95% confidence Interval 
csPCA = clinical significant prostatic adenocarcinoma;  PUC = prostatic urothelial carcinoma
TURBT = transurethral resection of bladder tumor;  RCP = radical cystoprostatectomy;  
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PUC-ducts only (N = 163) PUC-stroma (N = 149)
Univariable
analysis
Multivariable
analysis OR (95%CI)
Univariable
analysis
Multivariable
analysis OR (95%CI)
p = 0.94 - p = 0.021
OR 1.02 (0.99-1.03)
p = 0.10
p = 0.69 -
p = 0.27
-
p = 0.76 - p = 0.41 -
p = 0.61 - p = 0.73 -
p = 0.029
OR 2.64 (1.43-4.87)
p = 0.002
p < 0.001
OR 10.2 (6.60-15.70)
p < 0.001
p = 0.19 p = 0.021
OR 1.67 (1.05-2.67)
p = 0.029
p = 0.31 - p = 0.73 -
p < 0.001
OR 1.97 (1.38-2.81)
p < 0.001
p = 0.70 -
p = 0.032 - p < 0.001 -
p < 0.001
OR 2.24 (1.56-3.21)
p < 0.001
p = 0.001
OR 1.51 (1.03-2.21)
p = 0.034
p < 0.001
OR 2.54 (1.79-3.60)
p < 0.001
p < 0.001
OR 3.23 (2.21-4.72)
p < 0.001
p = 0.27 - p < 0.001
p < 0.001 - p < 0.001 -
CIS = carcinoma-in-situ;  LVI = Lymphovascular invasion
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Figure 1: Recurrence-free survival (A) and overall survival (B) stratified by
  presence of prostatic urothelial carcinoma 
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Discussion
More than half of the study patients had cancer involving the resected prostate. PCA and 
PUC were present in 37.9% and 21.1% of cases, respectively. Comparing the incidence 
among studies is challenging due to differences in study eras, patient populations and 
pathological processing.[5-12] To illustrate this point, a recent review described an 
average 28.5% PCA rate but PCA rates up to 50% to 60% were reported in the individual 
studies.[8,9,12] The high rate of PCA is not surprising, given the advanced age of patients 
with bladder cancer. Many of these PCAs may have remained clinically silent and yet 22.0% 
of incidental PCAs were clinically significant based on histopathological criteria. Although 
csPCA did not alter survival after RCP, it might impact survival when the prostate is preserved. 
 A few, mostly small studies mention the incidence of precancerous lesions in 
RCP specimens. HGPIN incidence rates of 14% to 75% in patients without PCA and 50% 
to 95% in patients with PCA were reported.[8,16,17] In our series, which to our knowledge 
is the largest to date, HGPIN was present in 51.2% of patients and it was also associated 
with PCA and csPCA. However, the clinical significance of this finding requires future 
investigation. Nonetheless, our study underscores the frequent involvement of the 
prostate with cancer or precancerous lesions at RCP.
 The AJCC TNM classification for bladder cancer was recently revised based on 
previous studies suggesting that the depth of PUC invasion affects prognosis.[18-22] In 
the current 7th edition prostatic urethral/duct invasion by bladder cancer is excluded as 
pT4a disease.[22] Our study supports this revision since the PUC-s prognosis was worse 
than the PUC-d prognosis. In addition, on univariable analysis contiguous prostatic 
stromal invasion was associated with decreased RFS compared to noncontiguous prostatic 
stromal invasion. This finding is consistent with our smaller previous study.[19] Notably, 
this effect was not seen on multivariable analysis (HR 1.65,p = 0.07), most likely due to 
the limited number of patients (29) with contiguous PUC-s. In contrast to PUC, csPCA was 
not associated with the prognosis after RCP, indicating that the prognosis after RCP relies 
on bladder cancer. Nonetheless, the treatment burden of csPCA may have been present 
since data on PSA recurrence were not available. 
 Concomitant carcinoma in situ and trigonal tumors were reported to be risk 
factors for PUC.[5,11,23] However, most groups did not analyze risk factors for PUC-d 
and PUC-s separately despite the difference in prognosis. In our study clinically nonorgan 
confined disease, multifocal disease and trigonal tumor location were independent risk 
factors for PUC-d and PUC-s. Carcinoma in situ in the transurethral resection specimen 
MaxThesis.indb   43 27-10-15   20:39
part ii • bladder cancer and the adjacent organs
44
was independently associated with PUC-d but not with PUC-s. With respect to PCA, a 
limited number of risk factors were identified. Pettus et al reported increasing age as a 
risk factor for PCA.[5] Voigt et al analyzed transurethral prostatic resection specimens and 
found that increasing body mass index and decreasing prostatic volume were associated 
with PCA.[24] We found that increasing age and PSA were independent risk factors for 
PCA and csPCA, while body mass index was not (data not shown). Prostatic volume was 
not available.
 An important finding of our study is that prostatic involvement cannot be ruled 
out using standard available preoperative data. For example, more than a third of patients 
60 years or younger with PSA 2.5 ng/ml or less had PCA. PUC was also present in 8% of 
patients younger than 60 years with disease less than cT2 located outside the bladder 
trigone. Others reported similar observations. [5,10] Ward et al noted a 23% PCA rate in 
patients with preoperative PSA less than 2.0 ng/ml and normal digital rectal examination.
[10] Pettus et al found that 41% of patients with cNMIBC had PUC. [5] Together these data 
suggest that performing prostate sparing cystectomy based on the standard available 
variables carries a considerable oncological risk.
 While preoperative magnetic resonance imaging, prostatic biopsies or 
transurethral resection may possibly increase the preoperative detection rate of prostatic 
involvement, to our knowledge the diagnostic panel that offers the optimal detection rate 
remains unknown. Also, oncological outcomes in prostate sparing cystectomy series are 
inconsistent. Some groups reported outcomes comparable to those of RCP, while others 
reported a remarkably high rate of metastatic disease.[1-3,25] These concerns, coupled 
with the consistent outcomes of radical cystoprostatectomy, suggest that a prostate 
sparing approach requires optimal patient selection and surgical technique to achieve 
adequate oncological control.
 This study has limitations. It was retrospective with the inevitable risks of 
selection bias and missing data. Whole mount step sectioning was not done that may 
have resulted in cancer under detection. Also, tumor volume was not part of the csPCA 
definition, possibly underestimating the incidence of csPCA. In addition, slides were not 
re-reviewed, allowing for interobserver variability. Routine prostatic biopsies were not 
done, although they may have preoperatively identified patients with prostatic tumor 
involvement. Lastly, data on recurrence and/or treatment for PCA after RCP were lacking, 
although cause of death was available. While we acknowledge these limitations, to 
our knowledge this is currently the largest study of this topic with comprehensive data 
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analysis and a standardized surgical technique.
Conclusions
More than half of the patients undergoing RCP for urothelial cancer of the bladder had 
cancer involving the prostate. PUC, particularly PUC-s, was associated with a worse 
prognosis, while the presence of csPCA did not alter survival. Preoperative clinical and 
histopathological risk factors are not reliable enough to accurately predict csPCA and/
or PUC.
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Abstract
Purpose
To evaluate pathological involvement of the reproductive organs in a cohort of female 
patients treated with anterior pelvic exenteration for invasive urothelial carcinoma of the 
bladder.
Materials and Methods
A total of 2,098 patients with bladder cancer underwent cystectomy at our institution 
between 1971 and 2008, including 458 females, of whom 411 had urothelial carcinoma 
of the bladder. Median follow-up was 12.2 years (range 0.1 to 35.5). We reviewed 
the clinicopathological features of female patients treated with cystectomy who had 
pathological reproductive organ involvement. Recurrence-free and overall survival is 
reported using Kaplan-Meier survival curves.
Results 
Of 411 patients with urothelial carcinoma of the bladder 267 underwent reproductive 
organ removal with cystectomy. A total of 20 patients (7.5%) had reproductive organ 
involvement, including 10 (3.8%) with vaginal, 2 (0.7%) with cervical and 1 (0.3%) with 
uterine involvement only, while the remaining 7 (2.6%) had multiple reproductive organs 
involved. Median age was 71 years. Clinical stage T4a was diagnosed in 25% of cases. A 
palpable mass, hydronephrosis and positive lymph nodes at anterior pelvic exenteration 
(each p < 0.001) were associated with reproductive organ involvement. Recurrence 
developed in 14 patients (70%) at a median of 7 months (range 1 to 22). Five-year 
recurrence free and overall survival rates were 14.9% and 8.8%, respectively.
Conclusions
The risk of reproductive organ involvement in female patients who undergo anterior 
pelvic exenteration for urothelial carcinoma of the bladder was about 7.5% with the 
vagina the most commonly involved organ. A palpable mass and hydronephrosis were 
among the preoperative clinical factors associated with reproductive organ involvement. 
The prognosis is poor in patients with reproductive organ involvement.
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Abbreviations and Acronyms
APE  = anterior pelvic exenteration 
BSO  = bilateral salpingooophorectomy 
OS  = overall survival 
RFS  = recurrence-free survival 
RO  = reproductive organ 
TAH-BSO = total abdominal hysterectomy-BSO 
UC   = urothelial carcinoma
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Introduction
In female patients with muscle invasive bladder cancer, APE is traditionally the treatment 
of choice. This operation includes cystectomy, bilateral pelvic lymph node dissection, 
hysterectomy, BSO and resection of the upper third of the anterior vaginal wall. [1] With 
the close proximity of the uterus, cervix and vagina, APE is believed to provide optimal 
local control since local tumor extension may affect these ROs. Although this approach 
aims to optimize local cancer control, removing ROs at radical cystectomy has a great 
impact on sexual outcomes. [2] While it is technically feasible to preserve ROs at radical 
cystectomy, the question remains whether the routine removal of ROs is required in all 
female patients. [3,4] 
 To answer this question, it is important to investigate the incidence of 
RO involvement. Moreover, to identify possible candidates for RO preservation, 
clinicopathological factors predicting RO involvement at APE must be identified. 
A few groups have investigated RO involvement at APE but most cohorts 
were rather small or included all types of histology.[5–10] As a result, data 
on risk factors for RO involvement are limited.[10] In this study we focused 
on the incidence of RO involvement in what is to our knowledge the largest 
reported cohort of female patients who underwent APE for UC of the bladder. 
 
Materials and Methods
A total of 2,098 patients underwent radical cystectomy for bladder cancer with intent 
to cure at our institution between 1971 and 2008, of whom 458 (21.8%) were female. 
To focus on female patients with bladder UC, 47 (10.3%) with nonUC histology 
were excluded from analysis. The total cohort consisted of 411 female patients. 
Clinical and pathological characteristics of all patients were prospectively collected 
and stored in our institutional review board approved bladder cancer database. 
 A total of 267 patients underwent APE, including removal of the 
bladder, bilateral pelvic lymph nodes, uterus, fallopian tubes and anterior 
vaginal wall.[11] TAH-BSO was done before cystectomy in 94 patients and 45 
underwent partial resection sparing at least 1 ovary, while data were missing on 
5. The ovaries were spared in young patients and based on urologist discretion. 
 All cystectomy specimens were examined using the same pathological 
protocol. Multiple sectioning and histological evaluation was performed on the primary 
bladder tumor, bladder wall (adjacent and distant bladder mucosa of the primary 
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tumor), uterus, cervix, vagina, fallopian tubes, ovaries and lymph nodes. Pathological 
evaluation of all parts of the specimen followed a standardized protocol for prosection 
and microdissection. Pathological tumor staging and grading were standardized to 
the American Joint Committee on Cancer 2002 TNM classification and 1973 WHO 
recommendations, respectively.[12,13] Pathological subgroups were divided based 
on tumors that were organ confined (pTa, pTis, pT1, pT2a and pT2b, N0), extravesical 
(pT3a, pT3b and pT4, N0) and lymph node positive. Lymphovascular invasion was 
defined as tumor cells in an endothelium lined space with no underlying muscular walls. 
 All patients were routinely followed postoperatively at 4-month intervals 
in year 1, 6-month intervals in year 2 and annually thereafter. Median follow-
up was 12.2 years (range 0.1 to 35.5). From the whole cohort 11 patients who 
were lost to follow-up were censored from analysis at the last follow-up date. 
 Time to OS was calculated from the date of radical cystectomy to the date of 
death from all causes. RFS was calculated from the date of radical cystectomy to the date 
of first documented clinical recurrence or the date of death, whichever occurred first. If 
lost to follow-up before recurrence, patients were censored at the date of last follow-up. 
A Kaplan-Meier curve was used to calculate survival functions. Chi-square analysis 
was performed to test associations between clinicopathological factors and 
RO involvement. Statistical analyses were performed using SAS®, version 9.2. 
 
Results
Of the 411 female patients with bladder UC, 267 underwent APE at cystectomy and 20 
(7.5%) had RO involvement (Table 1). Ten patients (3.8%) had vaginal involvement 
only, 2 (0.7%) had cervical involvement only and 1 (0.3%) had uterine involvement only. 
Seven patients (2.6%) had multiple reproductive organs involved. In 1 patient with tumor 
involvement of the fallopian tubes and deep cervix the ovary was also involved. This was 
the only case of ovarian involvement. In addition, in a patient with vaginal and cervical 
involvement, the urethra was positive for UC. In all cases of RO involvement direct tumor 
extension was the mechanism of involvement. 
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Table 1: Reproductive organ involvement in the present study and the literature
No. of 
pts
Histo-
logy
RO involvement (%)
Overall Uterus 
only
Vagina 
only
Cervix 
only
Multiple 
ROs
Salem et al. 5 250 All 12 (4.8) 1 (0.4) 11 (4.4) 0 0 
Chang et al. 6 68 All 2 (5.0)* 2 (5.0) 0 0 0 
Groutz et al. 7 37 All 1 (2.7) 1 (2.7) 0 0 0 
Chen et al. 8 115 TCC 6 (5.2) 0 2 (1.7) 1 (0.9) 3 (2.6)**
Varkarakis et al. 9 52 TCC 3 (5.8) 1 (1.9) 1 (1.9) 0 1 (1.9)
Ali-El-Dein et al. 10 98 TCC 7 (7.1) - - - -
Present series 267 TCC 20 (7.5) 1 (0.3) 10 (3.8) 2 (0.7) 7 (2.6)***
RO = reproductive organ; TCC = transitional cell carcinoma
*  Excluding third patient with primary uterine sarcoma with incidence based on 40 patients 
 with intact ROs removed.
**  Also urethral involvement in 2 patients 
***  Also ovarian involvement in 1 patient
 
Table 2 lists the clinical and histopathologic features of patients with RO involvement. A 
review of this cohort revealed a median age of 71 years (range 38 to 89). Of the patients 
95% had a high grade tumor. Clinical staging was done using bimanual examination and 
radiological imaging, mostly computerized tomography, in all patients preoperatively. 
Clinical stage T4a was diagnosed in 5 patients (25%), while 10 (50%) were thought to have 
organ confined disease preoperatively. Greater than 90% of the cases were treated in the 
computerized tomography era. Lymph node positive disease was found in 12 patients (60%). 
 Three (15%) and 7 patients (35%) underwent neo-adjuvant and adjuvant 
chemotherapy, respectively. Only 1 patient (5%) underwent orthotopic diversion. As 
expected, patients without RO involvement had less frequent lymph node involvement 
(24%) and a higher percent of orthotopic diversion (43%). 
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Table 2: Baseline characteristics of total study cohort 
Variable No of pts with RO 
involvement (%)
No of pts without RO 
involvement (%)
Total 20 391
Age
Less than 60  
 60-69 
 70-79 
 Greater than 80
 
6 (30) 
3 (15) 
6 (30) 
5 (25)
 
94 (24.0) 
143 (36.6) 
114 (29.2)
40 (10.2)
Urinary diversion
Orthotopic 
Non-orthotopic
 
1 (5) 
19 (95)
 
168 (43.0) 
223 (57.0)
Clinical tumor stage
pT2 or less 
Greater than pT2 
 
10 (50) 
10 (50)
 
370 (94.7) 
21 (5.4)
Pathological tumor stage
pT0-pTis 
pT1 
pT2a 
pT2b 
pT3a 
pT3b 
pT4a 
pT4b
 
0 
0 
0 
0 
0 
0 
19 (95) 
1 (5)
 
86 (22.0) 
62 (15.9) 
35 (9.0) 
62 (15.9) 
43 (11.0) 
100 (25.6) 
0  
3 (0.8)
Pathologic subgroups
pT0-2,pN0 
pT3-4, pN1-3 
pTany, pN1-3 
 
0  
8 (40) 
12 (60)
 
220 (56.3) 
76 (19.4) 
95 (24.3)
Tumor grade
Low 
High
 
1 (5.0) 
19 (95)
 
61 (15.6) 
330 (84.4)
Concomitant Cis
Present 
Absent
 
9 (45) 
11 (55)
 
217 (55.5) 
174 (44.5)
Multifocal disease
Present 
Absent
 
16 (80) 
4 (20)
 
274 (70.1) 
117 (29.9)
Lymphovascular invasion
Present 
Absent
 
10 (50) 
10 (50)
 
119 (30.4) 
272 (69.6)
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Margin status
Positive 
Negative
 
1 (5) 
19 (95)
 
2 (0.5) 
389 (99.5)
Urethral involvement
Present 
Absent 
Missing
 
1 (5.0) 
16 (80.0) 
3 (15.0)
 
4 (1.1) 
356 (91.0) 
31 (7.9)
Neo-adjuvant radiotherapy
Yes 
No
 
3 (15) 
17 (85)
 
25 (6.4) 
366 (93.6)
Neo-adjuvant chemotherapy
Yes 
No
 
3 (15) 
17 (85)
 
18 (4.6) 
373 (95.4)
RO = reproductive organ
 The clinical variables associated with RO involvement were hydronephrosis 
and a palpable mass (each p < 0.001). Hydronephrosis was present in 13 patients and a 
palpable mass was reported in 10 of 20. Of pathological factors in the radical cystectomy 
specimen associated carcinoma in situ, multifocality and lymphovascular invasion had no 
significant association with RO involvement. However, lymph node positive disease was 
associated with RO involvement (p < 0.001). Due to few patients with RO involvement, 
we could not analyze whether any associated variables had an independent association. 
 Disease recurred in 14 patients (70%) with RO involvement at a median of 7 
months (range 1 to 22). Five of these patients (25%) had local recurrence, which was 
biopsy proven when suspicious or equivocal, and 9 (45%) had distant metastases. Table 
3 shows a lower recurrence rate in female patients without RO involvement, as expected. 
Overall survival at 5 years was 56.8% for patients without RO involvement, which was 
significantly higher than the 8.8% in those with RO involvement (p <0.0001, figure 1A). 
Single RO involvement was present in 13 patients, of whom 8 died of bladder cancer. Six 
patients had 2 ROs involved, of whom 4 died of disease. The patient with involvement 
of 3 ROs also died of disease. Two and 5-year RFS in patients without RO involvement 
was 75.7% and 62.2%, respectively. In patients with RO involvement all 14 recurrences 
developed within 2years, resulting in a 2-year RFS of 14.9% (p < 0.001,figure 1B).
MaxThesis.indb   56 27-10-15   20:39
57
p
a
r
t i
i
Table 3: Overall survival and recurrence free survival stratified by reproductive organ 
involvement 
RO- involvement No RO involvement Total cohort
No of pts 20 391 411
Mean % overall survival (±SE)
2 year 29.4 ± 10.8 73.0 ± 2.3 71.0 ± 2.3
5 year 8.8 ± 7.7 56.8 ± 2.6 54.7 ± 2.6
Mean % recurrence free 
survival (±SE)
2 year 14.9 ± 9.5 75.7 ± 2.3 73.2 ± 2.3
5 year 14.9 ± 9.5 62.2 ± 2.7 60.1 ± 2.7
RO = reproductive organ; SE = standard error
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Figure 1: Overall survival (a) and recurrence free survival (b) of patients with (green 
curves) and without (blue curves) reproductive organ involvement (RO)
RO involvement 0yr 1yr 2yr
No events 0 10 4
No at risk 20 7 2
RO involvement 0yr 1yr 2yr
No events 0 9 4
No at risk 20 10 5
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Discussion
Anterior pelvic exenteration in females includes removal of the internal genitalia and 
causes a significant impact on quality of life. The functional and sexual impairments 
described include loss of libido, difficult intromission and lack of orgasm.[2,14] 
Improvement in surgical techniques with an increasing number of females undergoing 
orthotopic diversion has resulted in excellent functional and oncological outcomes in well 
selected patients.[14,15] 
 Despite advances in functional outcomes, little improvement has been made in 
preserving sexual function with routine removal of the ROs as the standard of care. RO 
preservation while performing orthotopic diversion is feasible and decreases the risk of 
neobladder-vagina fistula.[4,16] However, oncological safety has not been extensively 
studied. In the current series using a large, homogeneous cohort of 411 female patients 
267 underwent TAH-BSO at cystectomy, of whom 7.5% had RO involvement. Although a 
few groups have reported this topic with an incidence rate of between 2.7% and 5.8%, 
the cohorts have been rather small and/or included all histological types. [5–10] In the 
large series of 609 female patients undergoing cystectomy reported by Ali-El-Dein et al 
only 16.1% had UC (Table 1).[10] However, the incidence of RO involvement depended on 
histological tumor type. A significantly higher incidence was found in patients with UC than 
in those with squamous cell carcinoma (7.1% vs 1.8%). In smaller studies of UC only Chen 
[8] and Varkarakis [9] et al reported similar incidence rates of 5.2% and 5.8%, respectively. 
 We found the vagina to be the most frequently involved sexual organ. It was 
involved in 14 patients, of whom 10 had vaginal involvement only, while 4 had vaginal 
combined with other RO involvement. This corresponded to an overall incidence of 
5% of all cystectomy cases. In 15 patients (75%) UC was located at the posterior or 
the base of the bladder, suggesting that direct invasion may account for most RO 
involvement. Our finding is fairly consistent with those in the other UC only series 
by Chen [8] and Varkarakis [9] et al, in which the vagina was involved as a single 
organ or in combination with other organs in 4.3% and 3.8% of cases, respectively. 
 Survival of patients with RO involvement is generally poor. Five-year RFS 
was 14.9% in patients with RO involvement compared to 62.2% in those without RO 
involvement. A total of 14 patients (70%) in the RO group had recurrence, which was local 
in 5 and distant in 9, all within 2 years after APE with a poor survival outcome (fig. 1). 
We found no late recurrences at a median follow-up of more than 12 years. These poor 
outcomes in patients with RO involvement were expected and underscore the need for 
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aggressive treatment. Based on low overall incidence rates of RO involvement, it was 
suggested that routine removal of ROs would be unnecessary.[10] However, with RO 
involvement in approximately 1 of 13 women with 30% 2-year OS, we believe that preserving 
ROs in unselected female patients is not oncologically safe. However, we think that a 
subset of female patients may benefit from RO preservation. Unfortunately, identifying 
these patients remains a challenge with clinical under staging as a major drawback. 
 In this study 10 patients (50%) had RO involvement when the tumor was believed 
to be organ confined preoperatively (cT2) (50% up staging). To identify patients suitable 
for RO preservation, some groups investigated the association between histopathological 
variables and RO involvement. [9,10] Only 1 series included a sufficient number of patients 
to show an association between clinicopathological factors and RO involvement. [10] 
Ali-El-Dein et al found that higher tumor grade and lymph node metastatic disease were 
associated with RO involvement. They recommended not preserving ROs in these patients. 
 Although we agree that patients with lymph node metastases are not suitable 
candidates, this cannot adequately be determined preoperatively. Also, some patients with 
high grade disease may be suitable candidates for RO preservation but more preoperative 
factors must be analyzed. We found that hydronephrosis and a palpable mass were 
associated with RO involvement. Unfortunately, we did not identify a sufficient number 
of patients for multivariable analysis to investigate whether these variables are, in fact, 
associated with RO involvement. This clearly outlines the need for a large cohort and a multi-
institutional study to investigate which female patients are suitable for RO preservation. 
 The majority of RO involvement was a result of direct tumor invasion. Thus, 
when extensive disease is suspected at preoperative evaluation, RO preserving surgery 
should not be performed. We also emphasize that in the modern neo-adjuvant era 
neo-adjuvant chemotherapy is recommended for patients with preoperative suspicion 
of RO involvement. This might decrease the risk of pathological RO involvement. 
 The incidence of ovarian involvement is extremely rare. Of almost 1,000 female 
patients only 2 with ovarian involvement have been described (table 1). Groutz et al 
reported metastatic disease in 1 patient with a preserved ovary 2 years after cystectomy. 
[7] They stated that suboptimal initial treatment and a significant subsequent delay in 
cystectomy might have contributed to this outcome. The second patient with ovarian 
involvement was found in the current study. In this case all represented sections of the 
bladder, cervix and fallopian tubes were also involved with tumor. This is consistent 
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with findings that direct invasion is the mechanism of RO involvement. Therefore, 
ovarian preservation appears to be oncologically safe, especially in young females, 
if the tumor is not found to extensively invade outside the bladder intra-operatively. 
 Study limitations include its retrospective nature. Because some 
patients underwent TAH-BSO before cystectomy, the incidence rate of uterine 
involvement may have been underestimated. Also, oophorectomy was not 
routinely performed but rather based on urologist decision. However, because 
ovarian involvement is rare, it is unlikely that a significant number of cases 
would have been identified. Also, quality of life data are not discussed and the 
true effect of RO sparing on sexual activity may need more future investigation. 
Conclusions
The incidence of RO involvement in a large, homogenous cohort of female patients 
undergoing APE for bladder UC was approximately 7.5% with the vagina the most 
commonly involved organ. A palpable mass and hydronephrosis were among the 
preoperative clinical factors univariabely associated with RO involvement. Larger 
multi-institutional studies may be needed to determine additional risk factors for RO 
involvement and probably define the eligibility criteria for RO preservation.
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Abstract
Purpose
Survival data on urachal carcinoma are sparse due to the low prevalence of 
this cancer. We report urachal carcinoma clinical outcomes and prognostic 
factors in a large, population based cohort of patients with long term follow-up. 
 
Materials and Methods
Data were collected from the nationwide Netherlands Cancer Registry. Urachal carcinoma 
cases were also cross-referenced using the PALGA (Nationwide Network and Registry of 
Histology and Cytopathology) database. Pathology report summaries were reviewed. 
A total of 152 patients diagnosed with urachal carcinoma between 1989 and 2009 were 
included in analysis. The Sheldon staging system was used to classify urachal carcinoma. 
Median follow-up was 9.2 years. Primary outcomes were overall and relative survival. 
Prognostic factors were calculated using univariable and multivariable hazard regression 
models.
Results
The incidence of urachal carcinoma was 0.2% of all bladder cancers. A total of 45 patients 
(30%) presented with lymph node or distant metastasis. Five-year overall and relative 
survival was 45% and 48%, respectively. On multivariable analysis prognostic factors for 
impaired survival were lymph node metastasis (HR 1.7, 95% CI 1.2–2.6), tumor growth 
in the abdominal wall, peritoneum and/or adjacent organs (HR 5.2, 95% CI 2.6 –10.3), 
distant metastasis (HR 5.3, 95% CI 2.8 –9.9) and macroscopic residual tumor (HR 5.2, 
95% CI 1.2–21.8). 
Conclusions 
Urachal carcinoma is rare, accounting for 0.2% of all bladder cancers. Many patients 
present with advanced disease. The prognosis of urachal carcinoma depends 
mostly on tumor stage, particularly the presence or absence of metastatic disease. 
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Abbreviations and Acronyms 
GBA  = Population Municipality Registry 
NCR  = Netherlands Cancer Registry 
OS  = Overall survival 
PSM  = Positive surgical margin 
RS  = Relative survival 
UraC  = Urachal carcinoma
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Introduction
The urachus is a canal that connects the allantois to the fetal bladder. During fetal 
development the urachal lumen is obliterated into a fibromuscular cord stretching 
between the umbilicus and the bladder dome. Urachal anomalies such as UraC 
can develop if the urachal canal partly persists into adulthood. However, urachal 
malignancies are rare and account for less than 0.5% of all bladder cancers. [1] 
Patients with UraC often present with advanced disease that cannot be treated with surgery. 
While the reported results of a 5-fluorouracil/cisplatin based chemotherapy regimen are 
promising, [2] there is currently no standardized effective treatment for metastasis. Since 
UraC is also rather insensitive to radiotherapy, patients with metastasized UraC are likely to 
have a poor prognosis. Thus, adequate surgery is crucial in patients with localized disease. 
 Nonetheless, the optimal surgical procedure must be further defined. Partial 
cystectomy provides oncological outcomes similar to those of radical cystectomy.[1,3,4] 
However, it was suggested that umbilectomy and lymphadenectomy should be an integral 
part of surgery.[2–5] Although some groups have reported on UraC outcomes, most data 
are from referral centers with potential referral bias and fairly few patients. Moreover, 
even at referral centers primary treatment is heterogeneous. [4] For an uncommon 
disease such as UraC population based data are valuable since they provide unbiased 
epidemiological insight into the disease. Furthermore, with a larger study population 
and consequently higher power prognostic factors are more likely to be identified. 
 To our knowledge no population based study of UraC has been performed in 
Europe. We present data from a large, population based study with long term follow-up 
to provide insight into the clinical outcomes and prognostic factors of this rare disease. 
 
Materials and Methods
Data were collected from the nationwide, population based NCR. All primary cases 
documented with the ICD-3 topography code for urachus (C67.7) between 1989 and 2009 
were selected for analysis. Also, to cross-reference UraC cases reported in the NCR an 
additional search for UraC was performed in the PALGA database. [5] This database contains 
all reports generated by the pathology departments in The Netherlands. PALGA data were 
then matched with NCR data and summaries of all histopathology reports were reviewed. 
 Cases were included in study when the pathologist reported that the 
tumor was of urachal origin. Four patients with a history of gastrointestinal or 
urological malignancy were excluded to minimize the risk of including those 
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with nonprimary UraC. The final cohort consisted of 152 patients with UraC, 
including 98 from NCR and PALGA, 28 from NCR only and 26 from PALGA only. 
 UraC was staged according to the Sheldon staging system, which defines 4 stages, 
including I—no invasion beyond urachal mucosa, II—invasion confined to the urachus, III—
local extension into bladder (IIIA), abdominal wall (IIIB), peritoneum (IIIC) or viscera other 
than the bladder (IIID) and IV—metastasis to regional lymph nodes (IVA) or distant sites 
(IVB).[1] We defined 4 main treatment groups, that is 1) surgery, including patients who also 
received radiotherapy and/or chemotherapy, 2) radiotherapy without surgery, including 
those who also received chemotherapy, 3) chemotherapy and 4) other/no treatment. 
 Follow-up was completed until February 1, 2011 by record linkage to the nationwide 
GBA, which holds the vital status of all Dutch residents. OS was calculated using the Kaplan-
Meier survivor estimator. Since cause of death is not available in NCR or GBA, cancer 
specific survival could not be calculated. Instead, RS (which is the ratio of observed to 
expected survival in the general population of The Netherlands of the same age and gender) 
was calculated according to Dickman et al [6] as a good approximation of cancer specific 
survival. Univariable and multivariable hazard regression models were used to identify 
prognostic variables. All analysis was done using STATA®. The study required no formal 
ethics committee approval; instead the principles of the Helsinki Declaration were followed. 
 
Results
 
Cohort Characteristics
A total of 152 UraC cases were diagnosed with a median of 7.5 cases annually. UraC 
accounted for 0.2% of all bladder cancers and 20% of all bladder adenocarcinomas in 
The Netherlands. There was a slight increase in UraC diagnoses with time with 64 UraC 
cases diagnosed between 1989 and 1999, and 88 diagnosed between 2000 and 2009. 
Table 1 lists baseline characteristics. Of UraC cases 94% were adenocarcinoma. The 
male-to-female ratio was 1.4:1. Median patient age was 58 years (range 20 to 90). A total 
of 45 patients (29.6%) had metastatic disease at presentation, including 15 (33.3%) 
with regional lymph node metastasis only, which was clinically apparent in 10 and 
discovered after lymphadenectomy in 5. The other 30 patients (66.6%) presented with 
distant metastasis. The peritoneum was the most common site of distant metastasis. 
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Primary Treatment
A total of 104 patients (68.4%) were treated only at community hospitals. Overall 118 
patients (77.6%) underwent surgery, which was partial cystectomy in 81. Adjuvant or 
neo-adjuvant radiotherapy was administered in 30 operated patients (25.4%). Of the 100 
patients with clinical stage I–IIIA disease 94 (94%) were treated with surgery and 6 (6%) 
received primary radiotherapy. Treatment for stage IVB disease in 30 patients was rather 
heterogeneous and only 10 (33.3%) received systemic chemotherapy. For 5 patients 
this was the primary treatment while another 5 underwent chemotherapy combined 
with surgery and/or radiotherapy (Table 2). Information on lymphadenectomy status 
was available for 111 of 118 operated patients. Lymphadenectomy was done in 43 cases 
(36.4%) (Table 1).
Table 1: Baseline characteristics of 152 patients with urachal carcinoma 
No pts (%)
Gender
Male 
Female
 
88 (57.9) 
64 (42.1)
Age at diagnosis
Less than 45 
45-59 
60-75 
Greater than 75
 
30 (19.7) 
53 (34.9) 
56 (36.8) 
13 (8.6)
Tumor differentiation
Well  
Moderate 
Poor 
Not available 
13 (8.6) 
38 (25.0) 
34 (22.4) 
67 (44.0)
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Sheldon tumor stage* 
I 
II 
III 
IIIA 
IIIB 
IIIC 
IIID 
IV 
IVA 
IVB
 
0 
22 (14.5) 
85 (55.9)
74 (48.7) 
9 (5.9) 
1 (0.7) 
1 (0.7)
45 (29.6)
15 (9.9) 
30 (19.7)
Histology
Adenocarcinoma not otherwise specified 
Mucin-producing adenocarcinoma 
Singet ring cell adenocarcinoma  
Transitional cell carcinoma 
Undifferentiated carcinoma
 
50 (32.9) 
73 (48.0) 
20 (13.2) 
7 (4.6) 
2 (1.3)
Primary treatment
Surgery with/without radiotherapy or chemotherapy 
 - Urachal excision or TURBT 
 - Partial cystectomy 
 - Radical cystectomy 
Radiotherapy with/without chemotherapy 
Chemotherapy 
None/ no data available
 
118 (77.6)
17 (11.1) 
81 (53.3) 
20 (13.2)
10 (6.6) 
 8 (5.3) 
16 (10.5)
Lymph node dissection**
Yes 
No 
No data available
 
43 (36.4) 
68 (57.6) 
7 (5.9)
Surgical margin status**
Negative 
Microscopic positive 
Macroscopic positive 
Not available
 
76 (64.4) 
  9 (7.6) 
  6 (5.1) 
27 (22.9)
Treated a tertiary referral center
Yes 
No
 
48 (31.6) 
104 (68.4)
* Postoperative stage but clinical stage in non-operated patient 
** Operated patients only (n=118)
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Table 2: Treatment by clinical Sheldon stage 
No. 
Stage 
II (%)
No. 
Stage 
IIIa (%)
No. 
Stage 
IIIb-IIId 
(%)
No. 
Stage 
IVa (%)
No. 
Stage 
IVb (%)
Total No. 
(%)
Urachal excision or transurethral 
bladder tumor resection 
8 (15) 6 (13) 2 (17) - 1 (3) 17 (11)
Partial cystectomy 39 (74) 29 (62) 1 (8) 6 (60) 6 (20) 81 (53)
Radical cystectomy 5 (9) 7 (15) 4 (33) 1 (10) 3 (10) 20 (13)
Radiotherapy 1 (2) 5 (11) 1 (8) 1 (10) 2 (7) 10 (7)
Chemotherapy - - 1 (8) 2 (20) 5 (17) 8 (5)
No treatment / unknown - - 3 (25) - 13 (43) 16 (11)
Totals 53 (100) 47 (100) 12 (100) 10 (100) 30 (100) 152 (100)
Survival and Predictors of Survival
Median follow-up was 9.2 years. Median overall survival was 48 months. Three, 5 and 10-year 
OS was 55%, 45% and 39%, and 3, 5 and 10-year RS was 57%, 48% and 46%, respectively. 
Five-year RS was 37% (95% CI 20–54) at ages less than 45 years, 65% (95% CI 49–77) at 45 
to 59 years, 43% (95% CI 27–59) at 60 to 74 years and 17% (95% CI 1–55%) at 75 years or 
greater. Stage III–IV disease was most common (47%) in patients younger than 45 years. 
 Statistical significant survival differences were found among stages II or less, IIIA 
and IIIB or greater, respectively (p <0.0001, fig. A). For stage IIIA disease no significant 
survival difference was found for patients with bladder invasion only vs perivesical/
urachal fat invasion (p = 0.96). In patients with metastatic disease (stage IV) 5-year RS 
was 15% compared to 61% in those with nonmetastatic disease (stage III or less). Radical 
cystectomy did not provide an outcome superior to that of partial cystectomy (HR 1.00, 
95% CI 0.45–2.21, p = 0.996, fig. 1E). 
 On univariable analysis factors prognostic for OS were tumor growth in the abdominal 
wall, peritoneum and/or adjacent organs, lymph node metastasis, distant metastasis, 
microscopic PSM, macroscopic residual tumor, poor differentiation tumor grade and 
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signet ring cell adenocarcinoma subtype (Table 3). On multivariable analysis tumor 
growth in the abdominal wall, peritoneum and/or adjacent organs (HR 5.13, 95% CI 
2.57–10.30, p < 0.001), lymph node metastasis (HR 1.73, 95% CI 1.17–2.56, p < 0.006), 
distant metastasis (HR 5.28, 95% CI 2.81–9.94, p < 0.001) and macroscopic residual 
tumor (HR 5.20, 95% CI 1.23–21.84, p = 0.024) were independently associated with 
decreased OS (Table 3).
Table 3: Prognostic factors for overall survival
No. 
of pts
Univariable analysis Multivariable analysis
HR (95% CI) p-value HR (95% CI) p-value
Age
Less than 45 
50-59 years
60-74 years
Greater than 75 
30
53
56
13
1 
0.54 (0.29 – 0.99)
1.14 (0.65 – 2.00)
2.54 (1.20 – 5.40)
0.046
0.64
0.015
1
0.90 (0.45 – 1.81)
1.73 (0.88 – 3.42) 
4.36 (1.70 – 11.1)
0.78
0.11
0.002
Tumor stage **
T1-T2 
T3 
T4 
Tx 
51
55
21
25
1
1.21 (0.71 – 2.08)
5.71 (3.12 – 10.47)
0.48
< 0.001
1 
1.10 (0.62 – 1.95)
5.13 (2.57 – 10.3)
0.73
< 0.001
Histology
Adenocarcinonoma (not specified)
Mucin-producing adenocarcinoma 
Signet ring cell adenocarcinoma 
Transitional cell carcinoma
Undifferentiated carcinoma 
50
73
20
7
2
1
0.63 (0.39 – 1.02)
1.86 (1.03 – 3.36)
0.54 (0.13 – 2.27)
0.66 (0.09 – 4.89)
0.06
0.040
0.40
0.69
1
0.78 (0.45 – 1.36)
0.89 (0.41 – 1.93)
0.65 (0.15 – 2.86)
1.48 (0.18 – 12.07)
0.38
0.78
0.57
0.71
Tumor grade
Well 
Moderate
Poor
Not available
13
38
34
67
1
1.35 (0.50 – 3.63)
2.71 (1.04 – 7.13)
0.55
0.042
1
0.90 (0.32 – 2.54)
1.72 (0.56 – 5.21)
0.85
0.34
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Surgical margins *
Negative 
Microscopic positive 
Macroscopic positive 
Not available
76
9
6
27
1
3.64 (1.58 – 8.41)
8.26 (3.28 – 20.80)
0.002
< 0.001
1
2.11 (0.70 – 6.32)
5.20 (1.23 – 21.84)
0.18
0.024
Lymphadenectomy performed *
No 
Yes
Not available
68
43
7
1
1.09 (0.56 – 2.11) 0.80
1
0.80 (0.34 – 1.86) 0.59
Lymph node metastasis
No 
Yes 
137
15
1
2.40 (1.74 – 3.32) < 0.001
1
1.73 (1.17 – 2.56) 0.006
Distant metastasis 
No 
Yes 
122
30
1
3.49 (2.16 – 5.62) < 0.001
1
5.28 (2.81 – 9.94) < 0.001
Treatment hospital 
Community hospital
Referral center 
104
48
1
0.71 (0.45 – 1.14) 0.16
1
0.79 (0.45 – 1.40) 0.42
HR = Hazard ratio; 95%CI = 95% confidence interval
* Operated patients only 
** Postoperative stage but clinical stage in non-operated patients
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Figure 1: Overall survival in patients with urachal carcinoma by  
A) Sheldon stage    B) differentiation
C) surgical margin status    D) lymphadenectomy 
E) type of cystectomy  
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Discussion
Using a large, nationwide cohort with long-term follow-up this study provides valuable 
clinical information. Up to 30% of patients presented with regional or distant metastasis 
with subsequent poor survival outcomes. Distant metastasis was the most important 
prognostic factor and it was most common (47%) in patients younger than 45 years. 
These findings suggest that increased awareness of UraC is important, particularly 
in younger patients with urinary symptoms, since detection of UraC at an early stage 
benefits survival. Furthermore, no significant survival difference was found between 
patients with lymph node metastasis and those with distant metastasis. Survival 
in each group was poor with fewer than 20% surviving after 5 years. This clearly 
underlines the need for effective systemic chemotherapy regimens.[4,7] In patients 
with localized disease a long-term OS rate of up to 70% was reported in referral center 
series.[3,4]In our study using population based data we found a lower OS rate of 45% 
after 5 years. This finding is fairly similar that in a Canadian population based study 
with a 51% 5-year OS rate. [8] The difference between population and hospital based 
outcomes may have been caused by selective referral of patients to specialized centers. 
 Since most UraCs are adenocarcinoma invading the bladder dome, 
partial cystectomy may provide oncological safety and efficacy similar to those of 
radical cystectomy. While to our knowledge a randomized trial comparing these 2 
treatments is lacking, current literature suggests that partial cystectomy provides 
good oncological results. Herr et al reported excellent outcomes for partial 
cystectomy in a series of 50 patients. [4] Ashley et al compared the 2 treatments 
and found no significant difference in survival [2], similar to our findings (fig. 1E). 
 A number of studies demonstrate the importance of en bloc urachal resection at 
partial cystectomy, including the umbilicus, to provide optimal local control. [1–4] In our 
study we could not identify whether umbilical resection was done. Nonetheless, based on 
the current literature, en bloc resection of the urachal ligament including the umbilicus is 
important to achieve optimal local control. Data on the role of lymphadenectomy in UraC is 
limited. In 1 series some patients with node positive disease were cured by partial cystectomy 
and lymphadenectomy, although the number of resected lymph nodes did not correlate 
with survival. [4] In our population based study lymphadenectomy was done in 36.4% of 
cases. In patients treated with lymphadenectomy no significant survival advantage was 
found. However, patients were not randomized to treatment, and detailed information on 
lymphadenectomy and adjuvant therapy was not available. Thus, we suggest that the role 
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of lymphadenectomy for UraC should be further investigated in a multi-institutional study. 
 The Sheldon staging system, which defines 8 stages, potentially offers 
greater prognostication than other, more simplistic classifications. [2,8] In our 
study and that by Herr et al [4] a significant survival difference was found between 
stages IIIA or less and IIIB or greater disease. However, in our series perivesical/
urachal fat invasion was considered stage IIIA since survival was comparable to that 
of bladder confined tumors but significantly higher than that of abdominal wall 
invasion (stage IIIB). Nonetheless, our study confirms the finding that peritoneal or 
abdominal wall invasion confers a poor prognosis that can rarely be cured by surgery. 
 PSM was proposed as an independent prognostic factor.[1,2,4] In the study 
by Herr et al only 17% of patients with PSM survived compared to 77% with negative 
surgical margins.[4] In our series, as expected, macroscopic residual tumor was 
independently associated with decreased survival. Microscopic PSM was prognostic 
on univariable analysis but it did not remain an independent prognostic factor on 
multivariable analysis. This effect is most likely attributable to a stronger prognostic 
value of lymph node and distant metastatic disease. Thus, we believe that achieving 
negative surgical margins is important for local control, as suggested by others.[1-3] 
 An interesting finding was that most patients with UraC were treated at 
community hospitals. This differs from the only study addressing this topic, in 
which the referral hospital-to-community hospital treatment ratio was fairly equal.
[8] As in that series, we found no significant survival advantage for patients treated 
at referral hospitals. However, as demonstrated, survival in patients with stage IV 
disease is poor and to our knowledge there is no effective standard chemotherapy 
regimen. Treatment at referral hospitals offers the potential advantage of including 
patients with metastasized disease in clinical trials to improve the outcome. 
 Although population based studies are valuable, we acknowledge inherent 
limitations. 1) Detailed information was not always available. This was specifically true for 
umbilical resection at cystectomy, which was reported to be important for local control. 2) 
Since the GBA registry does not hold information on recurrence or cause of death, we could 
not report treatment after recurrence or disease specific survival. As a proxy for disease 
specific survival, we used relative survival. 3) UraC was diagnosed by different pathologists. 
Review pathology was not possible since we had no access to pathology specimens. 
However, to make the best effort to detect true UraC cases NCR data were cross-referenced 
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with PALGA data and pathology report summaries were reviewed. 4) Since this study was not 
randomized, confounding by indication may have influenced the effect of prognostic factors. 
 
Conclusions
Surviving this rare disease mainly depends on tumor stage, particularly the presence 
or absence of metastatic disease. Patients with localized disease can be treated well 
with surgery when umbilical resection is performed and negative surgical margins 
are pursued. If that is the case, partial cystectomy likely provides outcomes similar 
to radical cystectomy. The role and template of lymphadenectomy must be further 
investigated, preferably in a multi-institutional manner. Patients who present with 
distant metastasis have a poor prognosis. Early detection of UraC and the development 
of effective chemotherapeutic regimens are key factors to improve survival. 
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Abstract
Objectives
To investigate the role and extent of lymph node dissection (LND) in patients undergoing 
radical cystectomy for clinical non-muscle invasive bladder cancer (NMIBC).
Materials and Methods
Prospectively collected data of 637 patients who underwent radical cystectomy with 
intent-to-cure for urothelial carcinoma of the bladder between 2002 and 2008 were 
examined. Inclusion criteria were (a) clinical stage Ta, Tis-only or T1, (b) muscle-presence 
at diagnostic transurethral resection in clinical T1 patients, (c) no prior diagnosis of ≥T2 
disease, (d) no neo-adjuvant therapy and (e) lymphatic tissue sample submitted from 
all 13 pre-designated locations. Median follow-up time was 4.7 years. Recurrence-free 
survival (RFS) and overall survival (OS) were reported.
Results
A total of 114 patients were included of whom 9 patients (7.9%) had LN metastases (LNM). 
LNM were present in 6/67 (9.0%) patients with cT1, 3/25 (12.0%) patients with cTis-only 
and none of the 22 patients with cTa. Three out of 9 node-positive patients (33.3%) had 
LNM proximal to the aortic bifurcation. No skip metastases were found. After RC, 27 
patients (23.7%) were upstaged to muscle-invasive disease; of whom 16.7% had cT1, 
2.6% had cTa and 4.4% had cTis-only. Of the remaining 87 patients with pathological 
NMIBC, 1 patient (1.1%) had LNM, limited to the true pelvis. Five-year RFS was 82.3%, 
81.5% and 62.0% in patients with pathological NMIBC, clinical NMIBC and pathological 
muscle-invasive bladder cancer, respectively.
Conclusions
Routine LND is important in patients with cT1 and cTis-only bladder cancer, but may 
have limited value in patients with cTa. LNM beyond the boundaries of a standard LND 
occurred in up to one-third of node-positive patients. In the absence of skip metastases, 
however, performing a standard LND would correctly identify all node-positive patients. 
Whether removal of LNM proximal to the common iliac vessels provides a survival benefit 
remains to be evaluated in future prospective studies
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Introduction
Most patients who present with urothelial cancer (UC) of the urinary bladder have 
non-muscle invasive bladder cancer (NMIBC; Ta, Tis-only, T1). Despite intravesical 
treatment, patients with NMIBC are at risk of progression to muscle-invasive bladder 
cancer (MIBC). The risk of progression varies from less than 5% in low-risk patients 
up to 40-50% in high-risk patients with MIBC. [1] There is accumulating evidence 
that patients with progression from NMIBC to MIBC have a worse prognosis when 
compared with patients who had MIBC at initial presentation. [2] Hence, there is an 
increasing trend towards performing early radical cystectomy (RC) in NMIBC patients 
with a high risk of progression and/or patients who have failed intravesical therapy. 
 It is estimated that between 6-15% of patients who undergo RC for clinical NMIBC 
(cNMIBC) harbor lymph node metastases (LNM).[3-5] Although performing lymph node 
dissection (LND) in patients with cNMIBC may be beneficial, LND is often not performed, 
even in patients with MIBC.[6] In addition, it is unknown whether the template of LND in 
patients with cNMIBC should be similar to clinical MIBC, as lymph node (LN) mapping data 
is lacking. A recent study, however, suggested that with increasing clinical stage, more 
LNs should be removed, with a minimum of six LNs for cTa-cTis disease and a minimum of 
25 LNs in patients with ≥cT2 disease. [7] One caveat to this study’s conclusion is that the 
number of retrieved LNs cannot be translated into a reproducible surgical template as the 
total number of LNs is influenced by several factors. [8,9] In fact, a recent study suggested 
the thoroughness of LND to be of more importance than the number of removed LNs. [10] 
Thus, defining the optimal template of LND would serve the urologist as a better guideline. 
 In this study, we aimed to investigate the incidence and distribution of LNM in 
patients undergoing RC and LND for cNMIBC. In addition, we report survival outcomes 
for this cohort using a standardized ‘super’extended LND to the level of the inferior 
mesenteric artery takeoff.
Materials and Methods
 
Cohort selection
A total of 637 patients underwent RC with intent-to-cure for urothelial carcinoma (UC) 
of the bladder between May 2002 and December 2008. Included patients met all of the 
following criteria: (a) clinical stage Ta, Tis-only or T1 prior to RC, (b) muscle-presence at 
diagnostic transurethral resection of the bladder tumor (TURBT) in clinical T1 patients, 
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(c) no prior diagnosis of MIBC, (d) no neo-adjuvant chemotherapy or radiotherapy and 
(e) lymphatic tissue sample submitted from all 13 pre-designated locations. A total of 
114 patients were included in this study. Patients either had high-risk of progression 
(i.e. high grade tumor and/or concomitant Tis and/or lymphovascular invasion (LVI) at 
TURBT) and underwent early cystectomy or had recurrent/persistent disease despite 
intravesical therapy. All patients underwent ‘super’extended LND including the following 
boundaries: the inferior mesenteric artery takeoff proximally, the genitofemoral nerves 
laterally, the circumflex iliac vein and LN of Cloquet distally, the internal iliac vessels 
posteriorly, including the obturator fossa and presciatic (fossa Marcille) LNs, and the 
presacral LNs overlying the sacral promontory. LNs were submitted in 13 pre-designated 
anatomically defined packets as described previously and shown in Figure 1. [10] 
 
Clinical and pathological staging
Pre-operative clinical staging was based on tumor stage at TURBT specimen and 
results of cross sectional imaging and physical examination. Pathology specimens 
were routinely reviewed centrally at our institution. Multiple sections and histological 
evaluation were performed on the primary bladder tumor, bladder wall, and all LNs. 
LNs were identified visually and by palpation without clearing techniques, solvents 
or special stains. Pathological tumor staging and grading were standardized to 
the 2010 TNM classification of the American Joint Committee on Cancer and 1973 
World Health Organization recommendations, respectively. [11,12] For analytical 
purposes, the location of LNM was divided in 3 levels as described previously. [10,13] 
 
Data management and statistical analysis
Data were prospectively collected by a dedicated data entry team, double-checked by an 
experienced database manager, and stored in our secured and review-board approved 
database. Median follow-up time was 4.7 years. Kaplan-Meier plots were used to estimate 
overall survival (OS) and recurrence-free survival (RFS). Recurrence of disease included 
local recurrence (pelvic, urethral and upper tract) as well as the development of distant 
metastasis. The log-rank test was used to compare subgroups of patients. The Cox 
proportional hazard model was used to test the association of multiple variables with 
recurrence. The Mann-Whitney-U test was used to test the association of non-parametric 
variables. The level of statistical significance was set at p < 0.05. All p-values are two-
sided. 
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Results
Of the 114 patients included in this study, 67 patients (58.8%) had clinical T1, 25 
patients (21.9%) clinical Tis-only and 22 patients (19.3%) clinical Ta. Concomitant 
carcinoma-in-situ was present in 29 patients (43.3%) with cT1 disease. A total of 
59 (51.8%) patients underwent intravesical treatment prior to RC. The median 
number of TURBTs prior to RC was 2 (range: 1-18). Median time from first TURBT 
and last TURBT to RC was 5.0 months and 1.7 months, respectively. Clinical 
and pathological features of all patients at the time of RC are listed in Table 1. 
 
Table 1: Study cohort characteristics 
Number of patients (%)
Total cohort 114 (100)
Age
65 years or less 
Greater than 65 
 
54 (47.4) 
60 (52.6)
Gender
Male 
Female
 
95 (83.3) 
19 (16.7)
Clinical tumor stage and gradea
Ta, low grade 
Ta, high grade 
Tis, high grade 
T1, low grade 
T1, high grade
 
7 (6.1) 
15 (13.2) 
25 (21.9) 
2 (1.8) 
65 (57.0)
Pathologic tumor stageb 
pT0  
pTa  
pTis  
pT1  
pT2a  
pT2b  
pT3a  
pT3b  
pT4a 
 
13 (11.4) 
8 (7.0) 
29 (25.4) 
37 (32.5) 
6 (5.3) 
12 (10.5) 
4 (3.5) 
3 (2.6) 
2 (1.8)
Pathologic tumor gradeb,c
Low grade 
High grade
 
14 (13.8) 
87 (86.1)
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Carcinoma-in-situb,d
Yes 
No
 
76 (66.7) 
38 (33.3)
Multifocal diseaseb
Yes 
No
 
53 (46.5) 
61 (53.5)
Lymphovascular invasionb
Present 
Absent
 
19 (16.7) 
95 (83.3)
Lymph node metastasesb
Yes 
No
 
9 (7.9) 
105 (92.1)
a) Based on transurethral resection specimen 
b) Based on radical cystectomy specimen 
c) 13 patients had no evidence of disease 
d) Includes patients with pTis-only
 A total of 9 patients (7.9%) had LNM and stratified by clinical stage, LNM were 
present in 6 patients with cT1(9.0%), 3 patients with cTis-only (12.0%) and none of the 
patients with cTa. Of the 6 cT1 patients with LNM, 3 patients underwent 1 TURBT (with 
muscle presence) and 3 patients underwent 2,4 and 5 TURBTs, respectively. Of the latter 
group, detrusor muscle was present in at least the last TURBT prior to RC. Of note, 1 
patient with cT1 and LNM had concomitant carcinoma-in-situ on TURBT specimen. 
The histopathological characteristics of all 9 node-positive patients are summarized 
in Table 2. 
Table 2: Characteristics of the 9 node-positive patients 
Number of patients (%)
Clinical stage and gradea
Ta, any grade 
Tis, high grade 
T1, low grade 
T1, high grade 
 
0  
3 (33.3) 
0 
6 (66.7)
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Histologic de-differentiationa
None 
Micropapillary
 
8 (88.9) 
1 (11.1)
Concomitant carcinoma-in-situa
Yes 
No
 
4 (44.4) 
5 (55.6)
Lymphovascular invasiona 
Present 
Absent 
Not mentioned in pathology report
 
2 (22.3) 
3 (33.3)  
4 (44.4)
Pathologic tumor stageb
pT0/Ta/Tis 
pT1  
pT2a  
pT2b  
pT3a  
pT3b  
pT4a 
 
0  
1 (11.1) 
1 (11.1) 
2 (22.2) 
1 (11.1) 
3 (33.3) 
1 (11.1)
Pathologic tumor gradeb
Low 
High
 
0  
9 (100)
Concomitant carcinoma-in-situb
Yes 
No
 
7 (77.8) 
2 (22.2)
Lymphovascular invasionb
Present 
Absent
 
7 (77.8) 
2 (22.2)
Highest level of node-positive disease 
Level 1 
Level 2 
Level 3
 
6 (66.6) 
0  
3 (33.3)
Number of positive lymph nodes
1 
2 
>2
 
1 (11.2) 
2 (22.2) 
6 (66.6)
a) Based on transurethral resection specimen. 
b) Based on radical cystectomy specimen.
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 Age (p = 0.41), gender (p = 0.35), multifocal disease (p =1.00), number of TURBTs 
prior to RC (p = 0.90),time from last TURBT to RC (p = 0.40), and tumor stage (cTa/cTis 
vs cT1; p = 0.73), tumor grade (p = 0.34), LVI (p = 0.34), concomitant carcinoma in situ 
(p = 1.00) on TURBT specimen were all not associated with the presence of LNM (n=9). 
 The median number of removed LNs was 70 in node-positive and 68 in node-
negative patients. Figure 2 shows the highest level of positive LNs in node-positive patients, 
both as part of the total cohort (N=114) and all patients with LNM (N=9). Three node-positive 
patients had level 3 as the highest level involved with LNM, of whom all patients had level 
2 and level 1 involvement as well. Of these patients, 2 patients had cT1 and 1 patient had 
cTis-only. Pathological stage was T2a in 1 patient and T3b in 2 patients. The 5-year RFS and 
OS estimates for all cNMIBC patients were 81.5% and 77.4%, respectively (Figure 3AB). 
 In total, 27 patients (23.7%) were upstaged to MIBC at RC. Upstaging occurred 
in 3/22 patients (13.6%) with cTa, 5/25 patients (20.0%) with cTis-only and 19/67 patients 
(28.4%) with cT1. Of the remaining 87 patients with pNMIBC, only 1 patient (1.1%) had LNM, 
all confined to level 1. Both concomitant carcinoma-in-situ and LVI were present on the 
TURBT specimen. Final pathology showed a pT1 tumor with concomitant carcinoma-in-situ. 
 Five-year RFS and OS in all patients with pNMIBC was 58.8% and 62.0%, 
respectively (Figure 3AB). Presence of LNM was associated with decreased survival on 
both univariable analysis (p < 0.001) and multivariable analysis (HR 3.38 (95% confidence 
interval 1.34 - 8.51); p < 0.001) correcting for stage, grade, age and LVI at RC.
MaxThesis.indb   90 27-10-15   20:39
91
p
a
r
t i
ii
Figure 1: Anatomical boundaries of lymph node packets and corresponding level of 
lymph node dissection
Figure 2: Highest level of positive lymph nodes in patients with node-positive disease 
at the time of radical cystectomy 
* No patients had level 2 as the highest level of nodal involvement, as all patients with level 2 involvement also had 
level 3 involvement
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Figure 3. (a) Recurrence-free survival  and (b) overall survival in patients with clinical 
non-muscle invasive bladder cancer (NMIBC), pathological NMIBC and pathological 
muscle invasive bladder cancer (MIBC)
(a) Recurrence-free survival
(b) Overall survival 
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Discussion
The optimal surgical template for LND in patients who undergo RC for bladder cancer is a 
topic of continued debate. In patients with MIBC, a number of LN mapping studies have 
been performed to determine the lymphatic drainage aiming to define the optimal template 
of LND. [10,13] LN mapping studies in patients with cNMIBC, however, are lacking partly 
owing to the infrequent employment of RC and ‘superextended’ LND in these patients. 
The reason to perform RC differs among patients with cNMIBC. In the current study, the 
majority of patients underwent RC due to high risk of progression. The remaining patients 
had a low risk of progression, in particular patients with cTa, but had disease not amenable 
to endoscopic management, multiply recurrent disease and/or functional bladder issues. 
 We performed, to our knowledge, the first LN mapping study focusing on 
patients undergoing RC for cNMIBC. The rationale for focusing on clinical stage is based 
on the significant role it plays in the initial management of bladder UC. Though important 
for decision making, clinical stage correlates imperfectly to pathologic findings. Current 
literature reports understaging rates varying between 32% and 44%. [14-16] In this study, 
despite the inclusion of only cT1 patients who had detrusor muscle present at TURBT, 
up to 23% of patients were upstaged at RC. Thus, clinical understaging is a frequent 
finding which has implications for the role of lymphadenectomy as demonstrated in this 
study. Although only 1% of patients with pNMIBC had LNM, nearly 8% of patients with 
cNMIBC had LNM. Stratified by clinical stage, LNM occurred in 9.0% of cT1 patients, 
12.0% of cTis-only patients and none of the patients with cTa. These findings imply 
that LND may have limited value in cTa patients, but underscore the need for LND 
in patients with cT1 and cTis-only to adequately asses the nodal status. To investigate 
whether further risk stratification for LNM would be possible, univariable analysis was 
performed. None of the variables were statistically significantly associated with LNM, but 
it should be noted that these tests were likely underpowered as only 9 patients had LNM. 
 Performing extended LND is associated with increased surgical time although 
the 30-day morbidity appears to be equal compared to a standard or limited LND. [17,18] 
Nonetheless, it may benefit patients to reduce the template of LND, while maintaining 
oncologic efficacy. To date, however, it is unknown whether the extent of LND can be 
tailored based on risk stratification. Shariat et al.[7], analyzing over 4000 patients 
undergoing RC, aimed to define the minimum number of LNs that should be removed 
based on clinical stage. It was reported that in patients with cTa-cTis at least 6 LNs should 
be removed, while in T1 patients at least 10 LNs should be retrieved. Unfortunately, 
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as the number of LNs cannot be translated into a surgical template, the question 
whether ‘one template fits all’ remained to be answered. In this LN mapping study, 
all patients underwent ‘superextended’ LND with a median of 70 LNs removed, which 
is a higher number compared with most other series. [13,18] A total of 9 node-positive 
patients of whom 3 patients (33.3%) had LNM proximal the aortic bifurcation (Level 3; 
Figure 2). This is a slightly higher percentage compared to a recent large LN mapping 
study including all clinical stages, reporting 28% of patients with level 3 involvement. 
[10] The higher incidence in this study is likely caused by the relatively low number of 
node-positive patients. Nonetheless, both studies demonstrate that a substantial 
number of node-positive patients have LNM at level 3, regardless of clinical stage. 
Fortunately, none of the patients with level 3 involvement had skip metastases, which 
is similar to other studies reporting a very low incidence of skip metastases. [13,19,20] 
This finding suggests that if a standard LND had been performed, all patients with 
node-positive disease would have correctly been identified, although performance of a 
‘superextended’ LND might be of benefit in these patients. [18,19,21]Randomized studies 
are, however, needed to investigate the effect of (super)extended LND survival outcomes. 
 This study has important limitations. Despite prospective collection of data, this 
was a retrospective study with its inherent limitations. We present data from a single, 
tertiary referral center with high rate of referred patients and consequently variance in 
pre-cystectomy management. Not all cT1 patients underwent bimanual examination and 
or repeat TUR prior to surgery. Conversely, only patients who had presence of detrusor 
muscle at TURBT were included and the TURBT specimen was routinely reviewed at 
our institution. Although our RC cohort is one of the largest of its kind, the number of 
patients may not be sufficient to accurately reflect the distribution of LNM in all patient 
populations. In addition, only patients with cNMIBC who underwent RC were included, 
and the reported incidence of LNM may not reflect the incidence for all patients with 
cNMIBC. Furthermore, confounding by indication may have been present as the majority 
of patients who underwent RC were at high risk of progression. Acknowledging these 
limitations, this study provides insight into the incidence and distribution of LNM in 
patients undergoing RC for NMIBC.
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Conclusions
Routine LND is important in patients with cT1 and cTis only bladder cancer, but may 
have limited value in patients with cTa. Although LNM were rarely found in patients with 
pathologic NMIBC, pathologic upstaging to MIBC and subsequent presence of LNM was 
a common finding. LNM beyond the boundaries of a standard LND occurred in up to 
one-third of node-positive patients. In the absence of skip lesions, however, performing 
a standard LND would correctly identify all node-positive patients. Whether removal 
of LNM proximal to the common iliac vessels provides a survival benefit remains to be 
evaluated in future prospective studies. 
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Abstract
Context
Controversy exists regarding the therapeutic value of lymphadenectomy (LND) in patients 
undergoing radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC).
Objective
To systematically review relevant literature assessing the impact of LND on oncological 
and peri-operative outcomes in patients undergoing RC for MIBC.
Evidence acquisition
MEDLINE, MEDLINE-in-Process, Embase, the Cochrane Central Register of Controlled 
Trials and the Latin American and Caribbean Center on Health Sciences Information 
(LICACS) were searched up to December 2013. Comparative studies reporting on no, 
limited, standard, extended, and super-extended LND, and oncological and peri-operative 
outcomes were included. Risk of bias and confounding assessments were performed. 
Evidence synthesis
Twenty-three studies reporting on 19,793 patients were included. All but one study were 
retrospective. Planned meta-analyses were not possible due to study heterogeneity 
therefore data were synthesized narratively. There were high risks of bias and confounding 
across most studies, and extreme heterogeneity in the definition of the anatomic 
boundaries of LND templates. All seven studies comparing LND with no LND favored LND 
in terms of better oncological outcomes. Seven of 14 studies comparing (super-)extended 
with limited or standard LND reported a beneficial outcome for (super-)extended LND 
in at least a subset of patients. No difference in outcome was reported in two studies 
comparing extended and super-extended LND. The comparative harms of different 
extents of LND remain unclear. 
Conclusions
Although the quality of the data was poor, the available evidence indicates that any kind 
of LND is advantageous over no LND. Similarly, extended LND appears to be superior to 
lesser degrees of dissection, while super-extended LND offered no additional benefits. 
Data from ongoing randomized clinical trials will hopefully clarify remaining uncertainties.
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Patient summary
The current literature suggests that removal of lymph nodes in bladder cancer surgery is 
beneficial and might result in better outcomes in terms of prolonging survival. However, 
the quality of the available studies is poor and high quality studies are needed.
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1. Introduction
Lymphadenectomy (LND) combined with radical cystectomy (RC) is considered the 
standard of care for patients with muscle-invasive bladder cancer (MIBC). Up to 25% of 
patients harbor lymph node (LN) metastases at the time of RC, and the staging role of 
LND is unequivocal. In 1982, Skinner [1] was the first to report long-term survival in LN-
positive patients undergoing RC and LND without systemic treatment. The therapeutic 
value of LND, however, remains a topic of continuous debate. While the results of 
two ongoing randomized clinical trials (RCTs) evaluating the impact of different LND 
templates on survival are awaited, the current evidence base remains uncertain with 
regard to the true benefits and harms of LND. In this study, we systematically reviewed 
the available literature to evaluate the impact of the extent of LND on survival and peri-
operative outcomes in patients undergoing RC for MIBC.
2. Evidence acquisition
2.1 Search strategy
The review was performed in accordance with the PRISMA statement and principles 
outlined in the Cochrane Handbook for Systematic Reviews of Interventions. [2,3] Highly 
sensitive electronic searches were conducted to identify all reports of RCTs or non-
randomized comparative studies (NRCS) assessing LND in patients undergoing RC for 
MIBC. The searches were not limited by language or publication date. The databases 
searched were MEDLINE (1946 to December 2013), MEDLINE In-Process (December 
20th 2013), Embase (1974 to December 2013), Cochrane Central Register of Controlled 
Trials (The Cochrane Library, Issue 8, 2013) and Latin American and Caribbean Center 
on Health Sciences Information (LILACS; December 2013). The database search was 
complemented by additional sources, including the reference lists of included studies 
which were hand searched, and additional reports identified by an expert panel 
(European Association of Urology (EAU) Working Group on MIBC). Ongoing trials were 
identified on clinicaltrials.gov. The full search strategy is presented in Supplement 1. 
 Two reviewers independently screened titles and abstracts of all citations 
identified by the search strategies. Full text copies of all potentially relevant reports were 
obtained and independently assessed by the reviewers to determine whether they met 
the pre-defined inclusion criteria. Any disagreements were resolved by consensus or 
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arbitration by a third person. A data extraction form was developed specifically for the 
purpose of this assessment to collect information on study design, characteristics of 
participants, characteristics of interventions, and outcome measures. 
2.2 Inclusion and exclusion criteria
The inclusion criterion was comparative studies only, and these included RCTs, prospective 
NRCS, prospective observational studies with a comparator arm, and retrospective 
comparative studies. Registry or database studies were also eligible, if the analysis was 
clearly structured as a comparison between control and intervention groups. Studies with no 
comparator group (e.g. single-arm case series), non-effectiveness studies (e.g. nomogram 
studies), reviews, or studies with fewer than 10 patients in each arm, were excluded. 
 The study population was limited to patients with localized muscle-
invasive urothelial or squamous cell carcinoma of the bladder (cT2-4 N0M0). Studies 
including predominantly patients with variant histology other than squamous cell 
carcinoma were excluded because of its low incidence and the potentially different 
biological behavior of these cancers. Clinical staging was preferred, but if this was 
not reported, staging based on RC specimen was accepted. Studies with mixed 
populations (e.g. cTa, cTis, cT1) were retained for consideration for inclusion if there 
were no studies which included patients with MIBC exclusively. Studies including 
patients who underwent neo-adjuvant or adjuvant treatment were also retained. 
 The types of interventions included LND undertaken during RC for bladder 
cancer. Due to the expected heterogeneity in defining the extent of LND across studies, 
the extent of LND was determined a priori based on discussion in an expert panel (EAU 
Working Group on MIBC) and were categorized as follows: (1) limited LND (or L-LND): 
LND confined to the obturator and/or peri-vesical fossa only; (2) standard LND (or 
S-LND): LND performed up to the proximal boundary of the common iliac arteries; (3) 
extended LND (or E-LND): LND performed up to the proximal boundary of the crossing 
of the common iliac vessels with the ureters or the aortic bifurcation, with or without the 
pre-sacral lymph nodes; and (4) super-extended LND (or SE-LND): LND performed up to 
the proximal boundary of the inferior mesenteric artery. The primary outcome was overall 
survival (OS); secondary outcomes included recurrence-free survival (RFS), disease-free 
survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS) and peri-
operative outcomes (e.g. operative time, blood loss, lymphocele).
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2.3 Assessment of risks of bias
Two reviewers independently assessed the risk of bias (RoB) of individual studies. Any 
disagreement was resolved by discussion or reference to a third reviewer. The standard 
Cochrane Collaboration RoB tool [4] was used to assess the RoB in RCTs, whilst for NRCS, 
the RoB tool recommended by the Cochrane Non-Randomised Studies Methods Group 
was used. [5,6] In addition, for NRCS, the main confounders were identified a priori based 
on a study by Palmer et al. [7] In this study, a survey among bladder cancer experts was 
performed to identify and rank potential confounding variables and defining thresholds 
for imbalance for these variables. The main confounders identified are summarized in 
Table 1. Each confounder was assessed according to whether it had been considered by 
the authors, whether the confounder was balanced across the groups, and the degree to 
which adjustment had been made for the confounder. [7] The risk of confounding bias 
was considered to be high if the confounder was not described/considered, imbalanced 
between the groups or was not adjusted for in the statistical analysis. Review Manager 5.2 
was used to present these results (Table 1). [8]
2.4 Data analysis
A narrative synthesis was performed. [9] Descriptive statistics were used to summarize 
baseline characteristics data. For continuous outcomes, data were summarized using 
mean (+/- standard deviation if available) and median (+/- interquartile range if available); 
for categorical outcomes, data were summarized using proportions. For summarizing 
outcome data, categorical outcomes were presented as proportions at 5 and 10 year time 
points following surgery based on crude point estimates as reported by authors, with level 
of significance set at 5%. Outcomes at other time points were narratively described. For 
time-to-event data reported by authors using univariable or multivariable Cox regression 
analysis, data were summarized as hazard ratios (HRs) and 95% confidence intervals 
(CIs). 
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Table 1: Risk of bias assessment using the Cochrane risk of bias tool
Abd El Latif 2011
Abd El Latif 2012
Abdollah 2012
Abol-Enein 2011
Bostrom 2011
Brossner 2004
Brunocilla 2013
Dhar 2008
Dharaskar 2011
Finelli 2004
Holmer 2009
Hori 2013
Isaka 1985
Liu 2011
Miyakawa 1985
Poulsen 1998
Simone 2012a
Simone 2012b
Wang 2013
Yuasa 1988
Zehnder 2011
Zhang 2013
= High Risk of Bias
= Low Risk of Bias; the variable was either balanced between the groups 
   (assessed as ‘no’ or ‘small imbalance’) or was adjusted for in the analysis
= Unclear risk of Bias
Simone 2012a compared standard LND vs extended LND; 
Simone 2012b compared extended LND vs superextended LND
Jensen 2012
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3. Evidence synthesis
3.1 Quantity of evidence identified and characteristics of included studies
A total of 1897 abstracts were identified by the search (Figure 1). Of these, 38 were selected 
for full-text screening. One additional study was identified through reference searching. 
After full-text screening, a total of 23 studies met the inclusion criteria. [10-32] Seven 
studies were reported only in the form of conference meeting abstracts, while 16 studies 
were reported in full-text papers. With one exception, all studies were retrospective 
comparative studies. Sixteen studies were single-centre studies, of which eight studies 
used a historical cohort as control group, and seven studies were multicenter studies. 
3.2 Risk of bias and confounding assessment of included studies
Risk of bias (RoB) and confounding assessment for each of the individual studies were 
performed and the results are presented in Table 1. Due to the retrospective design in 22 
of 23 studies, there was high or unclear RoB across all domains. The issue of confounding 
was also poorly addressed by the majority of studies, as it was unclear in most studies if any 
of the confounding factors had been considered, either prospectively, or retrospectively 
through statistical adjustment.
3.3 Results of comparisons of interventions
3.3.1 No LND vs LND
3.3.1.1 Baseline characteristics
A total of seven studies comparing LND with no LND were identified, including a total 
of 13,833 patients (Table 2a). [10-16] The intervention differed among the studies and 
included any LND [10,14,15], L-LND [13], S-LND [11,12,16], E-LND [16] or SE-LND [16].
3.3.1.2 Oncological outcomes
Table 2b summarizes the oncological outcomes comparing no LND vs any LND. All studies 
reported a benefit for LND in at least one oncological outcome. Liu et al. [10] did not 
report any numerical data but stated that LND was associated with improved OS and DFS 
in pT1 patients only compared with no LND. 
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Figure 1: PRISMA flow diagram
3.3.1.3 Peri-operative outcomes
No studies reported on peri-operative outcomes.
3.3.2 Limited LND vs standard LND
No studies were identified for comparison of limited LND and standard LND.
3.3.3 Limited LND vs (super-)extended LND
3.3.3.1 Baseline characteristics
Five studies addressed this question involving a total of 1,394 patients (Table 3a). [17-21] 
Brossner et al. [21] focused on peri-operative outcomes. Bostrom et al. [19] compared 
L-LND with E-LND, however, an unknown number of patients in the E-LND group 
underwent SE-LND and over 50% of patients in the L-LND group did not undergo LND at all. 
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Table 2a: Descriptive outcomes of studies comparing no lymphadenectomy (LND) 
versus any LND
LE
Type of LND Number of patients
Time period of 
recruitment
C I C I C I
Liu 2011 [10] 3 No LND Any 334 1606 1995-2008
Isaka 1985 [11] 4 No LND Standard 15 80
1975-
1978
1979-
1988
Miyakawa 1985 [12] 4 No LND Standard 45 65*
1975-
1980
1980-
1984
Yuasa 1988 [13] 4 No LND Limited 8 22
1975-
1978
1979-
1985
Abdollah 2012 [14] 3 No LND Any 2789 8394 1988-2006
Zhang 2013 [15] 4 No LND Any 24 63 1997-2001
Brunocilla 2013 [16] 3
No or 
limited 
LND
Standard
116 
19 No-LND 
97 L-LND
94
10/1995-
12/2011
No or 
limited 
LND
Extended/
super- 
extended
116 
19 No-LND 
97 L-LND
62 
39 E-LND 
23 SE-LND
10/1995-
12/2011
C = control group;   I = intervention group  L-LND = limited LND   
S-LND = standard LND;   E-LND = extended LND SE-LND = superextended LND 
Neo-adj rad = neo-adjuvant radiotherapy N/A = not applicable;   NR = not reported 
* 70 patients were included of whom 65 patients underwent no LND
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Follow-up duration 
(range)
pN+  
(number, %)
pT stage  
(number, %)
(Neo-)adjuvant 
therapy  
(number, %)
C I C I C I C I
NR N/A NR NR NR
40 mo 
(5-143)
40 mo 
(2-110)
N/A 9 (11)
≤pT2: 10 (67)      
>pT2: 5 (33)
≤pT2: 55( 69)       
>pT2: 25 (31)
NR
Neo-adj 
rad 
58 (72)
NR N/A NR
≤cT2: 6 (13)
cT2: 24 (53) 
cTx: 15 (33)
≤cT2: 26 (37)
>cT2: 38 (54)   
cTx: 6 (9)
NR
Minimum 1 year N/A NR NR NR
NR N/A 2182 (26)
≤pT2: 1787 (64)
>pT2: 1002 (36)
≤pT2: 4157 (49)
>pT2: 4237 (51)
NR
2002-2011 NR N/A NR NR NR
Mean 59.2 mo 
(1-171)
26 (22) 28 (30) NR Excluded
Mean 59.2 mo 
(1-171)
26 (22) 19 (31) NR Excluded
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Table 2b: Oncological outcomes of studies comparing no lymphadenectomy (LND) 
versus any LND
 LND compara-
tor
OS (%) RFS/DFS (%)
5 year 10 year 5 year
10 
year
Liu 2011 [10]
No LND NR NR NR NR
Any LND NR NR NR NR
Isaka 1985 [11]
No LND 25.0 NR NR NR
Standard 64.0 p<0.05 NR NR NR
Miyakawa 1985 [12]
No LND 35.0 NR NR NR
Standard 66.0 p<0.05 NR NR NR
Yuasa 1988 [13]
No LND 50.0 NR NR NR
Limited 67.8 p<0.01 NR NR NR
Abdollah 2012 [14]
No LND ±41* 27.2* NR NR
Any LND ±47 p<0.01* 34.1 p<0.01* NR NR
Zhang 2013 [15]
No LND NR NR NR NR
Any LND NR NR NR NR
Brunocilla 2013 [16]
No/L-LND NR NR NR NR
1. S-LND NR NR NR NR
2. E/SE-LND NR NR NR NR
L-LND = limited LND;    S-LND = standard LND;  
E-LND = extended LND;   SE-LND = superextended  
NR = not reported;    NS = not significant 
OS = overall survival;    RFS = recurrence-free survival; 
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CSS/DSS (%) Multivariable Cox Regression analysis Authors conclusion
5 year 10 year Hazard Ratio (HR)
95%  
confidence 
interval
p-
value
NR NR NR NR NR Favors LND  
(pT1 only)NR NR NR NR NR
NR NR NR NR NR
Favors LND
NR NR NR NR NR
NR NR NR NR NR
Favors LND
NR NR NR NR NR
NR NR NR NR NR
Favors LND
NR NR NR NR NR
±58 52.5
Cancer specific mortality**
All patients  HR 1.33 
pTa-pTis:     HR 2.09 
pT1:                HR 1.60 
pT2:                HR 1.68 
pT3:                HR 1.15 
pT4:                HR 1.11
1.24 - 1.44 
1.16 - 3.79 
1.18 - 2.17 
1.47 - 1.91 
1.01 - 1.33 
0.96 - 1.28
< 0.01 
< 0.05 
< 0.05 
< 0.01 
NS 
NS
Favors LND 
(CSS < pT3 only)
±61 p < 0.01 57.5 p < 0.01 HR 1.00 (reference) - -
NR NR NR NR NR
Favors LND
NR NR NR NR NR
± 50 ± 35 HR 1.00 (reference) - -
Favors LND
± 60 p = 0.010 ± 75 p = 0.010 Cancer specific survival
Total cohort:  HR 0.99 0.55 – 1.35 0.49
± 78 p = 0.010 ± 75 p = 0.010 Cancer specific survival
Total cohort:  HR 0.46 0.37 – 0.89 0.036
DFS = disease-free survival;   CSS = cancer-specific survival  DSS = disease-specific survival 
The ± symbol indicates the Kaplan-Meier curve was used to estimate the percentage 
* Overall mortality  ** Adjusting for age, gender, race tumor grade and year of cystectomy
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Table 3a: Descriptive outcomes of studies comparing limited lymphadenectomy 
(LND) versus (super)extended LND
LE
Type of LND Number of patients
Follow-up duration 
(range)
C I C I C I
Hori 2013 [17] 4 Limited Extended 53 47 NR
Holmer 2009 [18] 4 Limited Extended 69 101
Median 94 
mo 
(61-122)
Median 
38 mo 
(13-70)
Bostrom 2011 [19] 4 Limited
Extended or 
super- 
extended
563 NR
Jensen 2012 [20] 4 Limited
Standard, 
extended 
or super-
extended
204 
202 L-LND 
2 no-LND 
265 
170 SE-LND 
46 E-LND 
49 S-LND
Median 
113 mo 
(86-143)
Median 
45 mo 
(24-84)
Brossner 2004 
[21]
3 Limited
Super-
extended
46 46 30 days
C = control group; I = intervention group  NR = not reported 
L-LND = limited LND;    S-LND = standard LND;  
E-LND = extended LND;    SE-LND = superextended LND 
 
Adj = adjuvant; neo-adj = neo-adjuvant; chemo = chemotherapy
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pN+   
(number, %)
pT stage  
(number, %)
Neo-adjuvant or  
adjuvant therapy 
(number, %)
C I C I C I
10 (19) 14 (30) NR NR
12 (17) 38 (38)
≤pT2: 46 (67)
>pT2: 23 (33)
≤pT2: 53 (52)
>pT2: 48 (48)
Neo-adj: excluded
Adj chemo 13% vs 16%
NR (7) NR (26) NR
Neo-adj: Excluded
Adj chemo: 1 vs 21%
43 (21) 61 (23)
≤pT2: 112 (55)
>pT2: 92 (45)
≤pT2: 160 (60)
>pT2: 105 (40)
Excluded
10 (22) 18 (39)
≤pT3a: 24 (52)
>pT3a: 22 (48)
≤pT3a: 28 (61)
>pT3a: 18 (39)
NR
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Table 3b: Oncological outcomes of studies comparing limited lymphadenectomy 
(LND) versus (super)extended LND
LND com-
parator
OS (%) RFS/DFS (%)
5 year
10 
year
5 year 10 year
Hori 2013 
[17]
Limited 61 NR NR NR
Extended 47 p=0.65 NR NR NR
Holmer 
2009 [18]
Limited NR NR ±66 ±65
Extended NR NR ±75 p=0.27
No cases 
p=0.27
Bostrom 
2011 [19]
Limited NR NR NR NR
Extended 
or super-
extended
NR NR NR NR
Jensen 
2012 [20]
Limited
All patients 55 
≤pT2  77
>pT2  43 
LN negative  66 
LN positive 12
NR
All patients 62 
≤pT2  83
>pT2  54 
LN negative  75 
LN positive 8
NR
Standard, 
extended 
or super-
extended
All patients  67  p<0.05 
≤ pT2  77  NS
>pT2  71  p<0.05   
LN negative     75  NS 
LN positive  38   p<0.05
NR
All patients  64 NS 
≤pT2  80 NS
>pT2  61 NS 
LN negative  74 NS 
LN positive  29 p<0.05
NR
Brossner 
2004 [21]
Limited NR NR NR NR
Super-
extended
NR NR NR NR
NR = not reported;   NS = not significant;   OS = overall survival;   
RFS = recurrence-free survival;  DFS = disease-free survival;  CSS = cancer-specific survival;
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CSS/DSS (%) Multivariable Cox Regression analysis Authors  conclusion
5 year 10 year Hazard Ratio (HR)
95%  
confidence 
interval
p-
value
73 NR NR NR NR No difference
50 p=0.27 NR NR NR NR
±66 No cases HR 1.00 (reference) - - Favors ex-
tended   LND in 
subgroup  
>pT2 and RFS 
only
±73 p=0.45 No cases
Disease specific  
mortality* 
All patients     HR 0.81  
≤ pT2         HR 0.80
>pT2         HR 0.54
Recurrence-free survival* 
All patients     HR 0.73 
≤ pT2         HR 0.88
> pT2         HR 0.42
0.44- 1.47 
0.28-2.32 
0.26-1.14
0.41 – 1.30 
0.34 - 2.30 
0.20 - 0.88
0.48 
0.68 
0.10
0.28 
0.79 
0.022
NR NR HR 1.00 (reference) - - Favors  
extended LND
NR NR
Disease specific survival 
All patients     HR 0.53
0.31 – 0.93 0.026
All patients 67 
≤ pT2  88     
>pT2  62  
LN negative               80 
LN positive 14
NR HR 1.00 (reference) - -
Favors extend-
ed LND (locally 
advanced dis-
ease only)
All patients  72 p<0.05 
≤ pT2  88 NS  
>pT2  62 p<0.05 
LN negative  80 NS 
LN positive  14 p<0.05
NR
Recurrence-free survival 
All patients HR 0.90
Disease specific survival 
All patients HR 0.71
Overall survival  
All patients HR 0.60
 
0.65 – 1.24
 
0.50 – 1.01
 
0.45 – 0.81
 
0.51
 
0.06
 
< 0.01
NR NR NR NR NR Comparable 
peri-operative 
outcomesNR NR NR NR NR
DSS = disease-specific survival.  * Adjusting for sex, age and adjuvant chemotherapy
The ± symbol indicates the Kaplan-Meier curve was used to estimate the percentage
MaxThesis.indb   115 27-10-15   20:39
part iii • bladder cancer and lymph node dissection 
116
3.3.3.2 Oncological outcomes
Table 3b summarizes the oncological outcomes comparing L-LND with E/SE-LND. Of the 
five studies included, three studies reported improvement of at least one oncological 
outcome for E/SE-LND. [18-20] Brossner et al. [21] did not report oncological outcomes, 
while Hori et al. [17] found no statistically significant difference in oncological outcomes 
for L-LND and E-LND performing univariable analysis.
3.3.3.3 Peri-operative outcomes
Jensen et al. [20] reported no prolonged operative time for E-LND compared with L-LND 
(mean 306 vs 302 minutes, p = 0.92). Brossner et al. [21], however, reported prolonged 
operative time for SE-LND compared with L-LND (median 330 vs 277 minutes, p < 0.01). 
This study reported no differences in number of blood units transfused (1.15 vs 0.38 
respectively, p = 0.37), lymphoceles (none in both groups), 30-day complication rate (11% 
vs 9% respectively, p=0.28), and 30-day mortality (3 vs 1 event respectively, p = 0.57). [21]
3.3.4 Standard LND vs (super-)extended LND
3.3.4.1 Baseline characteristics
Nine studies were identified involving 3,104 patients (Table 4a). [22-30] Four studies 
used data from the Cleveland Clinic. [22, 23, 25,28] Abd El Latif [23] differed from their 
previous study [22] by extending the study period by 2 years (2004-2010 vs 2006-2010). 
One study specifically looked at the outcomes of laparoscopic LND. [25]
3.3.4.2 Oncological outcomes
Table 4b summarizes the oncological outcomes comparing S-LND with E/SE-LND and 
contradicting results were reported. Four studies noted no difference in oncological 
outcomes between S-LND and E-LND [22-24,30], although only one study on data from 
multivariable analysis. [22] Three studies reported a benefit for E-LND and one study 
reported a benefit for SE-LND for at least one oncological outcome. Subgroup analysis 
in these studies revealed no consistent subgroup that benefited most from E-LND. For 
example, Poulsen et al. [26] reported a RFS benefit for E-LND in patients with organ-
confined disease, while Dhar et al. [28] only found a RFS benefit for patients with >pT2 
disease. 
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3.3.4.3 Peri-operative outcomes
Poulsen et al. [26] reported a lymphocele rate of 1.6% for E-LND and 1.5% for S-LND. One 
patient (0.8%) in the E-LND group died peri-operatively from complications unrelated 
to LND. Finelli et al. [25], performing laparoscopic LND, reported an estimated increase 
in operative time from 30-45 minutes for S-LND to 90 minutes for E-LND (no p-value 
reported). 
3.3.5 Extended LND vs super-extended LND
3.3.5.1 Baseline characteristics
Two multi-institutional studies, involving 1,462 patients were included. (Table 5a) [31,32]
3.3.5.2 Oncological outcomes
Table 5b summarizes the oncological outcomes comparing E-LND with SE-
LND. Both studies reported no statistically significant difference in survival 
outcomes between E-LND and SE-LND, irrespective of tumor stage or nodal status. 
 
3.3.5.3 Peri-operative outcomes
No studies reporting on peri-operative outcomes were identified. 
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Table 4a: Descriptive outcomes of studies comparing standard  
lymphadenectomy (LND) versus (super)extended LND
LE
Type of LND
Number of 
patients
Follow-up duration  
(range)
C I C I C I
Abd-El-Latif 2011 
[22]
3 Standard
Extended 
or super-
extended
122 199
Median 24 mo  
(IQR 12 - 36)
Abd-El-Latif 2012 
[23]
3 Standard
Extended 
or super-
extended
183 240 Median 24 mo
Dharaskar 2011 
[24]
4
Standard
a. en bloc
b. LN pack-
ets
Extended 51 27
a. median 24 mo 
(0-49) 
b. Median 14 mo 
(0-43)
Median 6 mo 
(0-37)
Finelli 2004 [25] 3 Standard Extended 11 11 Mean 11 mo (2-4)
Poulsen 1998 [26] 4 Standard Extended 68 126
Median: 5.14 yrs 
(0.2-7.9)
Median: 1.96 
yrs (0.3-4.7)
Simone 2012a [27] 3 Standard Extended 584 349 NR
Dhar 2008 [28] 3 Standard Extended 336 322
For RFS 25 mo 
(1.1-166)
For OS 36 mo       
(1.1-166)
For RFS 40 mo 
(range 1-229)
For OS 51 mo    
(range 1-229)
Abol-Enein 2011 
[29]
3 Standard
Super-
extended
200 200
50.2 months (IQR 69.0) for pa-
tients alive at last follow-up
Wang 2013 [30] 3 Standard Extended 42 33 NR
C = control group; I = intervention group; NR = not reported; Adj = adjuvant; neo-adj = neo-adjuvant; 
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pN+ 
(number, %)
pT stage  
(number, %)
Neo-adjuvant or  
adjuvant therapy  
(number, %)
C I C I C I
Excluded NR
Neo-adj: 17 (5) 
Adj: NR
NR NR NR
13 (26) 7 (26)
≤pT2: 32 (63)     
>pT2: 19 (37)
 ≤pT2: 20 (74)        
>pT2:7 (26)
NR
3 (27) 3 (27)
≤pT2: 5 (45)          
>pT2: 6 (55)
≤pT2: 9 (82)           
>pT2: 2 (18)
Neo-adj: NR 
Adj: chemo 2 (9)
15 (22) 35 (28)
≤pT2: 34 (50)      
>pT2: 33 (49)      
pTx: 1 (1)
≤pT2: 55 (43)         
>pT2: 69 (55)           
pTx: 2 (2)
Excluded
187 (32) 107 (31)
≤pT2: 271 (46)   
>pT2: 313 (54)
≤pT2: 192 (55)         
>pT2: 157 (45)
Neo-adj: Excluded-
Adj chemo 101 (11)            
Adj rad 8 (0.8)
44 (13) 83 (26)
≤pT2: 200 (60)   
>pT2: 136 (40)
≤pT2: 150 (47)        
>pT2: 172 (53)
Neo-adj: Excluded      
Adj: NR
48 (24) 48 (24)
≤pT2: 61 (31)     
>pT2: 139 (70)
≤pT2: 70 (35)        
>pT2: 129 (65)
0
NR NR Excluded
chemo = chemotherapy; rad = radiotherapy. IQR = interquartile range; RFS = recurrence-free survival;  
OS = overall survival
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Table 4b: Oncological outcomes of studies comparing standard lymphadenectomy 
(LND) versus (super)extended LND
LND  
compara-
tor
OS (%) RFS/DFS (%)
5 year 10 year 5year
10 
year
Abd-El-Latif 2011 
[22]
Standard NR NR NR NR
E/SE-LND NR NR NR NR
Abd-El-Latif 2012 
[23]
Standard ±58 NR NR NR
E/SE -LND ±40 p=0.14 NR NR NR
Dharaskar 2011 [24]
Standard No cases No cases NR NR
E-LND No cases No cases NR NR
Finelli 2004 [25]
Standard NR NR NR NR
E-LND NR NR NR NR
Poulsen 1998 [26]
Standard NR NR All patients 56 
≤ pT3** 85
>pT3 27 
pN0 71 
pN+ 7 
NR
E-LND NR NR All patients 62 p=0.33 
≤ pT3** 64 p < 0.02
>pT3 39 p = 0.87 
pN0 90 p < 0.02 
pN+ 24 p = 0.15
NR
L-LND = limited LND;   S-LND = standard LND;  E-LND = extended LND;  
E-LND = superextended LND,  NR = not reported;   LN = lymph node;  
OS = overall survival;   RFS = recurrence-free survival;  DFS = disease-free survival;  
CSS = cancer-specific survival;  DSS = disease-specific survival 
 
The symbol ‘±’ indicates the Kaplan-Meier curve was used to estimate the percentage
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CSS/DSS (%) Multivariable Cox Regression analysis
Authors  
conclusion
5 year 10 year Hazard Ratio (HR)
95% confi-
dence inter-
val
p-value
NR NR HR 1.00 (reference) - - No difference
NR NR Overall survival:  
All patients HR 2.50       
Cancer specific survival:
All patients HR 2.00
Recurrence-free survival: 
All patients HR 2.60
 
0.9 – 6.5
 
0.4 – 11.1
 
0.7 – 9.9
 
NR
 
NR
 
NR
NR NR NR NR NR No difference
NR NR NR NR NR
NR NR NR NR NR No difference
NR NR NR NR NR
NR NR NR NR NR Not assessed
NR NR NR NR NR
NR NR NR NR NR Favors E-LND
(≤ pT2 and pN0 
only)
NR NR NR NR NR
* HR was re-calculated using the same reference group (standard LND) as in the subgroup analysis 
** ≤pT3a indicated organ-confined disease in this study
*** adjusting for pT stage, pN stage, age, gender, tumor grade and histology
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Table 4b (Cont.) 
LND  
comparator
OS (%) RFS/DFS (%)
5 year 10 year 5 year
Simone 2012a [27]
Standard NR NR 42.6
E-LND NR NR 63.1 p<0.01
Dhar 2008 [28]
Standard pT2,N0 68 
pT2,N+ 64 
pT3,N0 26 
pT3,N+ 22
NR pT2,N0 67 
pT2,N+ 63 
pT3,N0 23 
pT3,N+ 19
E-LND pT2,N0 66  p = 0.12 
pT2,N+ 61  p = 0.10 
pT3,N0 46  p = 0.002 
pT3,N+ 42  p = 0.002
NR pT2,N0 77  p = 0.12 
pT2,N+ 71  p = 0.22 
pT3,N0 57  p < 0.01 
pT3,N+ 49  p < 0.01
Abol-Enein 2011 
[29]
Standard NR NR All patients  55 
LN- 66 
LN +            28
SE-LND NR NR All patients 67  p = 0.04 
LN - 72  p = 0.24 
LN + 48  p = 0.02
Wang 2013 [30]
Standard NR NR NR
E-LND NR NR NR
MaxThesis.indb   122 27-10-15   20:39
123
p
a
r
t i
ii
RFS/
DFS 
(%)
CSS/DSS (%) Multivariable Cox Regression analysis Authors  
conclusion
10 
year 5 year 10 year Hazard Ratio (HR)
95%  
confidence 
interval
p-value
NR 50.9 NR HR 1.00 (reference) - - Favours E-LND
NR 68.8 p<0.01 NR Disease free survival 
All patients HR 0.51* 
pT2 HR  0.41 
pT3  HR 0.55 
pT4  HR 0.33 
pN0  HR 0.63 
pN1 HR 0.19  
pN2 HR 0.40 
 
Cancer specific survival  
All patients HR 0.56* 
pT2 HR 0.40  
pT3 HR 0.65 
pT4 HR 0.33 
pN0 HR 0.54 
pN1 HR 0.15 
pN2 HR 0.45
 
0.40 – 0.65  
0.22 - 0.78 
0.40 - 0.77 
0.20 – 0.55 
0.44 – 0.91 
0.08 – 0.49 
0.24 – 0.67
 
0.42 - 0.73 
0.19 – 0.83 
0.44 – 0.94 
0.19 – 0.58 
0.30 – 0.95 
0.05 – 0.41 
0.25 – 0.80
 
< 0.01 
0.004 
0.001 
< 0.001 
0.011 
< 0.001 
< 0.001 
< 0.01 
0.011 
0.019 
< 0.001 
0.034 
< 0.001 
< 0.001
NR NR NR NR NR NR Favors E- LND
(≤ pT3 only)
NR NR NR NR NR NR
NR NR NR Disease free survival
HR 1.45***
1.06 – 1.99 0.02 Favors SE-LND
NR NR NR HR 1.00 (ref) - -
NR 59.0 NR NR NR NR No difference
NR 77.0 p=0.08 NR NR NR NR
MaxThesis.indb   123 27-10-15   20:39
part iii • bladder cancer and lymph node dissection 
124
Table 5a: Descriptive outcomes of studies comparing extended lymphadenectomy 
(LND) versus (super)extended LND
LE
Type of LND
Number of 
patients
Follow-up duration 
(range)
C I C I C I
Simone2012b [31] 3 Extended
Super 
extended
503 Median 9.9 years (0-22.3)
Zehnder 2011 [32] 3 Extended
Super 
extended
405 554 Median 10.9 years (0-24.1)
 
C = control group;  I = intervention group;   NR = not reported 
Adj = adjuvant;   neo-adj = neo-adjuvant;  chemo = chemotherapy
Table 5b: Oncological outcomes of studies comparing extended lymphadenectomy 
(LND) versus (super)extended LND
LND  
comparator
OS (%) RFS/DFS (%)
5 year 10 year 5 year 10 year
Simone 2012b [31]
Extended NR NR ±59 NR
Super- 
extended
NR NR
±64  
p=0.41
NR
Zehnder 2011 [32]
Extended ±54 ±42 ±61 ±59
Super- 
extended
±50  
p=0.45
±40  
p=0.45
±61  
p=0.75
±59  
p=0.75
NR = not reported;   OS = overall survival;    RFS = recurrence-free survival; 
DFS = disease-free survival;  CSS = cancer-specific survival;   DSS = disease-specific survival 
 
The symbol ± indicates the Kaplan-Meier curve was used to estimate the percentage
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pN+ 
(number, %)
pT stage  
(number, %)
(Neo-)adjuvant therapy  
(number, %)
C I C I C I
Excluded NR Excluded
NR 114 (28) 195 (35)
Neo-adj: excluded
Adj chemo: 46 (11)
Neo-adj: excluded
Adj chemo: 195 (35)
 
 
CSS/DSS (%) Multivariable Cox Regression analysis Authors  conclusion
5 year 10 year Hazard ratio
95% Confi-
dence interval
p-value
NR NR NR NR NR
No difference
NR NR NR NR NR
NR NR NR NR NR
No difference
NR NR NR NR NR
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3.4 Discussion
3.4.1 Principal findings
To the best of our knowledge, this study represents the most robust literature review 
focusing on the impact of the anatomical extent of LND on post-RC oncological and peri-
operative outcomes. The findings of this study suggest that any extent of LND is better 
than no LND for patients undergoing RC for MIBC, in terms of oncological outcomes. 
Additionally, E-LND might improve oncological outcomes compared with lesser degrees 
of dissection, although extending the dissection beyond E-LND is unlikely to yield any 
further benefits. With respect to peri-operative outcomes, a secondary outcome of this 
study, SE-LND resulted in increased operative time compared with less extended LND 
templates, but does not appear to substantially increase post-operative morbidity.
3.4.2 Clinical implications of our study findings
The data in this study support the routine performance of LND in patients undergoing RC. 
Whether the reported beneficial oncological outcomes are a result of stage migration (the 
so-called Will-Rogers Phenomenon), a true therapeutic benefit of LND, or a combination 
of both, remains uncertain. There is, however, a clear staging role of LND as supported 
by LN mapping studies. [33, 34] Thus, in spite of the lack of RCTs, the current evidence 
base is sufficiently convincing to recommend LND for patients undergoing RC for MIBC.
 While limited LND may contribute to disease staging, performing LND outside 
the true pelvis (i.e. ≥S-LND) should be considered a potential therapeutic intervention as 
skip nodal lesions are rare, therefore unlikely contributing to disease staging. [33,34] To 
date, however, questions remain about the potential therapeutic value of LND and what 
extent of LND is the most efficacious. Based on the current data, consisting of retrospective 
studies with a significant risk of bias and confounding, the evidence base is not strong 
enough to provide firm recommendations regarding the most optimal extent of LND. 
Conversely, these studies are currently the best available evidence and fairly consistently 
report an oncological benefit for E-LND compared with less extended LND templates. 
In addition, E-LND appears not to increase peri-operative morbidity. Collectively, there 
is accumulating evidence that E-LND may be beneficial for patients undergoing RC for 
MIBC and is therefore recommended in patients undergoing RC for MIBC. 
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3.4.3 How does this systematic review compare with other recent reviews?
To our knowledge, two systematic reviews on the importance of LND in bladder cancer have 
been published. [35,36] Fan et al. [36] performed a systematic review and meta-analysis 
of studies comparing E-LND and non-extended LND and its impact on RFS. The authors 
concluded that E-LND was associated with improved RFS compared with non-extended 
LND. Subgroup analysis revealed that patients with ≥pT3 bladder cancer, independently 
of LN status, benefit from E-LND. Tilki et al. [35] performed a systematic review only and 
concluded that the extent of LND may influence DFS after RC, independently of LN status 
and pT stage. 
 The outcomes of our present study are in line with these reviews. However, there 
are important methodological differences which deserve discussion. Tilki et al. [35] 
included studies using the LN count as a surrogate for the extent of LND. Although an 
association between LN count, the extent of LND or even post-RC outcomes have been 
suggested [37-39], using the LN count as a surrogate for the extent of LND has limitations 
as acknowledged by the authors. Differences in surgical technique, sample processing 
and pathologic assessment greatly influence the LN count and consequently affect 
reproducibility. [37,40,41] Furthermore, the LN count cannot adequately be determined 
intra-operatively whereas surgeons can adhere to anatomic templates, making studies 
comparing LND templates more clinically relevant. For these reasons, only studies 
describing anatomic templates for the extent of LND were included in our review. In 
addition, although Tilki et al. [35] described some studies comparing LND templates 
(references 26,28,29,32), an additional 19 studies were included in this study providing a 
more comprehensive overview of studies comparing different LND templates.
 The attempt by Fan et al. [36] to perform a meta-analysis is noteworthy. Yet, 
the results of this study should be interpreted with caution. Aside from the low quality 
studies included in the analysis with its associated bias, differences in the definition of 
the extent of LND were not adjusted for in this study. Reflecting the lack of consensus on 
what constitutes a limited, standard, and extended or super-extended LND, there was 
significant heterogeneity in the definition regarding the extent of LND across studies. 
To illustrate, Abol-Enein et al. [29] and Dhar et al. [28] were both classified as E-LND 
studies while the proximal boundaries were the inferior mesenteric artery and crossing 
of the ureter with the common iliac vessels, respectively. For this reason, we chose to 
define the LND templates a priori and, if necessary, re-classify accordingly if sufficiently 
large numbers of studies did not match our chosen definitions. Although the definitions 
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chosen for each of the LND templates may not be universally accepted by all clinicians, 
it at least allows for a certain degree of standardization, which enables a comparison of 
outcomes among different LND templates.
 
3.4.4 Strengths and limitations of the review
The strength of the current study is the comprehensive literature review evaluating 
the impact of the extent of LND on post-RC outcomes using a robust and transparent 
methodological approach based on Cochrane review principles, incorporating the 
assessment of RoB and confounding which are essential in any review involving non-
randomized studies. The search strategy was complemented by additional sources for 
potentially important articles, which included an expert panel (EAU Working Group 
on MIBC). The review was limited to comparative studies, in order to maintain at least 
moderate levels of evidence. Throughout the entire review process, peer review was 
obtained from the expert panel, which represents a reference group of international 
experts. This approach ensured a comprehensive review of the literature, whilst 
maintaining methodological rigour, and enabled the authors to put into clinical context 
the relevance and implication of the review findings. 
 The major limitation of the review is the quality of included studies; except for 
one prospective study, all studies were retrospective, non-standardized comparative 
studies with high risks of bias and confounding. This review highlights the lack of high 
quality and reliable evidence concerning the benefits and harms of LND during RC in 
terms of oncological and peri-operative outcomes. The results, on the other hand, are 
supported by the fact that these studies are fairly consistent in reporting an oncological 
benefit. Currently, two phase III RCTs, one in Germany and one initiated by the Southwest 
Oncology Group (SWOG S1011), evaluating the impact of different LND templates on 
survival are ongoing. The final results of these studies, which will take several years 
(personal communication), may provide a more definitive answer to some aspects of this 
important clinical question. Standardization of the LND templates and surgeon expertise, 
however, are of critical importance for the success of these trials.
4. Conclusions
This systematic review set out to determine the evidence base in regard with the comparative 
effectiveness of LND in patients undergoing RC for MIBC, in terms of oncological benefits 
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and peri-operative outcomes. The findings reveal a lack of randomized studies, and an 
evidence base derived mainly from retrospective studies with significant risks of bias 
and confounding. Nevertheless, the data indicate that any form of LND produces more 
favorable oncological outcomes compared with no LND. There was no evidence that LND 
results in increased peri-operative adverse events than no LND. In terms of how different 
extents of LND influence outcomes, the findings indicate that E-LND might be superior 
to lesser degrees of dissection from an oncological perspective; however, extending the 
dissection beyond this (e.g. SE-LND) is not beneficial. The results of ongoing RCTs will 
hopefully clarify the remaining uncertainties regarding the role of LND during RC for 
MIBC.
 References
1 Skinner DG. Management of invasive bladder cancer: a meticulous pelvic node dissection 
can make a difference. J Urol 1982;128:34-36
2 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic 
reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535
3 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. 
Available from www.cochrane-handbook.org.
4 Higgins JP, Altman DG, Gøtzsche PC et al. The Cochrane Collaboration’s tool for assessing 
risk of bias in randomized trials. BMJ 2011;343:d5928. doi:10.1136/bmj.d5928.
5 Reeves BC, Shea B, Wells GA. Classifying non-randomized studies (NRS) and the 
assessing the risk of bias for a systematic review. Workshop, 18th Cochrane Colloquium, 
Keystone 2010
6 Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized 
studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews 
of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. 
Available from www.cochrane-handbook.org.
7 Palmer DA. MacLennan S, Imamura M et al. Initial experience with a pilot Cochrane tool 
for applying a web-based survey of content experts to derive criteria for imbalance. 
Presented at the 19th Cochrane Colloquium, 19-22 October 2011, Madrid.
8 Review Manager (RevMan) [Computer program]. Version 5.2. Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2012.
MaxThesis.indb   129 27-10-15   20:39
part iii • bladder cancer and lymph node dissection 
130
9 Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: 
Presenting results and ‘Summary of findings’ tables. In: Higgins JPT, Green S (editors), 
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated 
March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.
org.
10 Liu J, Leppert J, Shinghal R, Gill H, Presti J, Gonzalgo M. Practice patterns of pelvic lymph 
node dissection for radical cystectomy from veterans affairs central cancer registry 
(VACCR). J Urol 2011; 185:e562
11 Isaka S, Okano T, Sato N, Shimazaki J, Matsuzaki O. Pelvic lymph node dissection for 
invasive bladder cancer. Nihon Hinyokika Gakkai Zasshi 1989;80:402-406
12 Miyakawa M, Oishi K, Okada Y, Takeuchi H, Okada K, Yoshida O. Results of the 
multidisciplinary treatment of invasive bladder cancer. Hinyokika Kiyo 1986;32:1931-
1939
13 Yuasa M, Yamamoto A, Kawanishi Y, Higa I, Numata A, Imagawa A. Clinical evaluation 
of total cystectomy for bladder carcinoma: a ten-year experience. Hinyokika Kiyo 
1988;34:975-981
14 Abdollah F, Sun M, Schmitges J et al. Stage-specific impact of pelvic lymph node 
dissection on survival in patients with non-metastatic bladder cancer treated with radical 
cystectomy. BJUI 2012; 109:1147-1154 
15 Zhang F, Wang F, Weng Z. Clinical significance of standard lymphadenectomy in radical 
cystectomy for bladder cancer. Journal of Practical Oncology 2013;28:284-286
16 Brunocilla E, Pernetti R, Schiavina R et al. The number of nodes removed as well as the 
template of the diseection is independently correlated to cancer-specific survival after 
radical cystectomy for muscle-invasive bladder cancer. Int Urol Nephrol 2013;45:711-719
17 Hori J, Tamaki G, Kita M, Iwata S, Matsumoto S, Kakizaki H. Survival impact of the extent 
of pelvic lymph node dissection in patients undergoing radical cystectomy for bladder 
cancer. Eur J Cancer 2013;49S1:S1-S22
18 Holmer M, Bendahl PO, Davidsson T, Gudjonsson S, Månsson W, Liedberg F. Extended 
lymph node dissection in patients with urothelial cell carcinoma of the bladder: can it 
make a difference? World J Urol 2009;27:521-526
19 Bostrom PJ, Mirtti T, Nurmi M et al. Extended lymphadenectomy and chemotherapy offer 
survival advantage in muscle-invasive bladder cancer. J Urol 2011;185:e640 
20 Jensen JB, Ulhøi BP, Jensen KM. Extended versus limited lymph node dissection in 
radical cystectomy: Impact on recurrence pattern and survival. World J Urol 2009; 27:521-
526 
MaxThesis.indb   130 27-10-15   20:39
131
p
a
r
t i
ii
21 Brossner C, Pycha A, Toth A, Mian C, Kuber W. Does extended lymphadenectomy increase 
the morbidity of radical cystectomy? BJUI 2004;93:64-66
22 Abd El-Latif A, Miocinovic R, Stephenson AJ et al. Impact of extended (e) versus standard 
lymph node dissection (sLND) on post-cystectomy survival (PCS) among patients with LN-
negative urothelial bladder cancer (UBC). J Urol 2011;185(4S):e759
23 Abd El Latif A, Miocinovic R, Stephenson AJ et al. Impact of extended versus standard 
lymph node dissection on overall survival among patients with urothelial cancer of the 
bladder. J Urol 2012;187(4S):e707
24 Dharaskar A, Kumar V, Kapoor R, Jain M, Mandhani A. Does extended lymph node 
dissection affect the lymph node density and survival after radical cystectomy? Ind J 
Cancer 2011;48:230-233 
25 Finelli A, Gill IS, Desai MM, Moinzadeh A, Magi-Galluzzi C, Kaouk JH. Laparoscopic 
extended pelvic lymphadenectomy for bladder cancer: technique and initial outcomes. J 
Urol 2004;172:1809-1812
26 Poulsen AL, Horn T, Steven K. Radical cystectomy: extending the limits of pelvic lymph 
node dissection improves survival for patients with bladder cancer confined to the 
bladder wall. J Urol 1998;160:2015-2019
27 Simone G, Papalia R, Ferriero M et al. Stage-specific impact of extended versus standard 
pelvic lymph node dissection in radical cystectomy. Int J Urol 2013;20:390-397
28 Dhar NB, Klein EA, Reuther AM, Thalmann GN, Madersbacher S, Studer UE. Outcome 
after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol 
2008;179:873-878
29 Abol-Enein H, Tilki D, Mosbah A et al. Does the extent of lymphadenectomy in radical 
cystectomy for bladder cancer influence disease-free survival? A prospective single-
center study. Eur Urol 2011;60:572-577
30 Wang G. Clinical significance of radical cystectomy with extended lymphadenectomy and 
influencing factors associated with recurrence of bladder cancer. Conference Meeting 
abstract MP08-19. Presented at: World Congress of Endourology; October 22–26, 2013; 
New Orleans, LA, USA.
31 Simone G, Abol-Enein H, Ferriero M et al. Extended versus super-extended PLND during 
radical cystectomy: comparison of two prospective series. J Urol 2012;187(4S):e708 
32 Zehnder P, Studer UE, Skinner EC et al. Super extended versus extended pelvic lymph 
node dissection in patients undergoing radical cystectomy for bladder cancer: a 
comparative study. J Urol 2011;186:1261-1268 
33 Vazina A, Dugi D, Shariat SF et al. Stage specific lymph node metastasis mapping in 
radical cystectomy specimens. J Urol 2004;171(5):1830-1834
MaxThesis.indb   131 27-10-15   20:39
part iii • bladder cancer and lymph node dissection 
132
34 Abol-Enein H, El-Baz M, Abd El-Hameed MA, Abdel-Latif M, Ghoneim MA. Lymph node 
involvement in patients with bladder cancer treated with radical cystectomy: a patho-
anatomical study-a single center experience. J Urol 2004; 172:1818-1821
35 Tilki D, Brausi M, Colombo R, Evans CP, Fradet Y, Fritsche HM et al. Lymphadenectomy 
for bladder cancer at the time of radical cystectomy. Eur Urol 2013;64:266-276
36 Fan X, Huang H, Bi L et al. Extended versus non-extended pelvic lymph node dissection 
and their influence on recurrence-free survival in patients undergoing radical cystectomy 
for bladder cancer: a systematic review and meta-analysis of comparative studies. BJUI 
2013; doi: 10.1111/bju.12371
37 Stein JP, Cai J, Groshen S et al. Risk factors for patients with pelvic lymph node 
metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept 
of lymph node density. J Urol 2003;170(1):35-41
38 Herr HW, Bochner BH, Dalbagni G et al. Impact of the number of lymph nodes retrieved on 
outcome in patients with muscle invasive bladder cancer. J Urol 2002;167(3):1295-1298
39 Leissner J, Hohenfellner R, Thuroff JW, Wolf HK. Lymphadenectomy in patients with 
transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. 
BJUI 2000;85:817-823
40 Dorin RP, Daneshmand S, Eisenberg MS et al. Lymph node dissection technique is more 
important than lymph node count in identifying nodal metastases in radical cystectomy 
patients: a comparative mapping study. Eur Urol 2011;60(5):946-952
41 Meijer RP, Nunnink CJ, Wassenaar AE et al. Standard lymph node dissection for 
bladder cancer: significant variability in the number of reported lymph nodes. J Urol 
2012;187(2):446- 450
MaxThesis.indb   132 27-10-15   20:39
133
p
a
r
t i
ii
Supplement 1
Embase 1974 to December 2013,
MEDLINE In-Process & Other Non-Indexed Citations 
MEDLINE 1946 to December 2013 
Ovid Multifile search URL: http://gateway.ovid.com  
 
1 urinary bladder neoplasms/
2 bladder cancer/
3 ((cancer$ or tumo$r$ or carcinoma or neoplas$) adj3 bladder).tw.
4 (squamous adj5 bladder).tw.
5 transitional cell carcinoma.tw.
6 transitional cell carcinoma/
7 Carcinoma, Transitional Cell/
8 or/1-7
9 Lymph Node Excision/
10 exp lymphadenectomy/
11 (lymphadenectomy or lnd).tw. 
12 (lymph node$ adj3 (dissect$ or excis$ or remov$)).tw.
13 or/9-12 
14 comparative study/ use prmz 
15 follow-up studies/ use prmz
16 time factors/ use prmz 
17 Treatment outcome/ use oemezd
18 major clinical study/ use oemezd
19 controlled study/ use oemezd
20 clinical trial/ use oemezd
21 (preoperat$ or pre operat$).tw.
22 (chang$ or evaluat$ or reviewed or baseline).tw.
23 (prospective$ or retrospective$).tw.
24 (cohort$ or case series).tw. 
25 (compare$ or compara$).tw.
26 case report/ use oemezd
27 case reports.pt. 
28 exp clinical trial/
29 Randomized Controlled Trials as Topic/ 
30 randomized controlled trial.pt. 
31 controlled clinical trial.pt.
32 randomization/ use oemezd 
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33 randomi?ed.ab. 
34 placebo.ab. 
35 drug therapy.fs. 
36 randomly.ab. 
37 trial.ab. 
38 groups.ab. 
39 (database$ or data?base$ or regist$).ab. 
40 or/14-39 
41 8 and 13 and 40 
42 (letter or editorial or comment*).pt. 
43 exp animals/ not humans/ 
44 41 not (42 or 43) 
45 remove duplicates from 44 
Cochrane Database of Systematic Reviews
Cochrane Central Register of Controlled Trials
The Cochrane Library (Issue 18 2013)
www.thecochranelibrary.com 
1 MeSH descriptor: [Urinary Bladder Neoplasms] this term only
2 MeSH descriptor: [Carcinoma, Transitional Cell] this term only
3 MeSH descriptor: [Carcinoma, Transitional Cell] this term only
4 bladder near/3 (cancer* or tumo*r* or carcinoma* or neoplas*)
5 squamous near/5 bladder
6 transitional cell carcinoma
7 #1 or #2 or #3 or #4 or #5 or #6
8 MeSH descriptor: [Lymph Node Excision] this term only
9 lymphadenectomy or lnd
10 (lymph node*) near/3 (dissect* or excis* or remov*)
11 #8 or #9 or #10
12 #7 and #11
LILACS (Latin American and Caribbean Center on Health Sciences Information)
http://lilacs.bvsalud.org/en/ 
 
Bladder cancer [Subject descriptor] or bladder and (cancer$ or tumo$ or carcinoma$ or 
neoplas$) [Words] and “LYMPHADENECTOMY” or lymph node dissection or lymph node 
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excision [Words]
Database of Abstracts of Reviews of Effects
Health Technology Assessment
 
Centre for Reviews and Dissemination 
www.crd.york.ac.uk/crdweb 
1. MeSH DESCRIPTOR Urinary Bladder Neoplasms
2. bladder adj3 (cancer* or tumor* or tumour* or carcinoma* or neoplas*)
3. MeSH DESCRIPTOR Carcinoma, Transitional Cell
4. transitional cell carcinoma
5. #1 OR #2 OR #3 OR #4
6. MeSH DESCRIPTOR Lymph Node Excision
7. lymphadenectomy or lnd
8. lymph node* adj3 (dissect* or excis$* or remov*)
9. #6 OR #7 OR #8
10. #5 AND #9
Clinicaltrials.gov 
lymphadenectomy | “Urinary Bladder Neoplasms” 
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Abstract
Purpose
Lymph node metastasis in patients who undergo radical cystectomy for bladder 
transitional cell carcinoma is considered a poor prognostic factor. However, 
patients with minimal lymph node involvement likely have a better outcome than 
those with extensive disease. We examined outcomes in patients with low volume 
lymph node metastasis and identified variables associated with disease recurrence. 
 
Materials and Methods 
Our institution maintains a database of 1,600 patients with bladder transitional 
carcinoma who underwent radical cystectomy from 1971 to 2005 with intent to 
cure. All patients with low volume lymph node metastasis, defined as 1 or 2 positive 
lymph nodes, without concomitant distant metastasis were included in study. 
 
Results 
A total of 181 patients were identified. Median follow-up was 12.8 years, during which 96 
patients experienced recurrence. Estimated 5 and 10-year recurrence-free survival was 43.8% 
and 40.9%, respectively. Multivariable analysis indicated that pathological stage/subgroup 
(RR 1.733, p = 0.015), lymph node density (RR 1.935, p = 0.014) and adjuvant chemotherapy 
(RR 0.538, p = 0.004) were independently associated with recurrence-free survival. 
 
Conclusions
A considerable proportion of patients with low volume lymph node metastasis in our 
cohort remained free of recurrence during follow-up. Extravesical tumor extension and 
lymph node density greater than 4% were associated with a higher recurrence risk and 
adjuvant chemotherapy was associated with a lower risk. Although some patients with 
low volume lymph node metastasis may be cured by surgery alone, these data support 
adjuvant chemotherapy in these patients.
Abbreviations and Acronyms
LND = lymph node density
LNM = lymph node metastasis
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Introduction
Radical cystectomy combined with appropriate lymph node dissection is standard 
treatment in patients with high grade invasive bladder cancer. [1] Metastasis are 
found in regional lymph nodes in approximately 25% of patients at surgery, which is 
associated with a higher incidence of disease progression.[1-3] Several variables were 
reported to provide risk stratification in patients with lymph node involvement after 
radical cystectomy, including the number of lymph nodes involved with tumor (nodal 
tumor burden), the primary bladder tumor pathological stage/subgroup and the extent 
of lymphadenectomy. [1-8]More recently lymph node density was identified as an 
independent prognostic factor. Lymph node density is defined as the number of lymph 
nodes involved with tumor divided by the total number of lymph nodes removed. [4,5] 
 In a large cohort from our institution approximately 50% of patients with node 
positive disease at radical cystectomy had only 1 or 2 nodes involved.[4] While it is likely 
that they have a better outcome than patients with higher volume LNM, to our knowledge 
there are no reports to date specifically of outcomes in these patients. Thus, we assessed 
clinical outcomes and identified independent prognostic variables in patients with low 
volume LNM.
Materials and Methods
Cohort Assembly
All 1,600 patients who underwent radical cystectomy for urothelial cancer at our institution 
with intent to cure between November 1971 and September 2005 were eligible for study 
inclusion. Data on all patients were collected using a standardized retrospective medical 
record review and stored in our institutional bladder cancer database. This established 
database includes information on all patients who undergo cystectomy at the department 
of urology at our institution and it is approved by the University of Southern California 
human subject committee. Of the 1,600 patients (23%) 369 had lymph node positive 
disease, including 181 (49%) with only 1 or 2 lymph nodes involved. These 181 patients 
comprise the study population.
Pathological Variables
All cystectomy specimens were examined using the same pathological protocol. Multiple 
sections and histological evaluation was performed on the primary bladder tumor, 
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bladder wall (adjacent and distant bladder mucosa of the primary tumor) and all lymph 
nodes. All bladder tumors were primary urothelial carcinoma. Patients with another 
primary tumor type, i.e. adenocarcinoma, squamous cell carcinoma etc, were excluded 
from study. Histological grading was done according to the method of Bergkvist and 
Moberger. [9] The 1997 American Joint Committee on Cancer TNM classification was used 
to pathologically stage bladder tumors. [10] Pathological subgroups were divided into 
organ confined (pTa, pTcis, pT1, pT2a and pT2b) and extravesical (pT3a, pT3b and pT4) 
tumors. No clearing techniques or solvents were used to identify lymph nodes. All lymph 
nodes were identified visually or by palpation.
Follow-up and Clinical Outcomes
All patients were routinely followed postoperatively at 4-month intervals in year 1, 
at 6-month intervals in year 2 and annually thereafter according to our database 
protocol. Follow-up consisted of physical examination and routine serum chemistry 
studies, including a biochemical liver profile and alkaline phosphatase determination. 
Radiographic evaluation of the urinary diversion, upper urinary tract with excretory 
urography or ultrasonography and chest radiography were done 4 months postoperatively 
and annually thereafter unless otherwise clinically indicated. Median follow-up in 
the 181 patients with low volume LNM was 12.8 years (range: 23 days to 34.6 years). 
 The primary outcomes of interest in this analysis were overall survival and 
recurrence-free survival. Time to overall survival was calculated from the date of radical 
cystectomy to the data of death from all causes. If lost to follow-up, patients were censored 
from analysis at the date of last follow-up. Recurrence-free survival was calculated from 
the date of radical cystectomy to the date of first documented clinical recurrence or death, 
whichever occurred first. If lost to follow-up before recurrence, patients were censored at 
the date of last follow-up. Operative mortality was defined as any death within 30 days 
after surgery. 
Statistical Analysis
Pearson’s chi-square or Fisher’s exact test was used to examine the association between 
categorical demographic and clinical variables. The Wilcoxon rank sum test was used 
to test differences in not normally distributed continuous variables between groups 
or subgroups. Kaplan-Meier plots were used to estimate the probability of overall and 
recurrence-free survival with time since radical cystectomy. The log rank test was used 
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to compare differences in survival or recurrence in subgroups. Proportional hazards 
models were used to estimate the independent relationship between various clinical 
and sociodemographic factors, and the 2 primary outcomes. All p values are 2-sided. 
 
Results
 
Patients
Of patients with low volume LNM, 118 (65.2%) had only 1 positive lymph node and 63 
(35%) had 2 lymph nodes involved. Operative mortality was low and occurred in 1 of the 
181 patients (0.55%) with low volume LNM. Median age in patients with low volume LNM 
was 66 years (range 36 to 88). Of the patients 55% had pT3a or higher disease (table 1). A 
total of 173 patients (96%) had localized lymphatic involvement, defined as involvement 
of the pelvic/external iliac, hypogastric, presacral or perivesical lymph nodes only. Eight 
patients (4%) had distant lymphatic involvement, including involvement of the common 
iliac lymph nodes in 4, interaortocaval lymph node involvement in 3 and para-aortic 
involvement in 1.
Table 1: Characteristics of 181 patients with 1 or 2 positive lymph nodes, 188 patients 
with more than 2 positive lymph nodes and all 369 node-positive patients after radi-
cal cystectomy
Patients with  
1 or 2 LN+ 
(n=181)
Patients with 
> 2 LN+  (n=188)
All patients with 
LN+ (n=369)
No. Age (%)
Greater than 65  
65 or less
 
91 (50.3) 
90 (49.7)
 
109 (58) 
79 (42)
 
200 (54.2) 
169 (45.8)
No. Gender (%) 
Male 
Female
 
142 (78.5) 
39 (21.5)
 
143 (76.1) 
45 (23.9)
 
285 (77.2) 
84 (22.8)
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Table 1: continued
No. Pathological stage (%) 
pT1 or less 
pT2a 
pT2b 
pT3a 
pT3b 
pT4
 
21 (11.7) 
18 (9.9) 
38 (21) 
28 (15.5) 
54 (29.8) 
22 (12.2)
 
14 (7.4) 
   8 (4.3) 
22 (11.7) 
32 (17) 
62 (33) 
50 (22.6)
 
35 (9.5) 
26 (7) 
60 (16.3) 
60 (16.3) 
116 (31.4) 
72 (19.5)
No. Pathological subgroup (%) 
Organ confined ( pT2b or less) 
Extravesical (greater than pT2b)
 
77 (42.5) 
104 (57.5)
 
44 (23.4) 
144 (76.6)
 
121 (32.8) 
248 (67.2)
No. Lymphovascular invasion (%) 
Present 
Absent 
Unknown
 
101 (56) 
58 (32) 
22 (12)
 
123 (65) 
40 (21) 
25 (14)
 
224 (61) 
98 (27) 
47 (12)
No. Neoadjuvant therapy (%) 
Systemic chemotherapy 
Radiotherapy
 
9 (36) 
16 (64)
 
9 (50) 
9 (50)
 
18 (42) 
25 (58)
No. Adjuvant therapy(%)
Systemic chemotherapy 
Radiotherapy 
Both
 
89 (97.8) 
2 (2.2) 
0
 
116 (96.7) 
2 (1.7) 
2 (1.7)
 
205 (97.2) 
4 (1.9) 
2 (0.9)
No. Positive surgical margins (%)
Present 
Absent
 
3 (1.7) 
178 (98.3)
 
6 (3) 
182 (97)
 
9 (2) 
360 (98)
No. peri-operative mortality (%)
Yes 
No
 
1 (0.6) 
180 (99.4)
 
4 (2.1) 
184 (97.9)
 
5 (1.4) 
364 (98.6)
Median yrs follow-up time 
(days - yrs range)
12.8 (23-34.6) 16.5 (5-30.6) 13.1 (5-34.6)
Median months overall survival 
(days-yrs range) 
36.4 (23-34.6) 19.5 (5-30.6) 25.2 (5-34.6)
Median months to recurrence 
(days-yrs range)
37.1 (23-25.0) 16.2 (5-21.5) 22.4 (5-25.0)
LN = lymph node
MaxThesis.indb   144 27-10-15   20:40
145
p
a
r
t i
v
Neo-adjuvant and Adjuvant Therapy
Neo-adjuvant therapy was given in 25 patients (13.8%), including 9 (5%) with neo-
adjuvant systemic chemotherapy and 16 (8.8%) with neo-adjuvant radiotherapy. A total 
of 91 patients (50.3%) received adjuvant therapy, including 2 (1.1%) with radiotherapy 
and 89 (49.2%) with chemotherapy. The most common adjuvant chemotherapy was 
cisplatin based chemotherapy in 70 patients, followed by carboplatin in 5, cisplatin and 
carboplatin in 3, cytoxan in 4 and another type in 4. In 3 patients the chemotherapy type 
was unknown. Five and 10-year overall survival rates in the neo-adjuvant therapy group 
were 30.2% and 17.2% versus 40.8% and 34.6% in the remaining 156 patients. While this 
difference did not attain statistical significance (log rank test p = 0.08), a larger sample 
size might have shown a statistical significant difference.
Recurrence Site
A total of 96 cases recurred during follow-up. Initial recurrence sites were the upper tract 
in 1 patient (0.6%), urethra in 3 (1.7%), local/pelvis in 10 (5.5%) and distant metastasis 
in 82 (45.3%). As expected, prognosis after recurrence was poor. Five and 10-year overall 
survival rates after recurrence were only 5.3% and 2.7%, respectively. 
Margin Status
Six patients had positive urethral margins and 3 had soft tissue margins. No patients 
had final positive ureteral margins. Five of 9 patients (56%) with positive margins and 
91 of 172 (55%) with negative margins had recurrence. The recurrence site did not 
necessarily correlate with urethral margin status since 4 patients with urethral margins 
had no recurrence, 1 had local recurrence and 1 had distant recurrence. No patient with 
positive urethral margins had urethral recurrence, partly because most of them also 
underwent urethrectomy at cystectomy or at a second operation. However, soft tissue 
positive margins correlated with the recurrence site. All 3 patients with positive soft tissue 
margins had recurrence and all recurrences were distal.
Recurrence-Free and Overall Survival 
Estimated 5 and 10-year recurrence-free survival rates in the 181 patients with low volume 
LNM was 43.8% and 40.9%, respectively. These recurrence outcomes were significantly 
better than in the 188 patients with more than 2 positive lymph nodes (p < 0.001, figure 1). 
On univariable analysis, the primary bladder tumor pathological subgroup bladder tumor 
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pathological subgroup was associated with recurrence. Patients with low volume LNM 
and an organ confined tumor had 52% and 48% 5 and 10-year recurrence free survival, 
respectively. In patients with extravesical tumor extension 5 and 10-year recurrence-free 
survival was significantly lower at 37% and 35%, respectively (p = 0.009, table 2). The 
89 patients (49%) with low volume LNM who received adjuvant chemotherapy had a 
more favorable recurrence rate on univariable analysis. Five and 10-year recurrence-free 
survival rates in this group were 54% and 52%, respectively. In contrast, 5 and 10-year 
recurrence-free survival in the remaining 92 patients (51%) was lower at 33% and 30%, 
respectively (p = 0.0022, table 2). In 84 patients with no neo-adjuvant or adjuvant therapy 
5 and 10-year survival was 27.2% and 17.5%, respectively (p < 0.0001).
Figure 1: Recurrence-free survival in 181 and 188 patients with low-volume lymph 
node metastasis (1 or 2 LN+) and more than 2 positive lymph nodes (>2 LN+), respec-
tively, after radical cystectomy
 Lymph node density was also associated with recurrence rates on univariable 
analysis. A lymph node density of 4% was chosen a priori based on the data spread to 
maximize statistical power. Recurrence-free survival was significantly lower in patients 
with a lymph node density of 4% or higher. Five and 10-year recurrence-free survival in 
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113 patients (62%) with lymph node density 4% or less was 52% and 50% vs 29% and 
26%, respectively, in 68 (38%) with lymph node density greater than 4% (table 2).
Table 2: Recurrence-free and overall survival in 181 patients with low-volume lymph 
node metastasis after radical cystectomy
Mean ± SE 
No recurrence probabiblity
Mean ± SE
Overall survival probabiblity
5 yrs 10 yrs p-
value
5 yrs 10 yrs p-
value
Node positive disease (all)
Greater than 2 positive nodes
2 positive nodes or less
0.34 ± 0.03
0.24 ± 0.04
0.44 ± 0.04
0.32 ± 0.03
0.23 ± 0.04 
0.41 ± 0.04
0.29 ± 0.02 
0.19 ± 0.03 
0.39 ± 0.04
0.22 ± 0.02
0.12 ± 0.03 
0.32 ± 0.04
Age
65 or less
Greater than 65
0.41 ± 0.05
0.47 ± 0.06
0.36 ± 0.05
0.47 ± 0.06
0.29
0.42 ± 0.05
0.37 ± 0.05
0.32 ± 0.05
0.32 ± 0.05
0.25
Gender
Male
Female
0.45 ± 0.05
0.41 ± 0.09
0.43 ± 0.05
0.33 ± 0.09
0.48
0.41 ± 0.04
0.34 ± 0.08
0.33 ± 0.04
0.28 ± 0.08
0.51
No. pos lymph nodes
One node involved
Two nodes involved
0.46 ± 0.05
0.39 ± 0.07
0.45 ± 0.05
0.33 ± 0.07
0.26
0.41 ± 0.05
0.36 ± 0.06
0.34 ± 0.05
0.28 ± 0.06
0.35
Lymph node density
4 % or less
Greater than 4 %
0.52 ± 0.05
0.29 ± 0.06
0.50 ± 0.05
0.26 ± 0.07
0.002
0.46 ± 0.05
0.28 ± 0.05
0.37 ± 0.05
0.23 ± 0.05
0.003
Pathological subgroup
Organ-confined (≤pT2)
Extravesical (>pT2)
0.52 ± 0.06
0.37 ± 0.05
0.48 ± 0.06
0.35 ± 0.05
0.009
0.53 ± 0.06
0.30 ± 0.05
0.46 ± 0.06
0.22 ± 0.04
<0.001
Lymphovascular invasion
Absent
Present
0.46 ± 0.06
0.42 ± 0.05
0.44 ± 0.06
0.39 ± 0.05
0.87
0.43 ± 0.06
0.36 ± 0.05
0.40 ± 0.06
0.26 ± 0.05
0.36
Adjuvant chemotherapy
Yes
No
0.54 ± 0.06
0.33 ± 0.06
0.52 ± 0.06
0.30 ± 0.05
0.002
0.52 ± 0.06
0.27 ± 0.05
0.48 ± 0.06
0.17 ± 0.04
<0.001
SE = standard error
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  On multivariable proportional hazards analysis the pathological tumor subgroup, 
adjuvant chemotherapy and lymph node density at a 4% cutoff were independently associat-
ed with time to recurrence and overall survival. Gender, age, lymphovascular invasion status 
and the number of positive lymph nodes (1 or 2) were not statistically significantly associated 
with time to recurrence or overall survival on univariable or multivariable analysis (table 3). 
  To identify prognostic factors in patients with low volume LNM who did not re-
ceive adjuvant or neo-adjuvant chemotherapy we performed subgroup analysis. When 
including 84 patients, lymph node density at a 4% cutoff and pathological tumor stage/
subgroup were independent prognostic factors of time to recurrence and overall survival. 
Patients with extravesical tumor extension or lymph node density greater than 4% had 
significantly lower recurrence-free and overall survival (table 3).
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Table 3: Multivariable analysis in 181 patients with low-volume lymph node metasta-
sis, including 84 patients without (neo)-adjuvant chemotherapy
Recurrence-free survival Overall survival
Haz-
ard 
radio
95% confi-
dence inter-
val
p-
value
Haz-
ard 
radio
95% con-
fidence 
interval
p-
value
Low volume LNM:
Patient age (greater than 65 vs 65 or less) 0.73 0.48 – 1.12 0.15 1.103 0.76 – 1.59 0.60
Gender (female vs male) 1.06 0.66 – 1.71 0.82 1.041 0.68 – 1.59 0.85
Number of positive lymph nodes (2 vs 1) 0.82 0.48 – 1.42 0.48 0.764 0.47 – 1.25 0.28
Lymphovascular invasion (present vs absent) 0.96 0.63 – 1.48 0.86 1.143 0.78 – 1.68 0.49
Lymph node density  
(greater than 4% vs 4% or less)
1.94 1.14 – 3.28 0.014 1.923 1.19 – 3.10 0.007
Pathological tumor stage  
(extravesical vs organ-confined)
1.73 1.11 – 2.70 0.015 1.896 1.28 – 2.82 0.002
Adjuvant chemotherapy (yes vs no) 0.54 0.35 – 0.82 0.004 0.483 0.33 – 0.70 < 0.001
Low volume LNM: no chemotherapy
Patient age (greater than 65 vs 65 or less) 0.69 0.38 – 1.23 0.21 1.13 0.68 – 1.87 0.64
Gender (female vs male) 1.05 0.53 – 2.05 0.89 0.97 0.55 – 1.73 0.92
Number of positive lymph nodes (2 vs 1) 0.66 0.32 – 1.36 0.26 0.65 0.34 – 1.25 0.20
Lymphovascular invasion (present vs absent) 0.73 0.39 – 1.36 0.33 1.11 0.65 – 1.90 0.71
Lymph node density  
(greater than 4% vs 4% or less)
2.48 1.24 – 4.97 0.010 2.24 1.20 – 4.19 0.012
Pathological tumor stage  
(extravesical vs organ-confined)
2.52 1.24 – 5.15 0.011 2.05 1.09 – 3.86 0.026
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Discussion
There is little doubt that positive lymph nodes after radical cystectomy are an adverse 
prognostic factor. However, it is important to identify variables that can further 
stratify the recurrence risk in patients with node positive disease since clinical 
outcomes in this group may vary greatly. Some studies indicate that patients with 
low volume lymph node disease may even be cured by surgery alone.[6,11,12] 
Our results indicate that patients with 1 or 2 positive lymph nodes may expect 
reasonable clinical outcomes since almost 40% did not have recurrence after 10 years. 
Furthermore, in this population pathological tumor stage, lymph node density and 
adjuvant chemotherapy were independently associated with disease-free survival. 
 The prognostic value of pathological tumor stage and adjuvant chemotherapy 
in this population is not surprising. It is generally thought that adjuvant chemotherapy in 
patients with high risk disease who do not receive neo-adjuvant chemotherapy provides 
a survival advantage, [3,4,13,14] although prospective studies supporting this view have 
been criticized for methodological problems.[15] Similarly pathological tumor stage 
has consistently been an independent predictor of survival in numerous studies.[1–4] 
 The observation that lymph node density is predictive in a population with low 
volume lymph node positive disease is somewhat unexpected. As previously described 
by Stein et al [4] and Herr, [5] lymph node density has been associated with bladder 
cancer recurrence. According to the literature a lymph node density of 20% to 25% is 
a cutoff above which recurrence-free survival is significantly higher.[4,5,8,13] While 
lymph node density was associated with recurrence in our study, the cutoff was lower 
at 4%. The fact that the numerator in lymph node density was fixed in this study at 1 or 2 
positive nodes implies that removing more lymph nodes likely influences recurrence-free 
survival in low volume LNM cases. In fact, a 4% cutoff suggests that in patients with 1 or 
2 positive lymph nodes removing at least 25 and 50 nodes, respectively, is associated 
with better recurrence-free survival. Leissner et al noted significantly higher survival 
in patients with 5 or fewer positive lymph nodes when more than 15 lymph nodes were 
removed. [11] Although the exact number of lymph nodes that should be removed at 
surgery remains unclear due to surgical and pathological variation among institutions, 
our study suggests a survival benefit in patients with low volume lymph node positive 
disease when more extensive lymphadenectomy is done. The exact reason why lymph 
node density is associated with recurrence-free survival in low volume lymph node 
positive cases is unclear but it is likely to be related to more accurate pathological staging 
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of the retroperitoneum. The likelihood that patients with 1 or 2 positive nodes truly have 
true low volume LNM increases when more nodes are removed, reflecting more adequate 
sampling (fig. 2). In turn more accurate staging leads to more appropriate application of 
adjuvant chemotherapy, possibly increasing survival. [16] 
Figure 2: Lymph node sampling in 2 identical patients with 5 positive lymph nodes, 
including 2 nodes at the obturator/hypogastric region and 3 nodes above the aortic 
bifurcation. 
Left: The lymph node dissection limited proximally by the common iliac bifurcation did not detect the 3 positive 
nodes above the aortic bifurcation. This patient would be incorrectly staged with low-volume LNM.
Right: With lymph node dissection carried up to the inferior mesenteric artery, sampling was more adequate since all 
5 positive lymph nodes were detected at surgery.
 Adjuvant chemotherapy in the setting of low volume lymph node involvement may 
provide a survival advantage and should be considered in all patients with this disease. 
However, almost a third of the patients who did not receive adjuvant chemotherapy survived 
for 10 years, underscoring the need for novel biomarkers or more refined prognostic models 
to better identify which patients with low volume LNM really need adjuvant therapy. Until 
such tests are available we must consider adjuvant chemotherapy in all patients with low 
volume LNM except those who cannot tolerate the well-known toxicity of platinum based 
chemotherapy. Specifically in patients with numerous co morbid conditions, advanced 
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age, poor functional status or renal insufficiency there is some use in identifying those 
who could potentially be observed and only receive chemotherapy if disease recurs. 
Our data indicate that lymph node density and primary tumor stage are independently 
associated with recurrence in patients who do and do not receive neo-adjuvant or 
adjuvant chemotherapy. Thus, in frail older patients with low volume lymph node 
involvement who are poor candidates for chemotherapy, it may be reasonable to observe 
them when lymph node density is less than 4% or disease is organ confined. However, 
these patients are in the minority. If a patient has the physical reserve to tolerate radical 
cystectomy, it is likely that the patient can also tolerate adjuvant chemotherapy, if needed. 
 As in all studies, our analysis has limitations. Despite promising outcomes in 
patients with low volume LNM all data were reviewed retrospectively. Moreover, no 
study patients were randomized to adjuvant chemotherapy, allowing selection bias to 
influence the results. Also, patients received various chemotherapy regimens, limiting 
our ability to make definitive statements on the effectiveness of adjuvant chemotherapy. 
 
Conclusions
Patients with low volume lymph node positive urothelial carcinoma who undergo radical 
cystectomy and lymph node dissection can expect reasonable clinical outcome. Extended 
lymph node dissection is crucial for accurate staging and may also have a therapeutic 
effect. Despite the potential curative effect of this aggressive surgical treatment, 
additional adjuvant chemotherapy might be of benefit. Furthermore, we identified 
important prognostic variables that may be useful when deciding whether to use adjuvant 
chemotherapy, including pathological stage and lymph node density.
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Abstract
 
Background
The current 7th edition of the American Joint Committee on Cancer TNM staging system 
for bladder cancer stages lymph node (LN)–positive disease based on LN location rather 
than LN size. In addition, common iliac LNs are now considered regional LNs. Whether 
these changes improve prognostication for node-positive patients, however, remains 
unclear.
Objective
To investigate whether the 7th edition of the TNM nodal staging system provides superior 
prognostication compared with the 6th edition.
Design, setting, and participants
Patients between 2002 and 2008 with LN metastases after radical cystectomy combined 
with extended or superextended LN dissection were included. Patients were staged using 
both TNM staging systems. Median follow-up was 54 months. 
Outcome measurements and statistical analysis
Kaplan-Meier curves were used to estimate overall survival (OS) and recurrence-free 
survival (RFS). Log-rank tests and Cox proportional hazard regression models were used 
to test associations of pathologic variables with OS and RFS.
Results and limitations
Included were 146 patients with LN metastases of whom 131 patients underwent 
superextended LN dissection and 15 patients underwent extended LN dissection. 
Although in the 7th TNM edition many patients moved from the N2 category to the N3 
category, RFS did not significantly differ within the nodal subgroups in either edition. LN 
metastases at or above the aortic bifurcation were not associated with decreased RFS (p = 
0.67). On multivariable analysis, the presence of extravesical disease (hazard ratio [HR]: 
2.84; p = 0.002), absence of adjuvant chemotherapy (HR: 0.32; p < 0.0001), and more 
than six positive LNs (HR: 2.72; p = 0.007) were associated with decreased RFS. This was 
a retrospective study with inherent limitations.
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Conclusions
LNs at or above the aortic bifurcation should be considered regional LNs. Neither the 6th 
nor the 7th TNM staging system performed well as a prognostic tool. A better staging 
system for LN-positive bladder cancer needs to be developed.
MaxThesis.indb   159 27-10-15   20:40
part iv • bladder cancer and prognosis
160
Introduction
The gold standard treatment for patients with muscle-invasive bladder cancer (MIBC) 
is radical cystectomy (RC) combined with lymph node dissection (LND). Approximately 
25% of patients with MIBC have lymph node metastases (LNMs) at the time of RC, 
which is associated with decreased survival.[1,2] Nonetheless, prognosis within 
the group of patients with LNMs varies. Although long-term survivors after surgery 
alone have been reported, other patients die of progressive disease despite adjuvant 
chemotherapy.[3] The American Joint Committee on Cancer (AJCC) TNM staging 
system accounts for the burden of nodal disease with three distinct categories.[4,5] In 
the 6th edition of the TNM staging system (2002), substaging of node-positive disease 
was based on the number and maximum diameter of LNMs. [4] In 2010 an update of 
the 2002 AJCC TNM staging system for bladder cancer was published. [5] In this 7th 
edition, substaging of nodal disease is based on lymph node (LN) location rather than 
LN size. In addition, LNMs at the common iliac vessels are considered regional LNs, 
whereas in the former edition involvement of these LNs was considered M1 disease. 
 It remains unclear whether the new nodal staging system improves 
prognostication in patients with LNMs. Although recent studies reported that LNMs at the 
common iliac vessels should indeed be considered regional LNMs [6,7], the location of 
LNMs does not appear to provide sufficient prognostication. To our knowledge, however, 
no study has directly compared the prognostic value of both the 2002 (6th edition) and 
2010 (7th edition) TNM nodal staging systems. In addition, whether LNs proximal to 
the common iliac vessels should be considered regional LNs is unknown. In this study, 
we investigated whether the changes in the 7th TNM nodal staging system improve 
prognostication for node-positive patients, analyzing a cohort of patients with LNMs who 
underwent extended LND or superextended LND to the level of the inferior mesenteric 
artery (IMA) takeoff and prospective LN mapping. In addition, we evaluated several 
LN variables to determine which LN factors may have independent prognostic value. 
 
Materials and methods
 
Patient selection and data collection
Data of patients treated with intent to cure RC for urothelial carcinoma of the bladder 
between 1971 and 2008 were prospectively collected in our database approved by the 
institutional review board. Starting in May 2002, LNs were submitted to the pathologist 
MaxThesis.indb   160 27-10-15   20:40
161
p
a
r
t i
v
in predesignated anatomically defined packets, allowing for location-based LN staging. 
Thus patients who underwent RC from May 2002 to December 2008 were eligible for 
inclusion (n = 637). Further inclusion criteria included the presence of regional or distant 
LNMs (n = 154; 24.2%) and an extended or superextended template of LND (n = 146). None 
of the patients had distant (organ) metastases at the time of RC. Superextended LND (n 
= 131) included the following boundaries: IMA (proximal), LN of Cloquet (distal), internal 
iliac vessels including obturator fossa and presciatic fossa (posterior), genitofemoral 
nerve (lateral), and presacral. Extended LND (n = 15) included the same lateral and distal 
boundaries, but the proximal boundary was defined as the level of the aortic bifurcation.
Pathologic analysis and staging
LNs were detected by palpation and microscopically, without the use of solvent techniques. 
The presence of an LN was defined as any aggregates of lymphocytes or lymphoid tissue 
that was at least partially encapsulated. Data on the number, size, location, and presence 
of extranodal extension in LNMs were collected. The RC specimen and LNs were analyzed 
by dedicated genitourinary pathologists.[8] Patients were staged according to the 6th 
TNM staging system (2002) and the 7th TNM staging system (2010) separately.[4,5] Table 
1 summarizes the modifications of the 7th edition TNM staging system compared with 
the 6th edition. To investigate the prognostic significance of defining regional and distant 
LNMs, survival analysis was performed both separating regional and distant LNMs and 
including patients with any LNMs. LN density was defined as the number of positive LNs 
divided by the total number of LNs removed.
Follow-up and clinical outcomes
Follow-up time was defined as the time from RC to the date of death (death from all 
causes) or to the date of last follow-up if the patient was still alive at the last follow-
up (censored). Median follow-up time was 54 mo (range:24 d to 7.7 yr). Kaplan-Meier 
plots were used to estimate the probabilities of overall survival (OS) and recurrence-free 
survival (RFS) over time since RC. The log-rank test was used to compare the differences 
of survival or recurrence in subgroups. The Cox proportional hazard model was used to 
test the association of multiple variables with recurrence and survival. The maximal chi-
square method was used to determine the optimal cut-off point for positive LNs.[9] All p 
values reported in the analyses are two sided with the level of significance set at p < 0.05. 
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Table 1: Nodal subcategories according to the 6th and 7th edition of the American 
Joint Committee on Cancer TNM nodal staging system
6th edition TNM staging system (2002) 7th edition TNM staging system (2010)
N1 Single LNM ≤ 2 cm Single LNM in the true pelvis
N2 Single LNM between 2-5 cm or
multiple LNM not greater than 5 cm
Multiple LNM in the true pelvis
N3 Any LNM >5 cm LNM to the common iliac vessels
M1 LNM at the common iliac vessels and/or 
metastatic disease in distant organs 
LNM at the aortic bifurcation and/or 
metastatic disease in distant organs
LNM = lymph node metastasis
Results
 
Clinical and pathologic characteristics
The cohort included 146 patients with LNMs. Median age was 68 yr (range: 41–88). The 
male-to-female ratio was 3.2:1. Superextended LND and extended LND was performed 
in 131 patients (89.7%) and 15 patients (10.3%), respectively. The median number of 
removed LNs was 71 (range: 15–170). The median number of positive LNs was 3 (range: 
1–97). Median LN density was 5%. Table 2 shows the distribution of various clinical and 
pathologic variables in patients with LNMs (including both regional and distant LNMs). 
Survival outcomes
Of all 146 patients with LNMs (regional and distant), 88 patients (60.3%) died (any cause), 
and 77 patients (52.7%) developed recurrent disease. The 5-yr RFS and OS was 40.3% and 
32.7%, respectively. 
MaxThesis.indb   162 27-10-15   20:40
163
p
a
r
t i
v
Table 2: Clinical and pathological characteristics divided per nodal substage 
2002 TNM staging system
(6th edition)*
2010 TNM staging system
(7th edition)*
All LN+
(n=146)
N1
(n=30)
N2
(N=110)
N3
(N=6)
N1
(N=33)
N2
(N=56)
N3
(N=57)
Tumor stage (%)
T0
Ta/Tis
T1
T2
T3
T4
3 (2.0)
2 (1.4)
6 (4.1)
26 (17.8)
82 (56.2)
27 (18.5)
-
1 (3.3)
2 (6.7)
10 (33.3)
13 (43.3)
4 (13.3
3 (2.7)
1 (0.9)
4 (3.6)
16 (14.6)
66 (60.0)
20 (18.2)
-
-
-
-
3 (50.0)
3 (50.0)
-
1 (3.0)
2 (6.1)
10 (30.3)
15 (45.5)
5 (15.1)
1 (1.8)
-
2 (3.5)
11 (19.7)
33 (58.9)
9 (16.1)
2 (3.5)
1 (1.8)
2 (3.5)
5 (8.7)
34 (59.7)
13 (22.8)
Extranodal extension (%) 32 (21.9) 4 (13.3) 26 (23.6) 2 (33.3) 7 (21.2) 10 (17.9) 15 (26.3)
Adjuvant chemotherapy (%) 84 (57.5) 18 (60) 65 (59.1) 3 (50) 19 (57.6) 35 (62.5) 32 (56.1)
Neo-adjuvant chemotherapy  
(%)
10 (6.8) 0 9 (8.2) 1 (16.7) 2 (6.0) 4 (7.1) 4 (7.0)
LN = lymph node
* Including patients with regional and distant lymph node metastasis
Survival analysis in the 6th TNM staging system
According to the 6th TNM edition, 28 patients (19.2%) were N1, 59 patients (40.4%)
 were N2, 2 patients (1.4%) were N3, and 57 patients (39.0%) had M1 disease. Five-year 
RFS was 53.6%, 39.5%, 0%, and 35.2% in N1, N2, N3, and M1 patients, respectively (p = 
0.31; Fig. 1b). Patients with M1 disease did not have significantly lower RFS compared with 
patients with regional LNMs (N3–N1) disease (p = 0.79). Including patients with distant 
LNMs (former M1 patients) in the nodal staging system, 30 patients (20.5%) had N1,110 
patients (75.3%) had N2, and 6 patients (4.1%) had N3 disease. The 5-yr OS in N1, N2, 
and N3 patients was 37.6%, 31.3%, and 0%, respectively (p = 0.28). The 5-yr RFS in N1, 
N2, and N3 patients was 53.5%, 37.2%, and 0%, respectively (p = 0.30). The proportion 
of patients receiving adjuvant chemotherapy was statistically similar among N-stage 
subgroups (Table 2).
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Table 3: Multivariable analysis including the 6th edition of the TNM staging 
system (2002)
All LN+ 
(n=146) 
(%)
Recurrence-free survival Overall survival
HR (95% CI) p-value HR (95% CI) p-value
Nodal stage (2002)*
  N1
  N2
  N3
30 (20.5)
110 (75.3)
6 (4.1)
1.00 (Reference)
0.80 (0.41 – 1.57)
0.96 (0.28 – 3.30)
0.51
0.95
1.00 (Reference)
0.93 (0.51 – 1.71)
1.18 (0.36 – 3.80)
0.81
0.78
Tumor stage 
  Organ-confined (≤ pT2b)
  Extravesical (> pT2b)
37 (25.3)
109 (74.7)
1.00 (Reference)
2.73 (1.42 – 5.25) 0.0027
1.00 (Reference)
2.20 (1.25 – 3.90) 0.0067
Lymphovascular invasion
  No
  Yes
41 (28.1)
105 (71.9)
1.00 (Reference)
1.54 (0.86- 2.73) 0.14
1.00 (Reference)
1.09 (0.65 – 1.82) 0.73
Number of LNM
  < 6 LNs
  ≥ 6 LNs
93 (63.7)
53 (36.3)
1.00 (Reference)
1.64 (0.99 – 2.71) 0.05
1.00 (Reference)
1.72 (1.07 – 2.75) 0.0244
Adjuvant chemotherapy
  No
  Yes
60 (41.1)
86 (58.9)
1.00 (Reference)
0.32 (0.21 – 0.49) < 0.0001
1.00 (Reference)
0.32 (0.21 – 0.49) < 0.0001
HR = hazard ratio;   CI = confidence interval;   LN = lymph node; 
LNM = lymph node metastasis * Including patients with regional and distant LNM
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Figure 1: (a) Overall survival and (b) recurrence-free survival in all patients with 
lymph node metastases according to the 6th edition of the TNM staging system 
(2002)
(a) Overall survival  
(b) Recurrence-free survival 
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Survival analysis in the 7th TNM staging system
According to the 7th TNM edition, 27 patients (20.6%) were N1, 50 patients (38.2%) 
were N2, 13 patients (9.9%) were N3, and 41 patients (31.3%) had M1 disease (LNMs 
at or above the aortic bifurcation). Patients who did not undergo superextended LND 
(n = 15) were excluded from this analysis. The 5-yr RFS was 54.0%, 35.6%, 53.9%, and 
27.0% for N1, N2, N3, and M1, respectively (p = 0.67; Fig. 2b). Patients with LNMs at 
or above the aortic bifurcation (M1) did not have a statistically significant lower RFS 
compared with patients with regional LNMs (N1–N3; p = 0.44). Including patients with 
distant LNMs (former M1 patients) in the nodal staging system, 33 patients (22.6%) 
had N1 disease, 56 (38.4%) patients had N2 disease, and 57 (39.0%) patients had 
N3 disease. The 5-yr OS was 37.9%, 33.0%, and 28.8% in N1, N2, and N3 patients, 
respectively (p = 0.29). The 5-yr RFS was 48.0%, 40.3%, and 35.2% in N1, N2, and N3 
patients, respectively (p = 0.65). The percentage of patients who received adjuvant 
chemotherapy was again statistically similar among N-stage subgroups (Table 2).
Table 4: Multivariable analysis including the 7th edition of the TNM staging 
system (2010) 
All LN+ 
(n=146) (%)
Recurrence-free survival Overall survival
HR (95% CI) p-value HR (95% CI) p-value
Nodal stage (2010)*
  N1
  N2
  N3
33 (22.6)
56 (38.4)
57 (39.0)
1.00 (Reference)
0.94 (0.50 – 1.74)
0.44 (0.18 – 1.07)
0.83
0.07
1.00 (Reference)
1.03 (0.57 – 1.85)
0.70 (0.31 – 1.61)
0.92
0.40
Tumor stage 
  Organ-confined (≤ pT2b)
  Extravesical (> pT2b)
37 (25.3)
109 (74.7)
1.00 (Reference)
2.88 (1.50 – 5.52) 0.0014
1.00 (Reference)
2.26 (1.23 – 3.99) 0.0050
Lymphovascular invasion
  No
  Yes
41 (28.1)
105 (71.9)
1.00 (Reference)
1.67 (0.95 – 2.96) 0.07
1.00 (Reference)
1.14 (0.69 – 1.90) 0.61
Number of LNM
  < 6 LNs
  ≥ 6 LNs
93 (63.7)
53 (36.3)
1.00 (Reference)
2.85 (1.36 – 6.00) 0.0056
1.00 (Reference)
2.25 (1.13 – 4.49) 0.0217
Adjuvant chemotherapy
  No
  Yes
60 (41.1)
86 (58.9)
1.00 (Reference)
0.34 (0.22 – 0.54) < 0.0001
1.00 (Reference)
0.32 (0.21 – 0.49) < 0.0001
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HR = hazard ratio;    CI = confidence interval;    LN = lymph node;  
LNM = lymph node metastasis  * Including patients with regional and distant LNM
Figure 2: (a) Overall survival and (b) recurrence-free survival in all patients with 
lymph node metastases according to the 7th edition of the TNM staging system 
(2010)
(a) Overall survival 
(b) Recurrence-free survival
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Prognostic factors
On univariable analysis, extravesical (≥pT3) disease (p = 0.0031), more than six positive 
LNs (p = 0.0015), positive soft tissue margins (p < 0.0001), and the absence of adjuvant 
chemotherapy (p < 0.0001) were associated with decreased RFS. Tables 3 and 4 show the 
results of the multivariable analysis including tumor stage, lymphovascular invasion, 
number of LNMs, adjuvant chemotherapy, and both editions of the TNM staging system 
separately. In both multivariable analyses, the presence of extravesical disease and use of 
adjuvant chemotherapy were independently associated with OS and RFS. In addition, in 
the multivariable analysis including the 7th edition staging system, more than six positive 
LNs was independently associated with decreased RFS and OS (Table 4).
Discussion
The presence of LNMs at the time of RC has consistently been associated with decreased 
survival [1–3]. However, because the prognosis within the group of patients with LNMs 
varies, the AJCC TNM staging system traditionally divides nodal disease into three 
categories. Although in the recent update of the staging system the three categories 
remain, size-based nodal staging has changed into location based nodal staging, and 
LNMs at the common iliacs are now considered regional LNMs [4,5]. In this study, we 
confirmed the finding of two recent studies demonstrating that inclusion of the common 
iliac nodes as regional LNMs is justified.[6,7] In addition, analyzing 41 patients with LNMs 
at or above the aortic bifurcation, we found that these patients did not have significantly 
lower RFS compared with patients with regional LNMs and should therefore be classified 
as nodal disease rather than distant metastatic disease. This outcome differs from a 
recent Danish study of 43 node-positive patients, reporting that LNMs above the aortic 
bifurcation were independently associated with decreased RFS. [6] Potential explanations 
for this difference may be shorter follow-up (not mentioned), lower sample size (seven 
patients with LNMs above the aortic bifurcation), differences in LND technique, or the 
exclusion of patients who received adjuvant chemotherapy in their study. 
 To our knowledge, this is the first study to critically analyze both the 6th and 
7th edition TNM nodal staging systems. In the 6th edition, the vast majority of patients 
had N2 disease, whereas the 7th edition staging system shifted many patients from 
the N2 category into the N3 category. However, it has been recently suggested that the 
location of LNMs is not an independent prognostic factor in patients with regional LNMs 
[6,7]. In this study, we found not only location-based nodal staging to have insufficient 
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prognostic value but also size-based nodal staging. This result was consistent regardless 
of the inclusion or exclusion of patients with distant LNMs. These findings suggest that 
the TNM staging system needs to be modified to further define the prognosis in node-
positive patients. 
 The only LN-related variable to be significantly associated with survival and 
recurrence was the number of LNMs, which is consistent with previous studies.[6,10,11] 
Although we found more than six positive LNs to be associated with decreased survival, 
the exact cut-off point for the number of LNMs remains uncertain because it has varied 
widely across previous large series.[3,6,10,11] Defining a strict cut-off point in this 
quantitative variable is not free of bias. For example, we previously reported more than 
eight LNMs to be independently associated with decreased survival using an older cohort 
of patients between 1971 and 1997.[11] However, it has been demonstrated that several 
factors influence total LN count, such as the technique and extent of LND, method of 
LN submission, and pathologic processing and evaluation.[12–14] Because practice has 
evolved during the last decade, for example routinely performing LN packaging, these 
differences likely explain the different cut-off findings. LN density is affected in similar, 
if not greater, fashion because this factor includes both the number of LNMs and the 
number of LNs removed. In the current study, we found a lower median LN density of 
5% compared with the 18% reported previously.[11] Thus the cut-off point of LNMs varies 
not only between institutions but also by era within an institution. In the absence of a 
worldwide standardization of factors influencing LN count, the number of LNMs cannot 
be adequately incorporated in the TNM staging system. Addition of a qualitative nodal 
variable, such as extranodal extension, would be easier to standardize and incorporate, 
but its prognostic value is under debate.[15–17] In this study, the presence of extranodal 
extension was not independently associated with RFS or OS, although accurate evaluation 
of this variable would require pathologic re-review of the specimens, which was not done 
for this study.
 This study has limitations that need to be acknowledged. First, despite the 
prospective collection of data, this is a retrospective study with its inherent limitations. 
Second, only patients who underwent extended (up to the aortic bifurcation, including 
common iliac and presacral LNs) or superextended LND were included in this study, 
and the extent of LND was not randomized. Nonetheless, 90% of patients underwent 
a superextended LND using very similar techniques. Finally, the use of neo-adjuvant 
chemotherapy was limited, and treatment with (neo-)adjuvant chemotherapy was 
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not randomized, predisposing to a potential selection bias. Also, intersurgeon and 
interpathologist variability may have affected LN location and LN count. However, this 
cohort comprises a homogeneous set of patients with a limited number of surgeons 
who were all institutionally trained. In addition, specimens were reviewed by dedicated 
genitourinary pathologists. Acknowledging these limitations, this study provides further 
insight into the prognosis of patients with LNMs and effectively compares the two 
most contemporary TNM staging systems using the largest reported cohort of patients 
undergoing (super)extended LND and LN mapping. 
 
Conclusions
This study demonstrates that both the 6th and 7th editions of the TNM staging system have 
limited prognostic value in the stratification of patients with LNMs. Although the number 
of LNMs was an independent prognostic factor, this variable is not uniformly analyzed 
worldwide. Improving the TNM system with regard to nodal staging will therefore require 
future studies to elucidate highly reproducible variables with significant prognostic value.
References
1 Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive 
bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666–675
2 Karl A, Carrol PR, Gschwend JE et al. The impact of lymphadenectomy and lymph 
node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol 
2009;55:826-835
3 Bruins HM, Huang GJ, Skinner DG, Stein JP, Penson DF. Clinical outcomes and 
predictors of recurrence in patients with low volume lymph node positive urothelial 
carcinoma following radical cystectomy. J Urol 2009;182:2182–2187
4 Sobin LH, Wittekind C. TNM classification of malignant tumors. ed. 6. New York, NY: 
Wiley-Liss; 2002.
5 Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Urinary bladder AJCC 
cancer staging manual. ed. 7. New York, NY: Springer; 2010. p. 497.
MaxThesis.indb   170 27-10-15   20:40
171
p
a
r
t i
v
6 Jensen JB, Ulhoi BP, Jensen KM. Evaluation of different lymph node (LN) variables 
as prognostic markers in patients undergoing radical cystectomy and extended LN 
dissection to the level of the inferior mesenteric artery. BJUI 2012;109:388–393
7 Tarin TV, Power NE, Ehdaie B et al. Lymph node-positive bladder cancer treated with 
radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur Urol 
2012;61:1025–1030
8 Cheng L, Montironi R, Davidson DD, Lopez-Beltran A. Staging and reporting of urothelial 
carcinoma of the urinary bladder. Mod Pathol 2009;22(Suppl 2):S70–95.
9 Miller R, Siegmund D. Maximally selected chi-square statistics. Biometrics 
982;48:1011-1016
10 Mills RD, Turner WH, Fleischmann A, Markwalder R, Thalmann GN, Studer UE. Pelvic 
lymph node metastases from bladder cancer: outcome in 83 patients after radical 
cystectomy and pelvic lymphadenectomy. J Urol 2001;166:19–23
11 Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node 
metastases following radical cystectomy with en bloc pelvic lymphadenectomy:the 
concept of lymph node density. J Urol 2003;170:35–41
12 Dorin RP, Daneshmand S, Eisenberg MS et al. Lymph node dissection technique is more 
important than lymph node count in identifying nodal metastases in radical cystectomy 
patients: a comparative mapping study. Eur Urol 2011;60:946–952.
13 Pagano F, Bassi P, Galetti TP et al. Results of contemporary radical cystectomy 
for invasive bladder cancer: a clinicopathological study with an emphasis on the 
inadequacy of the tumor, nodes and metastases classification. J Urol 1991;145:45–50
14 Stein JP, Penson DF, Cai J et al. Radical cystectomy with extended lymphadenectomy: 
evaluating separate package versus en bloc submission for node positive bladder 
cancer. J Urol 2007;177:876–881
15 Jeong IG, Ro JY, Kim SC et al. Extranodal extension in node-positive bladder cancer: the 
continuing controversy. BJUI 2010;108:38–43
16 Seiler R, Gunten M, Thalmann GN, Fleischmann A. Extracapsular extension but not 
the tumour burden of lymph node metastases is an independent adverse risk factor in 
lymph node-positive bladder cancer. Histopathology 2011;58:571–578
17 Fleischmann A, Thalmann GN, Markwalder R, Studer UE. Prognostic implications of 
extracapsular extension of pelvic lymph node metastases in urothelial carcinoma of the 
bladder. Am J Surg Pathol 2005;29:89–95
MaxThesis.indb   171 27-10-15   20:40
a)
b)
c)
MaxThesis.indb   172 27-10-15   20:40
173
p
a
r
t i
v
Bruins HM a, Aben KH b,c, Arends TJ c, 
Van der Heijden AG a, Witjes JA c
The impact of the time interval between 
diagnosis of muscle-invasive bladder 
cancer on staging and survival: 
a Netherlands Cancer Registry analysis
CHAPTER  9
Department of Urology, Radboud University Medical Center
Nijmegen, The Netherlands
Netherlands Comprehensive Cancer Organisation (IKNL) 
Utrecht, The Netherlands
Radboud Institute for Health Sciences (RIHS), Radboud University 
Medical Center, Nijmegen, The Netherlands
a)
b)
c)
MaxThesis.indb   173 27-10-15   20:40
part iv • bladder cancer and prognosis
174
Abstract
Introduction
Data from single-center series suggest that a delay in time to radical cystectomy 
(RC) more than 3 months after diagnosis of muscle-invasive bladder cancer 
(MIBC) is associated with pathological upstaging and decreased survival. 
Limited data is, however, available from population-based studies. In this 
study, the impact of delayed RC was assessed in a nationwide cohort. 
 
Materials and Methods
Patients who underwent RC between 2006 and 2010 with primary clinical T2-T4N0M0 
urothelial bladder cancer were selected using the Netherlands Cancer Registry (NCR) 
database. Data from the NCR was supplemented with data from the Nationwide Network 
and Registry of Histo- and Cytopathology (PALGA) database in case of incomplete 
information. The cohort was divided in patients who underwent RC ≤3 months (group I) 
versus patients who underwent RC >3 months (group II). Median time to RC, variables 
associated with delayed RC >3 and the impact of delayed RC on staging and overall 
survival (OS) were evaluated in patients who underwent neo-adjuvant therapy and 
patients who did not. 
Results
1,782 patients were included. Median follow-up time was 5.1 years for living patients and 
1.3 years for deceased patients. Median time to RC was 50 days (interquartile range (IQR): 
27 days) and 93% of patients underwent RC ≤3 months. Patients older than 75 years (OR 
0.50; 95CI 0.32-0.77), referred for RC (OR 0.41; 95CI 0.26-0.69) and treated in a university 
hospital (OR 0.34; 95CI 0.21-0.56) were less likely to undergo RC ≤3 months. Pathologic 
upstaging rate (43.9% vs 42.1%) and node-positive disease rate (20.2% vs 21.7%) did 
not differ for group I and II. Delayed RC >3months was not associated with decreased OS 
adjusting for confounding variables (HR 1.16; 95CI 0.91-1.48, p = 0.25). Median time to 
RC in patients that received neo-adjuvant therapy (n=105) was 133 days (IQR: 62 days). 
Adjusting for confounding variables, delayed RC>3 months was not associated with OS 
(HR 0.90, 95CI 0.45-1.82).
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Conclusions
The vast majority of patient underwent RC within 3 months after diagnosis of MIBC, as 
recommended in the EAU MIBC guideline. Delayed RC for more than 3 months had no 
adverse impact on staging and survival. 
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Introduction
Radical cystectomy (RC) is considered the standard treatment for patients with muscle-
invasive bladder cancer (MIBC). The aggressive nature of the disease requires timely 
treatment, but this can be challenging for various reasons. Thorough patient medical 
evaluation, pre-operative counseling and often, due to the increasing centralization 
of bladder cancer care, referral to another hospital is required. Also, patients may be 
reluctant to undergo major surgery and postpone the decision to undergo RC or request 
a second opinion. Furthermore, neo-adjuvant chemotherapy is increasingly used in 
MIBC patients. Collectively, these factors may contribute to a potential delay in RC. 
 The European Association of Urology (EAU) recommends to perform RC within 
3 months after MIBC diagnosis, as a delay of more than 3 months has been reported to 
increase the risk of progression and cancer-specific mortality.[1] This recommendation, 
however, relies heavily on data from referral centers with a selected cohort of patients 
that may not reflect the general population.[2-5] An unselected nationwide population-
based dataset could provide valuable information on the impact of delayed RC 
on the pathologic upstaging rate and survival, but such studies are scarce.[6,7] 
 In this nationwide study, the aim was to evaluate I) the median delay from MIBC 
diagnosis to RC and adherence to the EAU MIBC guideline recommendation concerning 
the timing of RC, II) what parameters are associated with prolonged time to RC, III) the 
impact of a delay of more than 3 months on staging and survival.
Materials and Methods
 
Patient cohort
Using the database of the Netherlands Cancer Registry (NCR), a nationwide cancerregistry, 
all patients who underwent RC between 2006 and 2010 with clinical T2-T4N0M0 urothelial 
carcinoma of the bladder were included. As the NCR records primary non-invasive and 
invasive cancer diagnoses, patients diagnosed with T1 invasive bladder cancer who 
progress to MIBC, could not be identified. Therefore, only patients with primary clinical 
T2-T4N0M0 urothelial bladder cancer were included. Patients with a partial cystectomy 
were excluded. The cohort was divided into 2 RC groups; patients who underwent RC 
≤3 months after transurethral resection of the bladder tumor (TURBT; group I) versus 
patients who underwent RC >3 months after TURBT (group II). Patients that received 
neo-adjuvant therapy were included were retained in this study, but analyzed separately. 
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Data retrieval and management
The secured NCR database holds patient and tumor characteristics as well as information 
on treatment and vital status. Vital status of all patients recorded in the NCR is updated 
annually through record linkage with the Dutch Municipality Registry (GBA) which includes 
information on birth, death and emigration of all Dutch inhabitants. Data is collected by 
an independent well-trained team of registration personnel. The date of TURBT in which 
MIBC was present, was not available in the NCR for all patients. Therefore, the dataset 
from the NCR was linked to the database held by the Nationwide Network and Registry 
of Histo- and Cytopathology (PALGA), containing all histopathologic reports generated 
in the Netherlands. Data concerning the date of TURBT with MIBC and the date of RC 
were anonymously linked to the NCR database through irreversible pseudonymisation by 
a Third Trusted Party (ZorgTTP, Houten, The Netherlands). The study received approval 
by the NCR internal ethics committee and data from the PALGA and NCR databases were 
anonymously provided to the principal investigator. 
Histopathologic and clinical variables
Pre-operative clinical staging was based on the TURBT specimen and results of cross-
sectional imaging and physical examination. Pathologic tumor staging was based on the 
RC specimen and standardized to the 2002 TNM staging system of the American Joint 
Committee on Cancer. [8] Pathologic upstaging was defined as a higher pathologic 
stage compared to the clinical stage, whereas pathologic downstaging indicates a lower 
pathologic stage compared to the clinical stage. 
Follow-up and statistical analysis
Follow-up was completed until the 31th of December 2013 and defined as time between 
TURBT and date of death or date of censuring whichever came first. Descriptive analyses 
were used to characterize both the total cohort and groups I and II. Univariable and 
multivariable logistic regression analyses were performed to identify factors associated 
with delayed RC. Overall survival (OS) was calculated from the time from TURBT to the 
date of death. Univariable and multivariable Cox proportional hazard regression analyses 
were performed to assess which clinical and pathologic variables were associated 
with OS. Different cut-off points concerning the time to RC were evaluated for survival 
differences by use of long-rank tests. The cut-off points used ranged from 12 to 20 weeks. 
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All of the above mentioned analysis were repeated for the neo-adjuvant group. Analyses 
were performed using SAS. 
Results
Table 1 summarizes the characteristics of the 1,782 included patients. Median time from 
MIBC to RC was 50 days (range: 1-295 days, interquartile range (IQR) 27 days). The 
median time to RC was longer for patients ≥75 years of age, for patients referred for 
RC and for patients treated in an university hospital (Table 1). Median follow-up time of 
patients alive at the 31th of December 2013 was 5.1 years (range: 0.7-8.0 years) and 1.3 
years (range: 0.1-7.3 years) for deceased patients. Increasing time to RC did not result in 
a higher pathologic upstaging rate (Table 2).
Table 1: Characteristics of the study population
Variable Number of patients (%) Median time to cystec-
tomy (days)
Total cohort 1,782 (100)
Gender
  Male 1325 (74.4) 50
  Female 457 (25.6) 49
Age
  < 60 years 392 (22.0) 48
  60-74 years 1004 (56.3) 49
  ≥75 years 386 (21.7) 54
Year of diagnosis
  2006 331 (18.6) 49
  2007 333 (18.8) 52
  2008 356 (20.0) 48
  2009 365 (20.5) 49
  2010 397 (22.3) 50
Clinical stage
  cT2 1534 (86.1) 50
  cT3 177 (9.9) 48
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  cT4 71 (4.0) 48
Pathologic stage 
  ≤pT1 55 (3.1) 49
  pT2 760 (42.6) 51
  pT3 735 (41.3) 48
  pT4 194 (10.9) 50
  pTx 38 (2.1) 56
Lymph node status
  No lymph node dissection 220 (12.3) 51
  Lymph node dissection 1562 (87.7) 50
    Negative   1245 (79.7)   50
    Positive   317 (20.3)   48
Adjuvant chemotherapy
  Yes 48 (2.7) 38
  No 1734 (97.3) 50
Referred for cystectomy
  Yes 310 (17.4) 64
  No 1472 (82.6) 48
Cystectomy hospital
  Non-university 1504 (84.4) 49
  University 264 (14.8) 63
Time to cystectomy 
  ≤ 4 weeks 186 (10.4)
  5-8 weeks 915 (51.3)
  9-12 weeks 507 (28.5)
  13-16 weeks 123 (6.9)
  >16 weeks 51 (2.9)
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Table 2: The impact of the time interval from muscle-invasive bladder cancer diagno-
sis to radical cystectomy on cancer staging 
Total cohort (n=1,782) Group I 
 
(RC < 3 months)
N=1659
Group II 
 
(RC > 3 months)
N=123
Number of pts 
(%)
Median time 
to RC in days 
(range)
Downstaging* 105 (5.9) 48 (15-176) 97 (5.9) 8 (6.5)
No staging difference* 924 (51.9) 50 (1-295) 863 (52.0) 61 (49.6)
Upstaging* 753 (42.3) 49 (7-245) 699 (42.1) 54 (43.9)
* Comparing clinical stage with pathological stage 
RC = radical cystectomy
 As shown in Table 3, a total 1,659 patients (93.1%) underwent RC ≤3 months 
(group I) and 123 patients (6.9%) did not (group II). Patients were less likely to undergo 
RC ≤3 months when older than 75 years (odds ratio (OR) 0.50; 95% confidence interval 
(95CI) 0.32-0.77), referred for RC (OR 0.41; 95CI 0.26-0.69) and treated in a university 
hospital (OR 0.34; 95CI 0.21-0.56; Table 3). Both the pathologic upstaging rate (43.9% vs 
42.1%) and rate of node-positive disease (20.2% vs 21.7%) did not differ for group I and II.
 
Table 3: Association of clinical and histopathologic variables with the time interval 
from muscle-invasive bladder cancer diagnosis to radical cystectomy 
Total 
cohort 
(n=1,782)
Group I 
(RC ≤ 3 
months, 
n=1,659) 
 
No of pts 
(%)
Group II
(RC >3 
months, 
n=123) 
 
No of pts 
(%)
Univariable  
logistic  
regression 
analysis for RC 
<3months  
 
OR (95% CI)
Multivariable 
logistic regres-
sion analysis 
for RC 
<3months
 
OR (95% CI)
Gender
  Male
  Female
 
1325
457
 
1228 (74.0)
431 (26.0)
 
97 (78.9)
26 (21.1)
 
0.76 (0.49-1.20
ref
 
0.79 (0.49-1.27)
ref
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Year of diagnosis
  2006
  2007
  2008
  2009
  2010
331
333
356
365
397
314 (18.9)
299 (18.0)
329 (19.8)
343 (20.7)
374 (22.6)
17 (13.8)
34 (27.6) 
27 (22.0)
22 (17.9)
23 (18.7)
ref
0.48 (0.26-0.87)
0.66 (0.35-1.23) 
0.84 (0.44-1.62)
0.88 (0.46-1.68)
ref
0.42 (0.22-0.80) 
0.61 (0.32-1.86)
0.82 (0.41-1.62)
0.73 (0.37-1.45)
Age
  Less than 60 years
  60-74 years
  75 years or greater
392
1004
386
371 (22.4)
942 (56.8)
346 (20.8)
21 (17.1)
62 (50.4)
40 (32.5)
1.16 (0.70-1.94)
ref 
0.57 (0.38-0.86)
1.42 (0.84-2.43)
ref 
0.50 (0.32-0.77)
Clinical stage 
   cT2
   cT3
   cT4
1534
177
71
1427 (86.0)
165 (10.0)
67 (4.0)
107 (87.0)
12 (9.8)
4 (3.2)
ref 
1.03 (0.56-1.91)
1.26 (0.45-3.51)
ref 
1.40 (0.72-2.75)
1.71 (0.56-5.27)
Pathological stage *
   pT1 or less
   pT2
   pT3
   pT4 
55
760
735
194
 
50 (3.0)
709 (42.7) 
690 (41.6)
176 (10.6)
 
5 (4.1)
51 (41.5)
45 (36.6)
18 (14.6)
 
ref
1.39 (0.53-3.64)
1.53 (0.58-4.04)
0.98 (0.35-2.77
 
ref
1.30 (0.47-3.64)
1.30 (0.46-3.64)
0.82 (0.27-2.56)
Referred for  
cystectomy
  Yes
  No
310
1472
260 (15.7)
1399 (84.3)
50 (40.7)
73 (59.3)
0.27 (0.19-0.40)
ref
0.41 (0.26-0.69)
ref
Cystectomy hospital **
  Community
  University 
1504
264
1430 (86.2)
216 (13.0)
74 (60.2)
48 (39.0)
ref
0.23 (0.16-0.34)
ref
0.34 (0.21-0.56)
* pathological stage was missing in 38 patients 
** patients who underwent radical cystectomy in a hospital outside the Netherlands were excluded 
RC = radical cystectomy;  OR = odds ratio;  95%CI = 95% confidence interval  
 In Figure 1 overall survival of both RC groups is presented. Log-rank analysis 
demonstrated no statistical significant difference between the groups (p=0.67), 
although, although after 3 years of follow-up patients in group I seem to have a better 
survival. Proportional hazards regression analysis showed that delayed RC >3 months 
was not associated with decreased OS (Hazard ratio (HR) 1.17; 95% confidence interval 
(95CI) 0.92-1.49). This finding did not change after adjustment for age, gender, pT stage, 
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pN stage, referral status and type of treatment hospital (HR 1.16; 95CI 0.91-1.48, p = 
0.25). As expected, age, pT stage and pN stage were independently associated with OS. 
 The impact of delayed RC on OS was assessed using several cut-off points 
ranging between 12 and 20 weeks. No statistical significant difference in OS was found in 
any of the used cut-off points. 
Figure 1: 
Overall survival in patients undergoing radical cystectomy within 3 months (blue 
line) or after 3 months (red line) after diagnosis of muscle-invasive bladder cancer
Neo-adjuvant therapy cohort
A total of 105 patients underwent neo-adjuvant therapy of whom 91 patients neo-adjuvant 
chemotherapy and 14 patients neo-adjuvant radiotherapy. Downstaging to pT0 occurred 
in 23 patients (21.9%). Of the 95 patients who underwent LND, 22 patients (23.2%) 
had node-positive disease. Three (2.9%) patients were treated with adjuvant therapy. 
Median time to RC was 133 days (IQR: 62 days) and 17 patients (16.2%) underwent RC 
≤3 months. The pathologic upstaging rate was higher in patients who underwent RC ≤3 
months compared to patients who did not (41.2% vs 15.9%; Chi2 p-value = 0.05). Median 
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follow-up time was 4.7 years (range: 0.5-7.6 years) for patients alive at 31th of December 
2013 and 1.2 years (range: 0.2-5.0 years) for deceased patients. OS was not statistically 
significantly different for group II compared with group I both on univariable analysis (HR 
0.82, 95CI 0.43-1.61) and adjusted for age, pT stage and lymph node status (HR 0.90, 95CI 
0.45-1.82). 
Discussion
To our knowledge, this study represents the first nationwide analysis in Europe to evaluate 
the impact of timing of RC on staging and survival outcomes in MIBC patients. The median 
time interval from MIBC diagnosis to RC was 50 days and adherence to the EAU MIBC 
guideline recommendation was good with 93% of patients undergoing RC ≤3 months. 
Delayed RC for >3 months was not associated with a higher upstaging rate or decreased OS. 
 Several factors may contribute to delayed RC and are both healthcare system-
related and patient-related. In this study, advanced age was associated with delayed RC 
that presumably reflects a higher comorbidity rate requiring extensive and time consuming 
pre-operative medical evaluation. Comorbidity has previously been associated with 
prolonged time to RC, in fact, Lee et al. reported it to be the second most important reason 
for delay after surgical schedule issues. [2] Hospital transition for RC was another factor 
independently associated with delayed RC, which has been reported in a recent study as 
well. [9] In the current study, 16% of patients who were referred to another hospital to 
undergo RC did not undergo RC ≤3months and the median time to RC was on average 2 
weeks longer compared to patients not referred for treatment to another hospital. After 
adjusting for referral status, treatment in a university hospital remained associated with 
delayed RC. The reason for this finding is unknown but may include both patient-related 
factors (comorbidity/performance score) as well as logistics within university hospitals. 
 A number of studies from tertiary referral centers have investigated the impact of 
time from MIBC diagnosis to RC on staging and survival. Sanchez-Ortiz et al. [5] reported 
one of the first studies in which a higher pathologic upstaging rate and decreased OS 
was found in patients in whom RC was delayed for >12 weeks. Later, several other studies 
have been performed using a similar cut-off point (i.e. 12 weeks / 3 months / 90 days), 
reporting conflicting results. In three studies, the pathologic upstaging and nodal 
disease rate were reported to be equivalent for patients who underwent RC ≤3 months 
and those who did not. [2-4] Chang et al. [10] reported higher extravesical disease rates 
in patients in whom RC was delayed for >3 months, although no association between 
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the time to RC and pathologic stage was found with time to RC as a continuous variable. 
 The impact of delayed RC on survival has been more extensively studied. In two 
studies, no association between prolonged time to RC and survival outcomes was found. 
[3,11] On the other hand, several studies did report poorer survival outcomes in patients 
with delayed RC >3 months [2,4,5,10] It should be noted, however, that most of these 
studies were single-center series with often small cohorts and excessive delays. In one 
study, only 19 patients did not undergo RC ≤3 months of whom 6 patients waited for over 
2 years.[5] The impact of delayed RC on staging and survival is probably better evaluated 
in an unselected population-based cohort with a larger study size. In our nationwide 
study, delayed RC >3 months was not associated with a higher upstaging rate, higher 
occurrence of nodal metastasis and OS. To our knowledge, two previous population-
based study studies have been performed, both focusing on survival outcomes lacking 
data to assess the upstaging rate.[6,7] Mahmud et al. [7], in a cohort covering the 
Quebec province in Canada, reported no association between the time to RC as a 
continuous variable and survival. Stratified by </>12 weeks delay, a delay of >12 weeks 
was independently associated with decreased survival calculated from date of diagnosis 
(HR1.7 95CI 1.2-2.4). Gore et al. [6] analyzed data of 441 patients included in the American 
SEER-medicare database and concluded that both disease-specific survival and OS was 
higher in patients with a time to RC of <12 weeks calculated from the date of diagnosis. 
It should be noted, however, that the date of biopsy that confirmed MIBC diagnosis 
was not available for all patients and that patients who underwent RC within 4 weeks 
or >52 weeks were excluded. As a result, only 65% of patients underwent RC within 12 
weeks compared to 90% in our cohort making comparison between studies challenging. 
 Limited data is available on the impact of prolonged time to RC in patients 
undergoing neo-adjuvant therapy (NAC). In one study, reporting on 153 patients, the 
median time from initiation of NAC to RC was 112 days and performance of RC within 10 
days following completion of NAC did not compromise survival.[12] In the current study, 
the median time from MIBC diagnosis to RC was 133 days. The upstaging rate was higher in 
patients who underwent RC ≤3 months. This finding is likely the result of lack of response 
or suffering from side-effects, although data on the number of chemotherapy cycles 
received by each patient was not available. Delaying RC for >3 months, however, had no 
adverse impact on OS. Collectively, the current available data suggests that even though 
NAC does often cause a delay in RC >3 months, oncological outcomes are not jeopardized. 
 The strong aspect of this study is the large unselected cohort of MIBC patients. 
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Nonetheless, this study is subject to limitations. This was an observational study based 
on available registry data. Factors associated with the timing and choice of treatment 
like comorbidity and performance were not recorded in the NCR and could therefore 
not be included in the analysis. The finding that OS appears to be better in patients who 
underwent RC ≤3 months after 3 years of follow-up is unlikely the result of timing of RC and 
is likely to be caused by initial differences between the two patients groups (like comorbid 
conditions or performance status). Also, findings from this study may not apply for patients 
who progressed from non-MIBC to MIBC as only primary MIBC patients were included. 
 
Conclusions
The median delay from MIBC diagnosis to RC in this nationwide study was 50 
days with over 93% of patients undergoing RC within 3 months, as recommended 
in the EAU MIBC guideline. Delaying RC for >3 months did not result in a higher 
upstaging rate, higher occurrence of nodal metastasis or decreased OS. In patients 
treated with NAC, a higher upstaging rate was found in patients who underwent 
RC ≤3 months, but OS was similar to patients with delayed RC > 3 months. These 
findings suggest that the current 3-month recommendation should not apply for 
patients undergoing NAC and that in patients not treated with NAC, it might serve as 
a reasonable guide rather than a fixed point in time within RC should performed. 
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General discussion and future perspectives
In spite of aggressive surgical management for muscle-invasive bladder cancer (MIBC), 
on average 50% of patients die of the disease, of which the majority dies within 2 years 
following treatment.[1] Even more alarming: survival of MIBC has hardly improved over 
the last 30 years.[2] These facts underscore the need for further research in this field, but 
also raises the question what should be the focus of our research and clinical activities to 
improve MIBC survival, while reducing treatment related morbidity. Although this thesis 
has addressed some questions regarding the staging, surgical treatment and prognosis 
of bladder cancer (BC), several issues remain unsolved and new questions have arisen. In 
the following section, the findings in this thesis will be discussed in a broader perspective 
and those areas in BC research that should receive (more) attention will be highlighted. 
  
Bladder cancer staging 
A major problem in the treatment of BC is the inaccuracy of clinical BC staging, with an 
estimated understaging rate of 32%-44%. [3-5] In chapter 5, it was demonstrated that 
clinical understaging affects the decision whether to perform lymph node dissection 
(LND) in patients with non-muscle invasive bladder cancer (NMIBC). Although lymph 
node (LN) metastasis were rarely found in patients with pathologic NMIBC, pathologic 
upstaging to MIBC and subsequent presence of LN metastasis was less uncommon. 
Based on this finding, it was concluded that LND should be performed in all patients with 
cT1 and cTis disease to adequately assess the nodal status. As LND in itself may not be 
free of harm, the aim should be to only perform LND in those patients that benefit from 
it. Therefore, it is important to improve on the clinical understaging rate. Arguably the 
most important step in clinical staging is to perform a radical transurethral biopsy of the 
bladder tumor (TURBT) with presence of detrusor muscle in the specimen. In our study, 
only patients with detrusor muscle in the TURBT specimen were selected. Nonetheless, 
still 25% of patients with NMIBC were upstaged to MIBC. This may in part be due to 
the lack of routine repeat TURBT in T1/high grade patients and bimanual palpation, 
two important components of clinical staging, which is a limitation of our study. [6-8] 
Therefore, to further investigate the role of LND in NMIBC, this study should be repeated 
in a prospective manner including all essential components of clinical staging (i.e. radical 
TURBT, repeat TURBT in high risk patients, bimanual palpation). 
 Next to clinical staging, there is a need for improved pathologic LN staging. 
Both the current 7th and previous 6th edition of the TNM nodal staging provide limited 
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risk stratification for BC recurrence and/or death (chapter 8). A nodal staging system 
providing prognostic information is important to improve on the selection of candidates 
that may benefit from adjuvant therapy. In chapters 7 and 8, we found the number of LN 
metastasis and LN density (ratio of positive LNs and LNs removed) to be independently 
associated with (recurrence-free) survival. It would seem obvious to develop a nodal 
staging system based on these parameters, however, it has extensively been reported that 
both parameters are influenced by several factors and that reproducibility worldwide is 
poor. [9] Hence, these quantative LN variables are less suitable to use in a nodal staging 
system. Qualitative LN variables on the other hand, may be more suitable as they are 
better reproducible. Recently, extranodal extension [10-11] and perinodal lymphovascular 
invasion [12] have been reported to be independently associated with prognosis. Future 
studies are required to externally validate the findings in these studies and, when the 
findings are repeated, to develop a new nodal staging system based on qualitative 
parameters. 
The role of lypmhadenectomy in bladder cancer
The staging benefit of LND in BC has been demonstrated in chapters 5 and 6, yet, the role 
of LND as a therapeutic intervention remains unclear. The impact of the extent of LND on 
survival outcomes after radical cystectomy (RC) was investigated in a systematic review of 
the literature (chapter 6). Based on 23 included studies, it was concluded that a LND up 
to the aortic bifurcation might be beneficial over less extended LND templates in terms 
of oncological outcomes, without a significant increase in treatment-related morbidity. 
Extending the LND cephalad of the aortic bifurcation was, however, not beneficial. Is 
this evidence sufficiently convincing to firmly recommend an extended LND in all MIBC 
patients? Not really. First, there was a clear lack of consensus on what is considered a 
limited, standard and (super)extended LND with definitions varying in virtually all of 
the 23 included studies. Although the extent of LND was often redefined for comparison 
purposes, this is not without bias. Second, all studies were subject to risks of selection 
bias and confounding. Although the systematic review was performed according to 
the highest methodological standards, it cannot compensate for the low quality of the 
individual studies. As such, a meta-analysis was not performed. Clearly, a randomized 
controlled trial (RCT) is needed to provide a definitive answer on whether a more extended 
LND provides a survival benefit over less extended LND templates. At the moment, two 
well designed RCTs are ongoing evaluating whether extended LND benefits disease free 
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survival compared with standard (American SWOG trial, NCT01224665) or limited (German 
LEA trial, NCT01215071) LND.[13-14] The first results are expected in 2015-2016 and are 
eagerly awaited. 
Surgery related morbidity and quality of life
To reduce RC related morbidity and improve the quality of life, modifications in the surgical 
technique have been suggested. A sexual organ preserving cystectomy (SOPC), preserving 
the prostate in males and reproductive organs (RO; vagina, uterus and/or ovaries) in 
females, is feasible but its oncological safety is under debate. In chapter 2, analyzing 
nearly 1,500 radical cystoprostatectomy specimens, it was demonstrated that the risk of 
prostatic urothelial carcinoma (PUC) and/or incidental prostate adenocarcinoma (PAC) 
can be as high as 50% in unselected male patients. In fact, this rate may even be higher 
would whole mount sectioning of the prostate have been performed instead of partial 
embedding. One of the study goals was to identify what patient and tumor characteristics 
are associated with PAC and PUC. We hypothesized that the routine available clinical and 
histopathologic variables may be useful in selecting candidates for a prostate sparing 
cystectomy. Although a number of risk factors were established, its absence did not 
rule out clinical significant PAC and/or PUC. These data suggest that careful patient 
selection is important and that routine available clinical and histopathologic variables 
should be extended with pre-operative evaluation of the bladder neck and prostate. This 
may include taking biopsies, although with increasing experience, MRI of the prostate 
might be an alternative in the future. To date, the diagnostic panel that offers the 
optimal detection rate of PUC and PAC in the least invasive manner is unknown. Next 
to optimal selection, SOPC requires an optimal surgical technique as metastatic spread 
is a concern raised in SOPC series that has been linked to the surgical technique.[15-
16] It has been demonstrated that when these criteria are met (optimal selection and 
surgical technique), comparable long-term oncological outcomes to RC can be achieved.
[17] In female patients, RO involvement is present in approximately 7.5% of patients 
and is associated with a poor 5-year recurrence-free survival of 15% (chapter 3). Similar 
to chapter 2, we aimed to establish risk factors for involvement of the RO. Patients 
with pre-operative signs of presence of extensive disease, such as hydronephrosis and 
palpable mass on bimanual palpation, were more likely to have RO involvement. Our 
study was, however, limited by the small cohort size prohibiting analysis to establish 
independent risk factors for RO involvement. To develop appropriate selection criteria in 
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female patients, a large and multi-institutional study of RC specimens including detailed 
clinical and histopathologic data is required. Nonetheless, this study underscores that, 
similar to male patients, strict patient selection is important when SOPC is considered. 
 Next to SOPC, a robotic assisted radical cystectomy (RARC) has been advocated 
to reduce the peri-operative morbidity rate. To date, the role of RARC is unclear. Although 
the use of RARC is rapidly increasing, it is still considered an experimental procedure 
lacking level 1 evidence supporting the claimed morbidity advantage over open RC.[18,19] 
Currently, a randomized study (RAZOR trial, NCT01157676) [20] is under way evaluating 
the oncological outcomes, complications and health-related quality of life. Until these 
data become available (expected 2017), RARC should be restricted to high-volume centers 
preferably in a clinical trial setting.
Bladder cancer prognosis and systemic (chemo)therapy
Bladder cancer is a heterogeneous disease that requires personalized treatment. In 
essence, this means selecting the right therapy for the right patient at the right time. 
In patients with locally advanced MIBC, the challenge is to identify those patients 
that might benefit from systemic therapy. In this thesis, a number of studies aimed to 
define pre-and postcystectomy clinical and pathologic variables that may improve risk 
stratification of disease-recurrence and/or BC death (chapters 7,8 and 9). For these 
studies, the RC database of the University of Southern California, considered to be the 
largest and highest quality RC database worldwide, was retrospectively reviewed. These 
studies are important as these parameters may be used in the selection of patients that 
may benefit from systemic treatment based on their high risk profile. Unfortunately, 
these parameters cannot be used to identify those patients that respond to (neo-)adjuvant 
therapy. Ideally, targeted treatment is based on both tumor characteristics and the (epi)
genomic background of the patient. Hence, the role of biomarkers in BC is under extensive 
investigation. Reports about potential new biomarkers have been published abundantly, 
particular in the field of p53 tumor expression, serum vascular endothelial growth factor 
and circulating tumor cells.[21-23] At the moment of this writing, however, no biomarker 
has reached the clinic as most have not been externally validated, have not appeared to 
be cost-effective or shown to alter treatment decisions. In particular internal and external 
validation is of great importance that is too often not performed prior to publication/
implementation. Future studies should aim to tackle these issues, as biomarkers likely 
have the future to further improve risk stratification and direct targeted treatment. 
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 The efficacy and timing of systemic therapy in adjunct to meticulous surgical 
treatment in patients with (locally advanced) MIBC is a topic of debate. Neo-adjuvant 
chemotherapy has been reported to improve the overall survival rate by 5-8%.[24] 
For adjuvant chemotherapy, evidence is less convincing with older RCTs facing 
methodological issues.[25,26] Recently, the results of the early closed EORTC 30994 trial 
(poor accrual) have been published reporting that adjuvant chemotherapy did not improve 
overall survival, but did improve progression-free survival.[27] In spite of the evidence 
favoring (mainly neo-adjuvant) systemic treatment in patients with locally advanced 
BC, its worldwide use is still low.[28,29] One of the reasons is the risk of overtreatment 
in patients without micro metastasis and delayed cystectomy in those patients that 
do not respond to chemotherapy (estimated 30-50%). With improved prediction of 
treatment response, the use of (neo-)adjuvant chemotherapy is likely to increase. 
 The role of immunotherapy as an alternative adjuvant treatment in MIBC is 
under investigation. [30,31]. Recently, very promising results have been published 
with the inhibition of the programmed death-ligand 1 by MPDL3280A in patients with 
advanced bladder cancer previously treated with chemotherapy. [31] In 2014, a phase II 
trial (NCT02108652) has been initiated and is currently recruiting patients. [32]
Concluding remark
It is obvious that staging, prognostication and treatment of MIBC can be further improved 
to reduce the still high mortality and morbidity rates. In this thesis it was demonstrated 
that a tailored approach in MIBC care is the next step forward that requires ongoing efforts 
to further unravel the individual nature of both the cancer and the patient. To achieve this 
goal, time, budget and strong collaborations are needed. 
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Summary
A short overview of the current challenges in the staging, treatment and prognostication 
of muscle-invasive bladder cancer (MIBC) is provided in part one (chapter 1). 
The second part of this thesis discusses cancer of the urinary bladder and its adjacent 
organs. To understand in which bladder cancer patient it might be oncologically safe 
to perform a sexual organ preserving cystectomy, knowledge about the incidence and 
risk factors of bladder cancer invading the adjacent sexual organs is important. Also, in 
male patients, the risk of incidental prostate cancer should be taken into consideration. 
 In chapter 2, the incidence and risk factors for prostatic urothelial carcinoma 
(PUC) and/or incidental prostate cancer (PCA) was assessed in 1,476 patients who 
underwent radical cystoprostatectomy. It was found that over 50% of patients had PUC 
and/or PCA. Clinical significant PCA and PUC invading the prostatic stroma (PUC-s) 
were present in 10.1% and 8.3% of patients, respectively. PUC-s was independently 
associated overall survival (HR 1.26, 95% CI 1.03-1.57) while PUC confined to the 
prostatic ducts was not (HR 1.00, 95% CI 0.82-1.24). Presence of PCA did not alter 
overall survival. Pre-operative risk factors for PUC-s included higher clinical stage, 
multifocal disease and trigonal tumor location. Increasing age and PSA were risk 
factors for clinical significant PCA. Absence of these risk factors, however, did not rule 
out PUC and/or PCA. Therefore, using standard pre-operative available risk factors 
alone to select candidates for prostate preserving surgery are likely inaccurate. 
 Chapter 3 describes the incidence and risk factors of urothelial carcinoma 
involving the adjacent reproductive organs (uterus, vagina and/or ovaries; RO) in female 
patients who underwent anterior pelvic exenteration. RO involvement was present in 7.5% 
of the 267 patients included. The vagina was the most frequently involved organ (5%), while 
the ovaries were least frequently involved (0.4%). Pre-operative variables associated with 
RO involvement were presence of hydronephrosis and a palpable mass on pre-operative 
bimanual palpation. These findings underscore that, equivalent to male patients, careful 
patient selection is important when a sexual organ-preserving approach is considered. 
 Cancer of the urachus (UraC), stretching between the umbilicus and the bladder 
dome, is rare and long-term survival data are scarce. In chapter 4, the 152 UraC cases 
diagnosed over a 20-year period in the Netherlands were analyzed. There was a wide 
variation in the primary treatment modality, but partial cystectomy was most common 
(53%). Up to 30% of patients had lymph node (LN) or distant metastatic disease at initial 
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presentation and these patients were often younger of age. Survival in this group was 
poor, with a 5-year overall survival rate of less than 20%. Increased awareness of UraC, 
particularly in younger patients with urinary symptoms, is important since detection of 
UraC at an early stage benefits survival. 
In the third part of this thesis, the role and extent of lymph node dissection (LND) in 
bladder cancer was discussed. 
 To evaluate whether LND benefits nodal staging in non-muscle invasive bladder 
cancer (NMIBC), a lymph node mapping study was performed in chapter 5. A total of 
114 patients with NMIBC who underwent radical cystectomy (RC) with ‘superextended’ 
LND were included, of whom 8% of patients had LN metastasis. Stratified by clinical 
stage, LN metastasis were present in 9% of patients with cT1, 12% of patients with cTis-
only and absent in patients with cTa disease. Metastatic LNs were found at or above 
the aortic bifurcation in 33% of node-positive patients, but all of these patients had 
positive LNs in the true pelvis as well. While LN metastasis were rarely found in patients 
with pathologic NMIBC (1%), pathologic upstaging to MIBC (found in 25% of patients) 
and subsequent presence of LN metastasis was more prevalent, although still not 
very common (8%). Thus, unless clinical staging is improved, LND benefits staging in 
all bladder cancer patients undergoing RC except for those patients with cTa disease. 
 In patients with MIBC, there is little doubt that LND is important from a staging 
perspective, but its therapeutic value remains unknown. In chapter 6 it was demonstrated 
that there is a lack of randomized studies on this topic and that the current evidence 
base is based on 23 mainly retrospective comparative studies with substantial risks of 
bias and confounding. Acknowledging these important limitations, these studies indicate 
that any form of LND produces more favorable oncologic outcomes compared with no 
LND. Extending the LND up to the aortic bifurcation might be superior to lesser degrees 
of dissection from an oncologic perspective; however, further extending the dissection is 
not beneficial. There is no evidence that LND substantially increases the number of peri-
operative adverse events compared to no LND.
Part four of this thesis addresses prognostication in MIBC patients. LN status is a well-
established prognostic factor in BC. Yet, survival within the node-positive group may vary 
greatly and it has been suggested that tumor burden may play a role.
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 In chapter 7, the long term survival outcomes and prognostic factors in 
patients with low-volume disease (i.e. 1 or 2 positive LNs) after RC were described. 
Nearly half of the patients with node-positive disease had low-volume node-positive 
disease. In this patient subgroup, up to 40% of patients did not have recurrence after 
10 years suggesting that reasonable clinical outcomes can be expected. Variables 
associated with recurrence-free survival included pathological tumor stage and lymph 
node density, the latter suggesting that removal of more LNs might be beneficial. 
 Chapter 8 reflects on the recent changes in the American Joint Committee on 
Cancer-TNM nodal staging system, which is used as a prognostication tool for node-
positive patients. Analyzing a large cohort of node-positive patients, it was found that the 
7th edition shifts many patients from the N2 category into the N3 category. The prognosis 
of patients with LN metastasis at the common iliac vessels did not differ from patients with 
N1-N2 disease, suggesting that common iliac LNs involvement may indeed reflect regional 
rather than distant metastatic disease. The 7th edition did, however, not outperform 
the previous 6th edition in terms of prognostication. In fact, both editions had limited 
prognostic value indicating the need for a better nodal classification system.  
In chapter 9, the impact of prolonged time to RC on staging and survival outcomes was 
assessed in a nationwide cohort of primary MIBC patients. The median time to RC was 
50 days and over 93% of patients underwent RC within 3 months after MIBC diagnosis as 
recommended in the MIBC guideline of the European Association of Urology. Time to RC 
was prolonged in patients older than 75 years of age, in referred patients and in patients 
treated in a university hospital. Delayed RC for >3 months was not associated with higher 
a mortality rate irrespective of whether neo-adjuvant chemotherapy was given. These 
data do imply that, if needed, time allows for extensive pre-operative medical evaluation 
and/or neo-adjuvant chemotherapy to improve on the medical condition of the patient or 
to reduce the tumor burden.
The final part includes the general discussion and future perspectives (chapter 10) and 
the summary of this thesis (chapter 11).
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Samenvatting
Het eerste deel (hoofdstuk 1) van dit proefschrift schetst een kort overzicht van de 
huidige problemen bij de stadiëring, behandeling en prognose bepaling van spierinvasief 
blaaskanker (SIBK).
In het tweede deel van dit proefschrift wordt ingegaan op blaaskanker en de omliggende 
(voortplantings)organen. Om te bepalen bij welke patiënten met blaaskanker het 
oncologisch verantwoord is om een seksueel orgaan sparende cystectomie (SOSC) te 
verrichten, is het belangrijk kennis te hebben van het vóórkomen van en risicofactoren 
op ingroei van blaaskanker in de omliggende voortplantingsorganen. Daarnaast dient bij 
mannen rekening gehouden te worden met het risico op de aanwezigheid van prostaatkanker. 
 In hoofdstuk 2 wordt ingegaan op de risicofactoren van doorgroei van het 
urotheelcarcinoom van de blaas in de prostaat in het algemeen (PUC), prostaatbuizen 
(PUC-d) en prostaat stroma (PUC-s) evenals het incidenteel aanwezig zijn van 
prostaatadenocarcinoom (PAC). Bij meer dan 50% van de 1476 patiënten die een 
radicale cystoprostatectomie hadden ondergaan, werd PUC en/of PAC gevonden. 
Klinisch significant PAC en PUC-s was aanwezig in respectievelijk 10,1% en 8,3% 
van de patiënten. Risicofactoren voor PUC-s waren een hoger klinisch stadium, 
multifocale ziekte en blaaskanker gelokaliseerd in het trigonum. Zowel een hogere 
leeftijd als hogere PSA waarde waren risicofactoren voor klinisch significant PAC. 
Belangrijk is de bevinding dat afwezigheid van deze risicofactoren PUC en/of PAC 
niet volledig uitsluit. Derhalve is het gebruik van deze risicofactoren alleen, niet 
voldoende voor het selecteren van geschikte patiënten voor een SOSC. De aanwezigheid 
van PUC-d was niet onafhankelijk geassocieerd met de overleving (HR 1,00, 95% 
betrouwbaarheidsinterval(BI) 1,03-1,57), maar de aanwezigheid van PUC-s was dit wel 
(HR 1,26, 95%BI 1,03-1,57). De aanwezigheid van PAC had geen invloed op de overleving. 
 Hoofdstuk 3 beschrijft het vóórkomen van en risicofactoren op doorgroei van 
urotheelcarcinoom van de blaas in de interne genitalia (IG; uterus, vagina, eileiders, 
eierstokken) van vrouwen die een voorste excenteratie van het kleine bekken hadden 
ondergaan. Ingroei in de IG was aanwezig in 7,5% van de 267 patiënten. De vagina 
was het vaakst betrokken (5%), terwijl ingroei in de eierstokken zeldzaam was (0,4%). 
Pre-operatieve parameters geassocieerd met een hogere kans op ingroei in de IG 
waren de aanwezigheid van hydronefrose en een palpabele massa bij bimanueel 
toucher. Deze bevindingen suggereren dat, evenals bij mannelijk patiënten, SOSC 
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niet in elke patiënt uitgevoerd kan worden maar strikte selectie noodzakelijk is. 
 Een carcinoom van de urachus (UraC), welke zich bevindt tussen de navel en 
het blaasdak, is zeldzaam en er is wereldwijd weinig data bekend over de lange-termijn 
overleving van deze ziekte. In hoofdstuk 4 werden 152 UraC gevallen, gediagnosticeerd 
in Nederland de afgelopen 20 jaar, geanalyseerd. Er bleek een grote variatie te bestaan 
hoe deze ziekte primair behandeld werd, waarbij een partiële cystectomie het meest 
voorkomend was (53%). In meer dan 30% van de patiënten was er bij de eerste presentatie 
reeds sprake van lymfekliermetastasen (LK) en/of metastasen op afstand en vaak betrof 
dit jongere patiënten. De overleving in deze groep patiënten is uitermate slecht, met een 
5-jaars overlevingspercentage van minder dan 20%. Kennis van deze ziekte bij de uroloog 
is van groot belang, met name bij jonge patiënten van mictieklachten, aangezien vroege 
detectie van UraC de kans overleving sterk kan vergroten.  
In deel drie van dit proefschrift wordt de rol van lymfeklierdissectie (LKD) bij blaaskanker 
besproken.
 Om te bepalen of het verrichten van een LKD zinvol is bij patiënten die een 
radicale cystectomie (RC) ondergaan voor niet-spierinvasief blaaskanker (NSIBK), werd 
in hoofdstuk 5 een zogenaamde lymfeklier (LK) ‘mapping’ studie verricht. Er werden 114 
NSIBK patiënten geïncludeerd die allen RC met zeer uitgebreide LKD tot aan de arteria 
mesenterica inferior hadden ondergaan. In totaal was er bij 7,9% van de patiënten sprake 
van LK gemetastaseerde ziekte. Van deze LK positieve patiënten had 33% LK metastasen 
ter hoogte van of proximaal van de aortabifurcatie, maar altijd in combinatie met 
aanwezigheid van LK metastasen in het kleine bekken. Er werden dus geen zogenaamde 
‘skip-metastasen’ gevonden. Gestratificeerd per klinisch stadium, had 9% van de cT1 
patiënten, 12% van de cTis patiënten en 0% van de cTa patiënten LK metastasen. LK 
metastasen waren uiterst zeldzaam indien NSIBK werd bevestigd in het RC preparaat 
(1%). In meer dan 25% van de gevallen werd echter toch SIBK gevonden met als gevolg 
dus een hogere kans op LK metastasen. Voor adequate stadiering is LKD derhalve 
aan te bevelen in alle patiënten die RC ondergaan voor blaaskanker (behalve cTa). 
Bij patiënten met spierinvasief-blaaskanker (SIBK) is er geen twijfel dat LKD bijdraagt aan 
de stadiëring, echter of de LKD zelf ook positief bijdraagt aan de overleving is onbekend. 
 In hoofdstuk 6 werd een literatuuronderzoek gericht op deze vraag. Er werden 
23 vergelijkende studies gevonden waarbij een uitgebreide LKD tot aan de aortabifurcatie 
lijkt te resulteren in betere oncologische uitkomsten ten opzichte van een minder 
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uitgebreide LKD. Het verrichten van een nog uitgebreidere LKD (‘superextended’) LKD 
lijkt echter geen overlevingswinst te bieden. Er is geen bewijs in de huidige literatuur 
dat het verrichten van een LKD de kans op peri-operatieve complicaties sterk vergroot 
ten opzichte van het niet verrichten van een LKD. Helaas zijn de huidige studies van lage 
kwaliteit waardoor er op dit moment geen harde conclusies getrokken kunnen worden. 
Deel vier van dit proefschrift behandelt de prognose van patiënten met SIBK. 
Hoewel de LK status één van de belangrijke prognostische parameters is, bestaan er 
desondanks grote verschillen in overleving binnen de groep patiënten met LK metastasen. 
Mogelijk speelt hierbij de uitgebreidheid van LK metastasen een rol. In hoofdstuk 7 worden 
de lange termijnuitkomsten beschreven van patiënten met laag-volume LK metastasen 
(gedefinieerd als 1 of 2 LK metastasen) na RC en LKD. In totaal hadden 181 van de 369 
patiënten (49%) laag-volume metastasen. In deze groep bleek 41% van de patiënten geen 
recidief van de ziekte te hebben binnen 10 jaar, hetgeen beduidend hoger was dan bij 
patiënten met >2 LK metastasen (23%). Er mag dus een redelijke overleving verwacht 
worden in de groep met laag-volume LK metastasen. Variabelen onafhankelijk geassocieerd 
met recidief-vrije overleving waren het pathologisch tumor stadium en LK densiteit, 
waarbij het laatste suggereert dat het verwijderen van meer LK een voordeel kan bieden. 
 Hoofdstuk 8 reflecteert op de recente veranderingen in de American Joint 
Committee on Cancer (AJCC)-TNM lymfeklier classificatie welke gebruikt wordt voor 
het stadiëren van patiënten met LK metastasen. Er werd een groot cohort van LK 
positieve patiënten geanalyseerd waarbij bleek dat veel patiënten die in de voorgaande 
6e editie (2002) als N2 werden geclassificeerd in de huidige 7e editie (2010) als N3 
worden geclassificeerd. De prognose van patiënten met LK metastasen ter hoogte van 
de iliacale vaten was niet statistisch significant verschillend ten opzichte van patiënten 
met N1-N2 ziekte, hetgeen suggereert dat LK metastasen op deze locatie mogelijk nog 
beschouwd kunnen worden als regionale ziekte in plaats van metastasen op afstand. De 
prognostische waarde van de huidige 7e editie lijkt echter niet beter ten opzichte van de 
voorgaande editie. Beide edities hebben beperkte prognostische waarde en daarom is er 
behoefte aan een nieuwe prognostische classificatie voor patiënten met LK metastasen.  
 In hoofdstuk 9 werd de invloed van de tijdsduur tussen de diagnose SIBK en 
RC op de stadiëring en overleving onderzocht in een Nederlands cohort van 1782 SIBC 
patiënten. De mediane duur tot RC was 50 dagen en meer dan 93% van de patiënten 
onderging RC binnen de door de Europese Associatie van Urologie (EAU) gestelde termijn 
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van 3 maanden. De tijdsduur tot RC was gemiddeld langer in patiënten ouder dan 75 jaar, 
patiënten verwezen RC en patiënten die RC ondergingen in een academisch centrum. Een 
vertraging van meer dan 3 maanden resulteerde echter niet in progressie van het stadium 
of lagere overleving, ook niet indien er neo-adjuvante chemotherapie was gegeven. Deze 
uitkomsten suggereren dat een langere wachttijd tot RC niet perse een negatieve invloed 
hoeft te hebben op de prognose.
Het laatste deel van dit proefschrift bevat de algemene discussie en toekomstperspectief 
(hoofdstuk 10) en de samenvatting (hoofdstuk 11). 
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